ESG REPORT 
2022/23

ABOUT THIS REPORT
REPORTING OVERVIEW    In 2022, Celltrion publicly announced its intent to 
implement ESG and report its ESG performance. Accordingly, this is the first 
Celltrion ESG report for 2022/2023. Each year, Celltrion will disclose its ESG ac-
tivities and performance across all areas of its business operations transparently 
through its ESG Report, and seek to actively communicate with stakeholders.
REPORTING PERIOD AND SCOPE    This report covers the period from 
January 1, 2022, to December 31, 2022, and describes Celltrion’s financial and 
non-financial activities and performance. Certain important events from the first 
half of 2023 are also included in this report. The financial data presented in the 
report includes the performance of subsidiaries based on consolidated K-IFRS, 
and the non-financial performance related to the environment and society is 
based on Celltrion’s separate standards. Unless stated otherwise, the reporting 
scope of non-financial performance is limited to Celltrion’s business sites in Korea 
(Plants 1 and 2, IBS Tower, and Seoul office).
REPORTING STANDARDS    This report was prepared in accordance with the 
GRI (Global Reporting Initiative) Standards, which are internationally recognized 
standards for sustainability reporting. The report incorporates various indexes 
of SASB (Sustainability Accounting Standards Board), TCFD (Task Force on Cli-
mate-related Financial Disclosures), U.N. SDGs (U.N. Sustainable Development 
Goals), and others.
REPORTING ASSURANCE    To ensure reliability of data, and credibility of 
this report, an independent third-party agency British Standards Institution (BSI) 
verified the contents. The Independent Assurance Statement is provided in the 
APPENDIX. 
INQUIRIES    If you have further inquiries or require additional information re-
garding this report, please contact us using the contact information provided 
below.
Department: Celltrion ESG Management Team
E-mail: ESG@celltrion.com
Website: www.celltrion.com
Contents
OVERVIEW
7
CEO’s Message
8
About the Company
9
ESG Management System
18
2022/2023 Highlights
20
BUSINESS STORY
3
MATERIAL ISSUES
21
Stakeholders’ Engagement
22
Double Materiality Assessment
23
· Issue 1.	Improving Access to 
25 
Medicines
· Issue 2.	Expanding the Global  
28 
Market to Create New Growth Engines
· Issue 3.	Expanding R&D and 
31  
Production Infrastructure
This report has been published as an 
interactive PDF with features such as page 
navigation, links to related web pages, and 
pop-ups.
INTERACTIVE PDF GUIDE
Contents page
See more details
Move to related pages
GOVERNANCE
67
Governance
68
Compliance and Ethical Management
78
Risk Management 
82
Supply Chain Management
86
Information Security
91
ENVIRONMENTAL
34
Environmental Management
35
SOCIAL
43
Talent Management
44
Human Rights Management
50
Safety and Health Management
55
Customer Satisfaction Management
60
Social Contribution
64
ESG FACTBOOK
96
Financial Information
97
Non-financial information
102
APPENDIX
113
GRI Standards Index
114
TCFD
116
SASB
117
UN SDGs
118
Independent Assurance Statement 
119
GHG Verification Report  
121
Awards and Association Memberships122
ESG Guidelines 
123
COVER STORY
The evening view of the Celltrion 
Global R&D Center, set to open in 2023, 
symbolizes the company’s commitment 
to advancing human health through 
unwavering dedication to R&D.

BIOSIMILARS
First Mover
The Beginning of a Great Journey
When everyone said it was impossible, we saw possibility.
It was the beginning of a great journey in the barren field of biotech industry.
Celltrion ESG Report 2022/23
3
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Unlimited Challenge
Ceaseless Pursuit of Challenge
When others said we had already made great achievements, we dreamed of 
even bigger goals. We are taking a bold stride towards greater innovation.
NOVEL THERAPEUTICS
Celltrion ESG Report 2022/23
4
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

CDMO
Reliable Quality
Trust-based Growth
When we were told we couldn’t go further, we strengthened our groundwork and broadened our reach.
A great partner along every step of the way.
Celltrion ESG Report 2022/23
5
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

SMALL MOLECULES
Market Expansion
A Great Journey, An Endless Story
When others say following a certain road is the only answer, we build a wider road. 
Celltrion changes the landscape of the global market.
Celltrion ESG Report 2022/23
6
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

CEO’s Message
8
About the Company
9
ESG Management System
18
2022/2023 Highlights
20
OVERVIEW
EXPAND SUSTAINABLE VALUE
We aspire to grow as a company that fulfills its social responsibilities 
and establishes a foundation for sustainable growth.

CEO’s Message
Dear Stakeholders,  
I sincerely thank all stakeholders who have shown great interest and support for Celltrion, a company that 
strives to create a bright future for the biotech industry in Korea and pursue the happiness of humanity.
Amid the growing importance of ESG management, Celltrion has initiated efforts to establish and implement 
an ESG system in earnest, designating 2022 as the first year of its ESG management. We aim to provide sus-
tainable healthcare services to enhance human health and welfare. To achieve this vision, the Corporate Sus-
tainability Division and an ESG Management Team under the division were created in April 2022. To actively 
promote ESG management, we also established the ESG Committee under the Board of Directors (BoD). The 
ESG Committee consists entirely of independent directors to ensure independence and transparency in man-
agement. Furthermore, various ESG policies related to biodiversity and BoD diversity and expertise have been 
established, laying down institutional foundations to achieve mid to long-term ESG management objectives.
In addition, Celltrion has been maintaining a global level management system by obtaining five international 
certifications in the following order: ISO 9001 (Quality Management System), ISO 14001 (Environmental Man-
agement System), ISO 45001 (Occupational Health and Safety Management System), ISO 37001 (Anti-Bribery 
Management System), and ISO 22301 (Business Continuity Management System) since 2020. In order to 
fulfill its responsibilities toward the environment and society, Celltrion has expanded its CSR activities through 
Celltrion Welfare Foundation, an affiliated organization, and through its own sharing programs, environmental 
management services, and charity activities. As part of the internalization of ESG management, Celltrion has 
identified major improvement tasks through an ESG-level diagnosis. Celltrion will continue upgrading its ESG 
management by checking the implementation and performance of improvement tasks in each ESG area.
The future ESG management strategy can be summarized as follows: First, we will participate in domestic and 
overseas activities to respond to climate change in line with the Korean government’s 2050 Carbon Neutral 
Strategy. Celltrion declared its support for the Task Force on Climate-related Financial Disclosures (TCFD), a 
financial disclosure consultation body, in January 2023 and will continue participation in the joint task of solving 
environmental issues. Second, internally, we will create a cooperative labor-management by building a sound 
working environment based on a healthy organizational culture and human rights management. Externally, we 
will form ESG partnerships with international organizations and partners to realize the value of win-win coop-
eration for sustainable management. Third, a transparent governance structure will be established to enhance 
Celltrion’s continuous growth and stakeholder value.
Celltrion will continue its challenging journey to consolidate its position as a global top-tier biopharmaceutical 
company. We will consider social and environmental impacts first and continue communicating with stake-
holders through ESG reports and various channels. We ask for your generous encouragement and interest in 
Celltrion’s ongoing journey seeking greater heights.
Woosung Kee
CEO
Celltrion ESG Report 2022/23
8
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Continued Growth
In the global biopharmaceutical market exceeding KRW 200 trillion, 
Korea’s share was close to zero, and there was hardly any awareness 
of biopharmaceuticals in Korea. For these reasons it was impossible 
to develop biopharmaceutical technology in the country. Therefore, for 
Celltrion to establish global competitiveness in the field of biotechnol-
ogy, we recognized that acquiring advanced technology should be the 
priority. Celltrion decided to acquire advanced technology and accumu-
late expertise through its Contract Manufacturing Organization (CMO) 
business, after securing production facilities. Traditional pharmaceutical 
powerhouses, such as the U.S., Germany, Switzerland, and Sweden, 
had mass cultivation facilities for biopharmaceutical production. Celltrion 
built a factory with top-tier production facilities in Songdo International 
City, Incheon, and signed a CMO contract with the global pharmaceu-
tical company BMS. With this, Korea gradually overcame the high entry 
barriers of global biotechnology. 
Celltrion’s product quality control principles and trust priorities earned 
the company the first FDA approval of an Asian facility in December 
2007. This was an official demonstration of Celltrion’s top-tier technolog-
ical capabilities, production facilities, and quality systems. Celltrion se-
cured momentum for continued growth by satisfying the US FDA’s strict 
cGMP (current Good Manufacturing Practice) requirements. Through 
continuous investment in research and development, Celltrion accom-
plished its goal of developing its own biosimilar called ‘Remsima1)’. Rem-
sima received unanimous approval from the European Medicines Agen-
cy (EMA) in August 2013. This signaled the beginning of the biosimilar 
market worldwide.
Our Way
About the Company
Win-win Management
Celltrion has overcome crises and grown into a global in-
tegrated pharmaceutical company representing Korea, 
with the help of its employees, shareholders, and society. 
Reciprocating their trust, Celltrion established Celltrion 
Welfare Foundation in 2006 to give back to society. Under 
the slogan “realizing welfare through awareness, empathy, 
and sharing,” the Foundation supports the underprivileged, 
mainly in the Incheon and Chungcheongbuk-do areas, 
where Celltrion’s business sites are located.
Contribution to the Nation Through Business
The epic story of Celltrion began with a small and obscure 
area of knowledge called biosimilars. Chairman Jungjin Seo, 
the founder of Celltrion, conceived a new vision for a busi-
ness, based on the firm conviction that fostering new indus-
tries can contribute to the development of the country.
At the time, Korea was a “barren land” in the pharmaceutical 
industry, and biotechnology was not even recognized as 
an industry in Korea. However, Chairman Seo realized that 
major biopharmaceuticals’ patents would expire one by one 
soon. Here, he saw the indefinite potential for the biosimilars 
business. So, he began laying the foundations for creating a 
new legend by building a state-of-the-art biopharmaceutical 
production plant in the Songdo International City, Incheon, 
to meet the pharmaceutical production requirements set by 
the regulatory agencies of advanced countries.
1) The Worlds’s First Antibody Biosimilar
Celltrion’s Story
Celltrion ESG Report 2022/23
9
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Core Values
Vision
Celltrion aims to establish itself as a global inte-
grated pharmaceutical company that realizes 
the value of promoting human health and wel-
fare by developing next-generation biophar-
maceuticals and small molecules. 
Antibody biopharmaceuticals have fewer side 
effects and better efficacy compared to small 
molecules. However, many patients do not 
have equal access to treatment at present due 
to the high prices of antibody pharmaceuticals. 
The biosimilars developed and sold by Cell-
trion provide the same therapeutic effects as 
original medicines but at lower prices, thereby 
providing more patients with opportunities for 
treatment. The antibody biosimilars initiated 
by Celltrion offer new hope for patients world-
wide. Celltrion will stay committed to develop-
ing and distributing the medicines necessary 
for humanity to lead healthy lives.
CREATIVITY
PROBLEM-SOLVING THROUGH CREATIVE IDEAS
Celltrion solves problems with new ideas by creative thinking or thinking 
outside the box. Their adventure of developing biosimilars took an unconven-
tional approach. Contrary to biotech companies’ typical business process of 
developing, producing, and selling new medicines, Celltrion acquired produc-
tion facilities first and developed products through CMO partnerships to learn 
advanced technologies. The global clinical trial conducted in 2010 was a 
notable case where Celltrion employees demonstrated their creativity. Due to 
low national and corporate awareness in the biotech industry, Celltrion faced 
difficulties in recruiting patients and obtaining regulatory approval for clinical 
trials. Celltrion overcame these challenges by establishing a global clinical 
trial task force team and developing innovative clinical trial strategies, such as 
conducting phases 1 and 3 clinical trials simultaneously and pursuing clinical 
trials of an asymmetric concept. 
THE SPIRIT OF SEEKING CHALLENGE
UNBEATABLE SPIRIT
It was a bold undertaking for a small Korean company with limited recogni-
tion to conduct global clinical trials and apply for product approvals. In the 
beginning, the global pharmaceutical industry had a cold stance towards 
Celltrion. Making the entry into the global pharmaceutical market, which had 
different healthcare and regulatory standards, was an adventurous endeavor. 
To counter physicians’ prejudice against biosimilars, Celltrion employees 
traveled around the globe to meet doctors who offered their perspectives to 
regulatory agencies. They organized seminars and promoted the efficacy of 
Remsima. Finally, the barriers of physicians’ prejudice were lowered. Celltri-
on’s venture into the global market, which began with an audacious endeavor, 
has paved the way for relentless pursuit of new horizons. 
COMPLIANCE WITH PRINCIPLES
PRIORITIZING FAITH AND TRUST
Celltrion values life and places emphasis on strict accountability. This is 
because even the slightest mistakes cannot be tolerated in the biopharma-
ceutical production process. Celltrion once faced a dilemma over profits. In 
2007, it was identified that the biopharmaceutical production process could 
have been contaminated. Although product contamination and efficacy were 
not confirmed, we adhered to our principles and chose to dispose of the 
manufactured products, recognizing that even the slightest possibility of con-
tamination cannot be tolerated. A significant loss followed, but we stood by 
our principles instead of seeking immediate profits, thereby winning customer 
trust. The decision also led to a flawless system for production and complete 
prevention of recurrence, laying the foundations for zero-contamination pro-
duction.
THE PURSUIT TO BE THE WORLD’S BEST
LEADING THE GLOBAL MARKET WITH TOP-TIER EXPERTISE
Only companies with top-tier technology survive in the biopharmaceutical 
industry. The first mover enjoys a great pre-emption effect and dominates the 
market. In this regard, Celltrion’s core value for corporate competitiveness 
is to become the best in the global market. In December 2007, Celltrion ac-
quired certificaiton by the U.S. FDA for its large-scale animal cell culture facili-
ties. It was the first such case in Asia and Celltrion grabbed global attention.
Celltrion demonstrated its expertise and competitiveness through quality au-
dits and regulatory agency approvals. This is why we have earned high praise 
from major industry representatives, who have said, “You are the best we 
have ever seen.”
Celltrion ESG Report 2022/23
10
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Business Strategy
Securing Production Infrastructure
Celltrion has secured its production capacity by utilizing in-house manufacturing facilities – Plant 1 
(102,000L) and Plant 2 (90,000L) that can produce drug substances (DS) and drug products (DP) – 
and overseas CMO companies. 
Meanwhile, as global demand for antibody medicines is expected to grow, we are constructing 
Plant 3 with a capacity of 60,000L to establish a multi-variety production and supply system.
Reinforcing Competitiveness through R&D 
In order to reinforce R&D capabilities, Celltrion invested approximately 20% of its annual revenue in 
R&D to expand the biosimilar pipeline and develop new antibody drugs.
Celltrion’s Biopharmaceutical R&D Center is developing next-generation medicines based on 
research capabilities and technologies accumulated across all phases related to bio-industry, in-
cluding exploration of drug candidates, development and expression of cell lines through genetic 
recombination, and equivalence assessment for product approval.
The Celltrion Global R&D Center, scheduled to open in 2023, will be a comprehensive pharmaceuti-
cal R&D hub, taking Celltrion’s R&D capabilities to the next level.
Plant 1
102,000 L
Plant 3
60,000 L
Plant 2
90,000 L
Total production 
capacity (planned)
 252,000 L
·12,500L×8 units
·1,000L×2 units 
(SUP)
·7,500L×8 units
·To be completed  
in 2023
·15,000L×6 units
Production Plants
· Plant 1: U.S. FDA approval for Asia's first animal cell culture facility
· Plant 2: Capable of managing the entire production process from manufacturing DS to final injection 
packaging
· Plant 3: Facilities with minimum change-over and multi-variety production
Research Areas
· Biosimilars (Anti-cancer/immunotherapy/targeted therapy)
· New biological drugs (New antibody drugs/convergence technologies /ADCs/biospecific antibody)
· Value-added small molecules (Platform technology-based new drug development/expansion of  
the brand portfolio targeting major diseases/responding to unmet medical needs)
Celltrion ESG Report 2022/23
11
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

24
Product Development
Celltrion has made remarkable achievements by pioneering a new industry called “antibody biosimi-
lars,” for the first time in the world, in the “barren land” of the pharmaceutical industry.
Celltrion plans to launch at least one follow-on biosimilar every year by 2030.
Celltrion will continue making active investments while leveraging synergies in capacities for devel-
opment, production, and distribution of new antibody drugs and small molecules as well as antibody 
biosimilars that have high growth potential. With this, we will pave a new way in the global pharma-
ceutical market.
PRODUCT LAUNCH TARGET
At least one launch a year until 2030
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
· Remsima/Inflectra (CT-P13)   · Remsima SC (CT-P13 SC)   · Truxima (CT-P10)   · Herzuma (CT-P6)   · Yuflyma (CT-P17)   · Regkirona (CT-P59)   · Vegzelma (CT-P16)
· Immune system disorders (2)   · oncology (3)
· Immune system disorders (5)   · oncology (1)   · other (1)
· XOLAIR biosimilar (CT-P39)   · PROLIA biosimilar (CT-P41)   · EYLEA biosimilar (CT-P42)   · STELARA biosimilar (CT-P43)   · ACTEMRA biosimilar (CT-P47)
Target no. of  
products to launch
7
5
5
7
Under sales
Under  
clinical trial
Process 
development
Cell line 
development
판매 중
7
No. of products 
launched 
Celltrion ESG Report 2022/23
12
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Company Profile
Introduction
Celltrion is a global integrated pharmaceutical company in Korea con-
ducting R&D and production of antibody biopharmaceuticals and small 
molecules.
Celltrion has set a new paradigm in the global biopharmaceutical market 
by successfully developing the world’s first antibody biosimilar, and has 
been providing advanced treatment options for a healthy and happy life 
by the rapid development of treatments during the global COVID-19 pan-
demic.
Celltrion has achieved remarkable results by pioneering paths not taken 
by others and will continue to grow as a global pharmaceutical company 
with differentiated business strategies such as small molecules, develop-
ment of new drugs, and digital healthcare platform business.
Celltrion will pursue growth to become a global integrated pharmaceuti-
cal company while making ceaseless efforts to realize the value of human 
health and welfare.
Company
Celltrion, Inc.
Date of establishment
February 26, 2002
No. of employees
2,263 (As of the end of December 2022)
Type of business
Manufacturing of pharmaceutical compounds and 
antibiotics
Address
23 Academy-ro, Yeonsu-gu, Incheon
Celltrion ESG Report 2022/23
13
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

History
Beginnings 
 2002
Groundwork  
 2008
Expansion  
 2014
Consolidation 
 2022
Securing a Path of Accelerated Growth
In 2016, Celltrion also obtained the FDA’s approval for the distribution of Rem-
sima in the United States, thereby securing access to the land of new oppor-
tunities. Celltrion is also developing new therapeutics and new technologies, 
including antibody medicines and biobetters, and is evolving into a global inte-
grated pharmaceutical company.
Consolidating the Basis for 
Growth
From 2003 to 2008, Celltrion con-
solidated its basis for pioneering 
uncharted territories and achieving 
continual growth. The company 
conquered the numerous challeng-
es it encountered in the process.
Opening the era of 
biosimilars
The world’s first antibody biosimilar, 
Remsima, was approved by the 
EMA in August 2013, signaling the 
start of Celltrion’s global expansion. 
The company established its sec-
ond plant, further augmenting its 
production capacity, to ensure sta-
ble supply around the world.
The dawn of legendary 
boldness and creativity
Jungjin Seo, the company chair-
man, first founded Nexol in 2000 to 
examine diverse business oppor-
tunities. Seo established Celltrion 
in 2002 and began to research the 
resources necessary for biophar-
maceuticals production facilities.
• Oct. 2001  
Signed a MOU for the creation of  
a joint venture company
• Feb. 2002  
Founded Celltrion
• Jun. 2005  
Supply agreement with BMS 
(Bristol-Myers Squibb)
• Jul. 2005  
Mechanical completion of Plant 1
• Dec. 2007  
Plant 1 obtained cGMP facility 
approval by the US FDA
• Aug. 2008  
Listed on KOSDAQ
• May 2010  
Secured investment from Temasek 
Holdings, Singapore
• Oct. 2011  
Construction of Plant 2 was  
completed
• Jul. 2012  
Remsima approved in Korea (MFDS)
• Aug. 2013  
Remsima approved in Europe (EMA)
• Jan. 2014  
Herzuma approved in Korea (MFDS)
• 	Mar. 2015  
Introduced a new 
management system with 
professional executives
• 	Jun. 2015  
Plant 1 and Plant 2 
received approval from 
the U.S. (FDA) on all 
cGMP manufacturing 
facilities
• 	Apr. 2016  
Remsima approved  
in the U.S. (FDA)
• 	Oct. 2016  
Achieved KRW 1 trillion 
in cumulative export of 
Remsima
• 	Nov. 2016  
Truxima approved in 
Korea (MFDS)
• 	Feb. 2017  
Truxima approved in 
Europe (EMA)
• 	Feb. 2018  
Listed on KOSPI 
Herzuma approved in 
Europe (EMA)
• 	Nov. 2018  
Temixys approved in the 
U.S. (FDA) 
Truxima approved in the 
U.S. (FDA) 
• 	Dec. 2018  
Herzuma approved in the 
U.S. (FDA) 
Designated as a long-
term supplier for HIV 
international procurement 
program 
• 	Jan. 2019  
Filed global patent 
application for  
Remsima SC
• 	Apr. 2019  
Linezolid approved  
in the U.S. (FDA)
• 	Nov. 2019  
Remsima SC approved  
in Europe (EMA)
• 	Feb. 2020  
Achieved KRW 1 trillion 
of annual revenue  
Remsima SC approved in 
Korea (MFDS)
• 	Jun. 2020  
Acquired Primary Care 
product assets for Asia 
Pacific markets from 
Takeda Ltd.
• 	Aug. 2020  
Herzuma earned WHO 
Prequalification status
• 	Feb. 2021  
Yuflyma approved in 
Europe (EMA)
• 	Sep. 2021  
Regkirona approved in 
Korea (MFDS) 
• 	Nov. 2021  
Regkirona approved in 
Europe (EMA)
• 	Aug. 2022  
Vegzelma approved in 
Europe (EMA) 
• 	Sep. 2022  
Vegzelma approved in 
the U.S. (FDA)
• 	May. 2023  
Yuflyma approved in  
the U.S. (FDA)
Celltrion ESG Report 2022/23
14
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Global Partnership
Celltrion has created an ecosystem for collabo-
ration with partners in various fields to achieve 
bigger and more meaningful outcomes for the 
biopharmaceutical industry.
Through collaborative partnerships, Celltrion is 
strengthening its competitiveness in the global 
market and securing a sustainable growth en-
gine.
Global Network
Celltrion has established direct distribution networks1) in more than 90 countries, including Japan, Australia, United Kingdom and Germany, 
in addition to the U.S. and Canada, two of the world’s largest markets for pharmaceuticals.
Celltrion leverages its global network and partnerships to gain access to markets in each country and increase the cost competitiveness of its products.
● Manufacturing Sites
● Sales & Marketing Offices
● Sales & Marketing Offices (in process)
United States
Brazil
Argentina
Mexico
Colombia
Peru
Chile
Japan
Hong Kong
Philippines
Australia
New Zealand
Singapore
Thailand
Korea
Turkey
Hungary
Italy
Portugal
Ireland
UK
Switzerland
Belgium
Norway
Denmark
Netherlands
Germany
AMERICA
ASIA
EUROPE
Venture Fund
Mirae Asset Capital
KDB Bank
1) It is about Celltrion Healthcare, which is in charge of the global distribution and sales of Celltrion’s biopharmaceuticals.
CMO
Lonza
Teva
Iksuda Therapeutics
R&D
Celltrion ESG Report 2022/23
15
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Small Molecules
CDMO (Contract Development  
and Manufacturing Organization)
Novel Therapeutics
Biosimilars
Business Overview
Business Areas
First Mover
Developed and produced the world’s first antibody 
biosimilar.
11
Number of biosimilars  
(6 commercialized/5 under clinical trials)
60.6%
Remsima’s share in the European market  
(As of the end of December 2022)
Celltrion is developing antibody biosimilars that are 
equivalent in efficacy to more expensive biophar-
maceuticals, but available at a lower cost so that 
more people can benefit from affordable treatment.
Proven to be equivalent in quality, efficacy, and 
safety to the original drug, biosimilars can replace 
expensive biopharmaceuticals, provide access to 
treatment for patients at a reasonable cost, and 
save healthcare costs, thereby improving the effi-
ciency of medical welfare.
Celltrion is currently developing more antibody 
biosimilars following the commercialization of 
six antibody biosimilars, including Remsima, the 
world’s first antibody biosimilar for the treatment of 
autoimmune diseases; Herzuma for the treatment 
of breast cancer; and Truxima for the treatment of 
blood cancers.
New Drug Formulation
Developed the world’s first subcutaneous formulation of 
biosimilar infliximab, Remsima SC.
ADC, Double Antibody Technology
This is a next generation therapeutic technology. We are 
currently developing anti-cancer ADC biobetters through 
joint research with global pharmaceutical companies.
Microbiome
Developed Live Bacterial Products (LBP)
Through a change in formulation, Celltrion suc-
cessfully developed and commercialized the 
world’s first subcutaneous formulation of biosimilar 
infliximab, Remsima SC. Remsima SC targets pa-
tients who are satisfied with the efficacy of Remsi-
ma’s reference product infliximab but want or need 
a subcutaneous formulation, as well as patients 
taking the globally reputed biopharmaceuticals 
Humira and Enbrel, which are TNF-α inhibitors in 
the SC formulation, but are experiencing lack of 
effectiveness or side effects.
Antibody-drug conjugate technology is a next-gen-
eration therapeutic method that combines antibod-
ies that target cancer cells selectively with antican-
cer drugs to eliminate cancer cells more effectively.
Celltrion is working with global pharmaceutical 
companies to develop ADC biobetters for multiple 
tumor targets, including breast cancer.
One-stop Process
One-stop process from contract development to 
contract manufacturing.
U.S. FDA cGMP Certified
Top-tier manufacturing facilities and quality management 
systems
Know-how and Advanced Technologies
Abundant clinical and regulatory experience and 
advanced production facilities
Celltrion develops and produces high-quality 
pharmaceutical products that meet our partners’ 
needs based on top-tier production facilities and 
specialized workforces. The CDMO business is 
about developing a partner’s drug candidate by 
providing expertise in the processes of develop-
ment, production, clinical operations, and approval 
and sharing development costs. With Celltrion’s 
capabilities, partners can develop drug candidates 
rapidly and Celltrion can secure priority rights to 
those candidates, enabling both companies to ac-
complish efficient growth.
Open Innovation
Introduced/co-developed pipeline and platform 
technologies.  
New drug (CT-G20), new formulation (Donepezil patch)
Primary Care Business in Asia
Expanded the brand portfolio for cardiovascular/
metabolic diseases.
Core R&D Therapeutic Areas
Development of drugs in the various areas
With its Global Chemical Project (GCP), which 
expands Celltrion’s portfolio and reinforces sales 
of small molecules, Celltrion aims to grow into a 
fully integrated pharmaceutical company by enter-
ing the small molecule sector that occupies two-
thirds of the global pharmaceutical market. Starting 
with the HIV drug Temixys, the first incrementally 
modified new small molecule approved by the U.S. 
FDA in 2018, Celltrion acquired Takeda’s originals 
(Actos, Nesina, Edarbi, etc.) and 18 OTC products 
for the Asia-Pacific region (9 countries) in 2020. 
Based on the world’s first approval of Donepezil 
patch formulation by the Ministry of Food and Drug 
Safety in 2021, we supply small molecules in vari-
ous disease areas such as the circulatory system, 
endocrine system, nervous system, and oncology/
immunology to domestic and overseas markets. 
Celltrion ESG Report 2022/23
16
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Business Performance
Financial Performance
Despite the economic uncertainty and the subsequent deterioration in economic situations worldwide, Celltrion achieved KRW 2.3 trillion of revenue on a consolidated basis, which corresponds to approx-
imately 21% increase year-on-year, on account of continued growth driven by the rapid growth of Remsima IV’s share in the US market and launch of the new product Vegzelma. However, operating profit 
went down by approximately 13% year-on-year to KRW 647.2 billion due to changes in product mix and temporary costs related to diagnostic kits.
Category
2019
2020
2021
2022
Revenue
11,285 
18,493 
18,934 
22,840 
Cost of sales
(4,950)
(8,215)
(8,058)
(12,513)
Gross profits
6,335 
10,279 
10,876 
10,327 
Selling and administrative expenses
(2,520)
(3,055)
(3,434)
(3,855)
Operating profits
3,815 
7,223 
7,442 
6,472 
Profit for the year
3,010 
5,178 
5,795 
5,378 
※ Profit for the year in the consolidated profit & loss statement is attributable to controlling interest 
Summary of Consolidated Income Statement (Unit: KRW 100 million)
Category
2019
2020
2021
2022
Revenue
9,819 
16,898 
16,158 
19,375 
Cost of sales
(4,105)
(7,343)
(6,860)
(10,521)
Gross profits
5,714 
9,555 
9,299 
8,854 
Selling and administrative expenses
(2,080)
(2,457)
(2,127)
(2,665)
Operating profits
3,634 
7,098 
7,172 
6,189 
Profit for the year
2,898 
5,143 
5,760 
5,114 
Summary of Non-consolidated Income Statement (Unit: KRW 100 million)
Operating Profit Margin/Net Profit Margin (Unit: %)
Operating Profit Margin/Net Profit Margin (Unit: %)
2019
27
34
2019
30
37
2020
28
39
2020
30
42
2021
31
39
2021
36
44
2022
24
28
2022
26
32
● Operating Profit Margin  ● Net Profit Margin
● Operating Profit Margin  ● Net Profit Margin
Celltrion ESG Report 2022/23
17
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

The Way Forward for ESG Management
ESG Management System
ESG has emerged as a key driver of corporate management activities due to the strengthening of ESG regulations and the growing demand for ESG information from key stakeholders. In 2022, Celltrion offi-
cially announced its intent to implement ESG management. We also aim to realize the value of improving human health and welfare by providing sustainable healthcare services by means of an ESG manage-
ment system.
ESG Strategy Framework
Mid/Long-Term Roadmap for ESG Management
1) Joined the TCFD in Jan. 2023
Vision
A global integrated pharmaceutical company that promotes health  
and welfare for all by developing next-generation biopharmaceuticals  
and small molecules
Building a sustainable healthcare ecosystem  
based on ESG management
Environment
Pursue green 
management for the 
future environment
· Set GHG reduction targets 
and declare Net Zero 
vision and roadmap
· Join the TCFD1) and make 
a public announcement
· Build an environmental 
performance assessment 
system
Society
Create social value 
through win-win 
cooperation
· Strengthen human rights 
management
· Conduct a survey 
and announce the 
management results for 
employee human rights 
and engagement 
· Advance CSR strategies
Governance
Establish 
exemplary 
governance
· Enhance the transparency 
and independence of 
the board of directors 
operation
· Spread ethical 
management/culture
· Manage ESG-related risks 
in the supply chain
Goals
Direction for 
Each Area
Imple- 
mentation 
Tasks
Consolidation of ESG Management 
· Strengthen the monitoring of ESG management 
· Advance ESG management and expand its scope
Expansion of ESG Management 
· Conduct ESG activities and respond to the demand for 
ESG information
· Achieve the milestones of ESG improvement tasks and 
manage performance
Introduction of ESG Management
· Build an ESG governance system
· Identify major improvement tasks through ESG diagnosis 
(Set ESG goals and directions)
2030
2025
2022
Celltrion ESG Report 2022/23
18
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Established  
ESG Management System
· Established a dedicated ESG organization 
	 (April 2022)
· Established ESG Committee (August 2022)
· Set ESG Policies (November 2022)
Certified with  
5 ISO standards
· ISO 9001 
(Quality Management Systems)
· ISO 14001 (Environmental Management Systems)
· ISO 45001 (Occupational Health and Safety 
Management Systems)
· ISO 37001 (Anti-Bribery Management Systems)
· ISO 22301 (Business Continuity Management 
Systems)
Joined the TCFD (January 2023)
Obtained Grade B in the comprehen-
sive evaluation conducted by Korea 
Institute of Corporate Governance and 
Sustainability (KCGS)
(C in Environmental, B+ in Social management,  
B in Corporate governance)
ESG Governance
Major Achievements of ESG Performance
ESG Governance System
As the first step toward promoting ESG management, Celltrion created the ESG Committee, the top 
decision-making body, in August 2022 to establish an ESG governance framework. Before estab-
lishing the ESG Committee, we launched the ESG Management Team, a dedicated working-level 
organization under the Corporate Sustainability Division, and a working group to establish an ESG 
management governance system. Celltrion will grow into a leader in ESG management by establish-
ing sustainable management strategies and discussing the way forward for the overall ESG areas.
Working Group
Independent 
ESG Advisory 
Organization
Advisor
Identify agenda 
items 
Discuss issues
ESG Committee
(Under the BoD)
ESG Management 
Team
ESG Management 
Consultative body 
(CEO)
Review and propose 
agenda items
Report 
progress
Deliberation/Approval of 
strategies and agenda items
Check outcomes and 
improve performance
Top  
Decision-making 
Body
Working Group
Dedicated 
organization
ESG
Celltrion ESG Report 2022/23
19
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

2022/2023 Highlights
Designated as a Global Biotechnology Workforce 
Development Hub
· Provided field training as part of the Global Biotechnology Workforce 
Development Hub training 
· The program was attended by 106 production staff members from 
25 LIC/MICs as well as 32 Korean trainees
Reduced more than 
5% of air pollutants 
Celltrion’s Plant 2 reduced more than 5% of air pollutants through a 
voluntary agreement signed in January 2022 on reducing particulate 
matter. In return, the City of Incheon provided incentives to Celltrion 
Plant 2 from 2022 to 2023, allowing the Plant to reduce the frequency 
of self-measurement of pollutants. 
Supported communities that have suffered damage
· Provided support for the 
Samcheok and Uljin areas that 
suffered damages due to wildfires 
Monetary and pharmaceutical support
· Donation to help residents recover 
from flooding 
KRW 600 million 
· Donation to help residents 
recover from the wildfire 
KRW 538 million
Expanded core infrastructure
· Expanded biopharmaceutical production capacity  
(Plant 3 to be completed in 2023)
· Enhanced R&D capabilities  
(Celltrion Global R&D Center to be completed in 2023)
Win-win cooperation with biotech startups 
· Jointly runs Shinhan Square Bridge Incheon Program with Shinhan 
Financial Group through a consortium 
· Contributed to the identification and nurturing of startups by running 
an open innovation program in the bio healthcare sector
2022 Korea Youth Bio Academy 
· Nurtured future biotechnology talents
Celltrion ESG Report 2022/23
20
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

MATERIAL 
ISSUES
Stakeholders’ Engagement
Double Materiality Assessment
Issue 1. Improving Access to Medicines
Issue 2. Expanding the Global Market  
to Create New Growth Engines
Issue 3. Expanding R&D and  
Production Infrastructure
22
23
25
28
31
BE A PIONEER
With the pioneer spirit, Celltrion will realize ESG management in the bio market.

Stakeholders’ Engagement
Celltrion pursues active communication with various stakeholders, such as customers, shareholders, investors, the central and local governments, etc. In order to strengthen stakeholder engagement,  
each functional department of our company has a channel for ongoing communication with stakeholders.
We strive to engage in sustainable communication with stakeholders by understanding their expectations and needs and reflecting them in the overall business activities.
Customers
Local Communities
Shareholders and Investors
Major Communication Channels
•AGMs
•Regular reports
•Investor relation (IR)
•Website
•ESG Report
Interests and Expectations
•Transparent information sharing 
•Risk management
Local 
Communities
Customers
Suppliers
Central and Local 
Governments
Shareholders 
and Investors
Employees
Stakeholders
Major Communication Channels
•Website, Customer Center 
•Official social media channels 
(Company’s blog, Instagram, 
YouTube, and Facebook pages)
•Global exhibition booths
Interests and Expectations
•Resolve customer complaints
•Identify abnormal cases or side 
effects of products, and improve 
quality
•Share the company’s latest news
•Brand promotion and global 
partnering
Major Communication Channels
•Official letters about the Celltrion 
Welfare Foundation’s business 
(Distributed at government offices)
•Website
Interests and Expectations
•Support for the underprivileged 
classes
•Balanced development of  
local communities
Employees 
Major Communication Channels
•Newsletters via the company Intranet
•Regular letters with the CEO’s 
message
•Celltrion Labor-management Council
•ER Team, Corporate Culture 
Department
•Grievance Committee
•Tongnamu (communication) channel
Interest and Expectations
•Vitalize internal communication
•Establish a horizontal 
organizational culture
•Manage labor-management 
relations
•Create sound organizational 
culture
•Handle employees’ grievances
Suppliers
Major Communication Channels
•Business review meetings 
(e.g. JSC, QBR, etc.) 
•Online/offline issue management 
meetings
•Weekly technical meetings 
(Weekly video conference for  
the tech. department)
Interests and Expectations
•Win-win cooperation partnership
•Mutual and continued growth 
•Compliance with fair trade 
principles
•Vitalize communications with 
suppliers
Central and Local Governments
Major Communication Channels
•Regular reports
•ESG reports
•Emails for external cooperation
•Conference in the Incheon Free 
Economic Zone (IFEZ)
Interests and Expectations
•Complying with fair trade and  
anti-bribery principles
•Transparent sharing of corporate 
information 
•Faithful tax payment
•Investment and employment 
status
Celltrion ESG Report 2022/23
22
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Double Materiality Assessment
Celltrion conducted a double materiality assessment that considers the impact of the external environmental and social factors on the company’s financial value  
as well as the impact of the company’s business activities on environment and society. A total of 41 issues to be reported were prioritized in consideration of financial,  
environmental and social importance; following this, 3 core issues and 7 issues to be reported were identified. 
Celltrion will conduct a materiality assessment annually and will maintain transparency in communicating with stakeholders.
1) To be done in line with impact assessment by issue (Financial performance and reputation). 
* The double materiality assessment and the ESG report were presented to the management in September 2022 for interim reporting, followed by reporting to the ESG Committee in May 2023.
A pool of issues to be 
reported was created
Prioritized Topic Set
Core issues 3
Issues to be reported 7
Major Topics and Priority
Materiality assessment
Issue Pool – 41
Materiality test results
Financial Impact
Environmental and Social Impact 
Internal data  
review
CEO’s Message, 
Celltrion Group  
Vision 2030
Internal data 
review
Media  
analysis
Approx. 100 media 
outlets
Media  
research
International 
standard analysis
GRI
SASB
UN SDGs
UNGC
DJSI
KCGS
ISO 26000, etc.
Result of reviewing 
international 
standards
Stakeholder  
survey1)
Employees, 
shareholders/investors
Suppliers,  
ESG experts
Results of stakeholder surveys
Benchmarking of 
peers
Domestic and  
overseas leading 
companies in the 
pharmaceutical/
biotechnology  
industry
Companies in 
the same/similar 
industries
Analysis of 
international 
standards
Results of 
media surveys 
Benchmarking 
results
Stakeholders’ 
surveys
Industrial 
issues
Materiality Assessment Process
Celltrion ESG Report 2022/23
23
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Double Materiality Assessment
Materiality Assessment Metrics
Result of Materiality Assessment
Materiality Map
Material Topics
● High    ◐ Medium    ○ Low
No. Category
Topics
impact 
Report 
Page
Alignment 
with GRI 
topics
Financial Environmental 
and social 
➊
Customers/ 
Products
Improving access to 
medicines
●
●
25-27
203-2
➋
Management/ 
Economy
Expanding the global 
market to create  
new growth engines
●
●
28-30 
201-1
➌
Customers/
Products
Expanding R&D and 
production infrastructure
●
●
31-33 
Non-GRI
➍
Management/
Economy
Reinforce global 
competitiveness
●
●
11 
Non-GRI
➎
Customers/
Products
Reinforce the reliability and 
stability of products
◐
●
61-62 
416-1
➏
Supply Chain
Establish and manage a 
sustainable supply chain
◐
◐
87-90 
414-1, 414-2
➐
Supply Chain
Strengthen support for 
win-win cooperation with 
suppliers
◐
◐
87-90 
308-2, 414-2
➑
Environment
Respond to climate change
◐
◐
38-40 
305-1, 305-2
➒
Community
Reinforce social 
contribution and support 
activities
◐
◐
65-66 
413-1
➓
Management/ 
Economy
Secure the soundness and 
transparency of governance
◐
◐
71-72 
Non-GRI 
10
8
6
4
2
0
2
0
4
6
8
10
Financial impact
Core issues
Issues 
to be reported
Potential 
issues
Environmental and social impact
1
2
3
4
5
6
7
9
10
8
Impact on business
Celltrion ESG Report 2022/23
24
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

IMPORTANCE 
The demand for biopharmaceuticals continues to grow as 
population aging accelerates worldwide. However, biophar-
maceuticals are very expensive owing to their enormous 
development costs, so medically underserved populations 
who cannot afford the high prices do not have access to 
treatment in many cases. Biosimilars have attracted much 
attention on account of their potential to address this health-
care inequity, as they can replace expensive biopharma-
ceuticals, providing patients with access to treatment, and 
reducing healthcare costs. In addition, there is a growing 
societal demand for equal access to medicines, so various 
measures to improve access are being explored globally.
APPROACH 
Celltrion started developing biosimilars with the aim of 
providing more patients with access to treatment at more 
reasonable prices. Through our ceaseless efforts, we have 
successfully obtained approval for the new drug Regkirona 
and a total of six antibody biosimilars, including Remsima, 
the world’s first antibody biosimilar for the treatment of auto-
immune diseases, Herzuma for breast cancer treatment and 
Truxima for blood cancer treatment. Celltrion’s biosimilars, 
which are currently available globally, have the same efficacy 
as expensive original drugs but are available at a lower cost, 
offering therapeutic benefits to more patients. In addition, 
we are exerting various efforts to improve access to medi-
cines, including the joint construction of a digital healthcare 
ecosystem and development of treatments for COVID-19.
PERFORMANCE
Improving Access to  
Medicines
ISSUES - 01
* As of the end of December 2022
Therapeutic antibody  
pipelines 
5
No. of countries  
that approved Regkirona
36
Approved therapeutic  
antibodies
7
COVID-19 patients injected  
with Regkirona
52,000
(Korea)
Celltrion ESG Report 2022/23
25
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Medical 
Technology
IT 
Technology
Creating a Digital Healthcare Ecosystem
Digital healthcare aims to provide personalized medicine suit-
able for each patient’s characteristics, from treatment to disease 
prevention, through the convergence of medical technology with 
IT technology. To implement such personalized medicine, var-
ious types of patient data are required, and it is also necessary 
to secure the technical skills to analyze the data. Celltrion aims 
to develop customized and data-based disease prevention and 
management solutions by building a healthcare data integration 
platform. Celltrion’s digital healthcare business aims to develop 
a patient-centered medical ecosystem by utilizing not only med-
ical information but also health information in combination with 
advanced ICT technologies and creating valuable new services 
through collaboration with various industries. Celltrion took part 
in the Governance Council of Klaytn, a blockchain platform, 
along with ‘GroundX’ from 2019 to October 2022, for a full-
fledged digital healthcare business. We are also conducting joint 
research with a healthcare data analysis company in Finland 
to explore new business avenues related to digital healthcare 
using medical data from Finland. In addition, we developed and 
launched a remote patient monitoring solution for patients with 
inflammatory bowel disease through joint research with Gil Hos-
pital in 2020. In the future, Celltrion will lead the efforts to build a 
digital healthcare ecosystem by gradually expanding its digital 
healthcare business.
Creating Social Value
When the outbreak of the pandemic in 2020 created an urgent 
need for COVID-19 treatment, Celltrion promptly initiated the 
development of novel antibody therapeutics, leveraging its years 
of expertise in development and capacity for production. We 
started development in February 2020, shortly after the WHO 
declared a public health emergency, and in about a year, we 
identified COVID-19 antibodies and sequentially produced re-
sults with nonclinical and clinical trials in phases 1, 2, and 3. This 
led to authorization for conditional marketing from the Ministry of 
Food and Drug Safety (MFDS) in February 2021, and emergency 
use recommendation by European Medicines Agency (EMA) in 
March 2021. Following the completion of Phase 3 clinical trial, 
we obtained full marketing authorization from the MFDS in Sep-
tember 2021 and the EMA in November 2021. As a result, the 
full-scale domestic supply of Regkirona Inj. was started in Febru-
ary 2021, and as of December 2022, we were able to administer 
the treatment to approximately 52,000 patients in Korea. We 
supplied the drug at a base rate  without margins so that a large 
number of patients could receive the treatment, and the fast 
and effective treatment contributed significantly to reducing the 
occurrence of severe cases. As of December 2022, we obtained 
approval for Regkirona Inj., from a total of 36 countries, thus im-
proving access to COVID-19 treatments globally.
Digital Healthcare
Personalized disease 
prevention and 
management solutions
Klaytn Governance Council1)
1) Project ended in October 2022.
Joint research on new digital  
healthcare business items
Access to Medicines Policy
Celltrion has established the Access to Medicines Policy to 
promote human health and welfare and support underserved 
patients who have difficulties in accessing medicines through 
the development of affordable next-generation medicines. The 
policy consists of the following basic principles: developing 
innovative products that facilitate access to medicines; partic-
ipating in initiatives related to healthcare assistance in the least 
developed countries (LDCs); supporting local post-marketing 
monitoring of medicines; providing support to local manufactur-
ers and healthcare workers; cooperating with local regulatory 
authorities; providing free medicines to underprivileged classes; 
and considering access to medicines when applying for pat-
ents in LDCs and low-income countries. To improve access to 
medicines substantially, we encourage all stakeholders in our 
business relationships, including the Celltrion headquarters, do-
mestic and overseas corporations, and subsidiaries, as well as 
our suppliers, to comply with this policy.
Access to Medicines Policy 
Celltrion ESG Report 2022/23
26
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Development and Expanded Supply of Biosimilars
Celltrion has contributed to improving patients’ access to medicines by developing superior biosimilars and making them available 
globally at lower costs than the original medicines. Celltrion’s biosimilars include Remsima, the world’s first antibody biosimilar, followed 
by Remsima SC, Yuflyma, and anticancer drugs such as Truxima, Herzuma, and Vegzelma. Remsima has been approved in 100 coun-
tries as of 2022, along with our other products approved in multiple countries, enabling us to provide treatment to more patients world-
wide. In addition, we are continuously expanding our biosimilar pipeline. Our development areas include ophthalmology, allergy, and 
endocrinology in addition to immunology and oncology where we already obtained approval. We are in the final stage of Phase 3 clinical 
trials and are preparing to obtain approval for the following: XOLAIR biosimilar (CT-P39) for urticaria and asthma; EYLEA biosimilar (CT-
P42) for wet-age-related macular degeneration and diabetic macular edema; STELARA biosimilar (CT-P43) for psoriasis and inflamma-
tory bowel diseases; and PROLIA biosimilar (CT-P41) for postmenopausal osteoporosis.
Overview of Approval of Therapeutic Antibodies (As of the end of December 2022)
CASE
Project
Celltrion 
product
Ingredients 
Indications 
Areas of 
treatment
Date of first 
approval
Countries  
that approved 
the drug
No. of countries 
that approved 
the drug
CT-P6
CT-P10
CT-P13
CT-P13 SC
CT-P16
CT-P17
CT-P59
HERZUMA
TRUXIMA
REMSIMA
REMSIMA SC
VEGZELMA
YUFLYMA
REGKIRONA
Trastuzumab
Rituximab
Infliximab
Infliximab
Bevacizumab
Adalimumab
Regdanvimab
Breast cancer,  
gastric cancer
Non-Hodgkin’s lymphoma, 
rheumatoid arthritis
Rheumatoid arthritis, 
inflammatory bowel 
disease
Rheumatoid arthritis, 
inflammatory bowel 
disease
Metastatic carcinoma of 
the colon or rectum, breast 
cancer, non-small cell lung 
cancer 
Rheumatoid arthritis, 
inflammatory bowel 
disease
COVID-19
New Therapeutic Antibodies 
Biosimilars
Oncology
Oncology, immunology
Immunology
Immunology
Oncology
Immunology
Infectious diseases
January 15, 2014 (Korea)
July 16, 2015 (Korea)
July 20, 2012 (Korea)
November 22, 2019 
(Europe)
August 18, 2022 (Europe)
February 11, 2021 (Europe)
February 5, 2021 (Korea)
US, Europe, Korea
US, Europe, Korea
US, Europe, Korea
Europe, Korea
US, Europe, Korea
Europe, Korea
Europe, Korea
94
87
100
48
34
41
36
* The above approval status is as of the end of December 2022. In May 2023, Yuflyma obtained the FDA’s approval for eight indications, including Rheumatoid arthritis and Crohn’s disease.
Celltrion ESG Report 2022/23
27
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

IMPORTANCE 
The biopharmaceutical industry has gained attention as a fu-
ture growth industry that creates added value, and its global 
market size continues to grow. As a result, competition is 
intensifying among biopharmaceutical companies in each 
country to maintain a competitive edge in the growing global 
market. Only companies that are lead the race to develop 
new drugs can expect sustainable growth, so biopharma-
ceutical companies are reinforcing R&D capabilities and 
actively pursuing global partnerships through open innova-
tion to secure technological competitiveness and thereby 
preempt the market. In addition, efforts are being made to 
expand the global supply chain to ensure stable supply and 
effective marketing of drugs.
CELLTRION’s APPROACH
Celltrion explores domestic and overseas markets actively 
to realize its vision of becoming a global integrated 
pharmaceutical company. As part of its global market 
expansion strategy, Celltrion is creating new growth engines 
through new drug development, expansion of the supply 
chain, product innovation and new businesses. For new 
drug development, Celltrion is collaborating with partners 
in various areas through open innovation while reinforcing 
R&D capabilities. Celltrion is securing new markets through 
global M&As while expanding medicine supply networks 
and enhancing supply stability. Product value and customer 
satisfaction are also being improved through continuous 
innovation. Furthermore, Celltrion has made inroads into 
the digital healthcare market with the launch of a self-
management solution for bowel diseases.
Expanding the Global Market 
to Create New Growth Engines
ISSUES - 02
PERFORMANCE
Countries where Celltrion applied  
for a patent on Remsima SC
Approx. 130 countries
Countries where Celltrion  
established direct  
distribution networks 
Approx. 90 countries
Remsima’s European  
market share 
60.6%
* As of the end of December 2022
Celltrion ESG Report 2022/23
28
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Reinforcing Competencies for New Drug 
Development 
Global Joint Development and Open Innovation
Celltrion has formed active networks with global biotechnology 
companies, universities, and research centers to co-develop 
new drugs while strengthening collaboration through active open 
innovation. In September 2022, Celltrion signed an agreement 
with Abpro Corporation, a US-based biotechnology company, 
to jointly develop and commercialize ABP102, a bispecific an-
tibody-based anti-cancer drug candidate, and made an equity 
investment to form a long-term partnership. Celltrion also signed 
a joint research agreement with Pinotbio and other biotechnol-
ogy companies in Korea, and is actively conducting research to 
internalize capabilities to develop Antibody-Drug Conjugates 
(ADC). In 2021, we invested USD 47 million in Iksuda Therapeu-
tics, a UK-based ADC developer, along with Mirae Asset Finan-
cial Group and others to secure a major shareholder position.
Developing Microbiome Therapeutics
Since the world’s first microbiome therapeutic was approved 
by the U.S. FDA, expectations for therapeutic effectiveness and 
future market growth have been growing. In this regard, Celltrion 
is developing microbiome-based Live Biotherapeutic Products 
(LBPs), prioritizing diseases with high unmet medical needs. 
We are working with KoBioLabs for R&D to develop treatments 
for irritable bowel syndrome and atopic dermatitis, and with 
LISCure Biosciences to develop treatments for Parkinson’s dis-
ease, a degenerative neurological disease. Celltrion will continue 
expanding its new pipeline through open innovation in collabora-
tion with biotech companies that possess strong technological 
capabilities.
Expanding Global Supply Network 
Reinforcing the Global Sales Network
Celltrion has established direct distribution networks in more 
than 90 countries, including the United States and Canada, two 
of the world’s largest pharmaceutical markets, as well as Japan, 
Australia, United Kingdom, and Germany. Based on internally 
secured networks and partnerships, Celltrion strives to secure 
access to more markets and stably supply medicines to patients 
around the world. Currently, antibody biosimilar products such 
as ‘Remsima’, ‘Herzuma’, ‘Truxima’, and ‘Yuflyma’ are sold in 
the global market after receiving approval in various countries, 
including the U.S., Europe, and Korea. In addition, we have also 
established a strong presence in the global small molecule mar-
ket, supplying our first incrementally modified HIV drug, Temixys, 
and developing a generic product for Pfizer’s COVID-19 drug, 
‘Paxlovid’, which is undergoing prequalification by the WHO. 
In 2020, Celltrion successfully acquired Takeda Pharmaceuti-
cal’s primary care products in the Asia-Pacific region through a 
M&A, securing the patents, trademarks, and sales rights for 18 
prescription and over-the-counter drug brands. By adding the 
strong small molecule product line to its globally competitive bio-
pharmaceutical product line, Celltrion has laid the foundations 
for becoming a global integrated pharmaceutical leader.
Enhanced Medicine Stability and Productivity 
Stronger Stability in Medicine Supply
Celltrion is constantly checking and managing external factors to 
maintain stability in the supply of biopharmaceuticals and small 
molecules. In order to understand and address apparent impact 
factors, risk factors and impacts are identified and checked 
continuously. In response to Japan’s export restrictions, Celltrion 
was able to manage impact effectively by checking lead times 
and availability of raw materials based on the previously estab-
lished raw materials database. In addition, during the COVID-19 
pandemic, damage to suppliers was checked constantly and 
flexible responses were mobilized in emergencies in collabora-
tion with key partners such as raw material suppliers, Contract 
Manufacturing Organizations (CMOs), and Contract Research 
Organizations (CROs). Celltrion responds proactively to po-
tential impact factors as well. Amid the growing importance of 
eco-friendly purchasing, Celltrion is engaged in discussions with 
our suppliers regarding the purchase of FSC-certified materials 
for the secondary packaging of biopharmaceuticals. In line with 
the rising demand for localized supply, Celltrion also joined a 
government-led initiative for ‘strengthening the competitiveness 
of biomaterials, parts, and equipment,’ contributing to the suc-
cessful implementation of government policies.
Strengthening Productivity Through Process Innovation
Celltrion continues improving productivity per unit of time (Titer 
Improvement, TI) through introducing innovations in cell culture 
and purification processes for approved biosimilar products. 
Truxima TI (CT-P10 TI), a productivity improvement project for 
Truxima (CT-P10), was approved in Europe, and a variation ap-
proval was obtained in the U.S., in March 2023. Process devel-
opment and validation for Herzuma TI and Remsima’s second TI 
are underway. Following minimization of environmental impact 
through active process innovation efforts, Celltrion will be able to 
increase sustainability for the value of patient safety and life pro-
tection. 
Celltrion ESG Report 2022/23
29
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Active Product Innovation
Launch of Remsima SC, the World’s First SC Formulation of Infliximab
Celltrion’s leading next-generation product, ‘Remsima SC’, is a subcutaneous (SC) formulation of 
infliximab. Through obtaining the patent for Remsima SC, Celltrion will be able to secure exclusive 
rights to its formulation and administration method in over 130 countries. As a self-administered 
treatment, the product is expected to see gradual increase in its global market share based on its 
contributions to patients’ access to treatment while improving patients’ quality of life. Recently, Cell-
trion applied for FDA approval in an effort to enter the US market. 
Launch of Yuflyma, the world’s first high-concentration biosimilar of Humira
Celltrion has received approval from the European Medicines Agency (EMA) for Yuflyma, the world’s 
first high-concentration biosimilar for the autoimmune disease treatment Humira. This high-con-
centration product requires only half the dose of the existing low-concentration biosimilars and is 
free of citrate, which can cause pain. According to assessments, Inflammatory Bowel Disease (IBD) 
patients were satisfied with Yuflyma. It has also been well received by local healthcare providers, 
especially because its shelf life is twice that of the original drug Humira. Based on the high level of 
satisfaction reported by patients and medical staff, Celltrion expects to see a rapid increase in the 
global market share of the high-concentration Yuflyma. 
CASE
Completed application for a patent on Remsima SC,  
a subcutaneous formulation of infliximab. 
Approximately 13 countries
Celltrion ESG Report 2022/23
30
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

IMPORTANCE 
As economic depression continues worldwide following 
the global COVID-19 pandemic, the demand for affordable 
and highly efficient biosimilars remains high. In addition, an 
increasing number of countries are adopting favorable bi-
osimilar policies and awareness of biosimilars is improving 
among doctors and patients, both factors contributing to 
the growth of the biosimilar industry. As a result, there is in-
tensifying competition among pharmaceutical companies 
to develop new drugs and take an advantageous position 
in the market. In response to these market changes, global 
pharmaceutical companies are reinforcing R&D capabilities 
and expanding production facilities to strengthen their core 
competitiveness and secure future growth engines through 
proactive investments.
APPROACH 
Celltrion is expanding its investment in core infrastructure, 
including R&D and production facilities, to continue sus-
tainable growth by securing a strong competitive edge in 
the global market. As part of this, Celltrion is pursuing the 
construction of Global R&D Center and Plant 3 with a total 
investment of KRW 500 billion. The Celltrion Global R&D 
Center, with its state-of-the-art research facilities, will serve 
as the hub for developing next-generation drugs in various 
fields such as biopharmaceuticals and small molecules. 
In addition, the establishment of the new 60,000L Plant 3 
is expected to enable a more stable supply of drugs. With 
the expansion of core infrastructure, Celltrion will have 
enhanced capacities to respond proactively to the rapidly 
growing global demand for biopharmaceuticals while further 
strengthening R&D and production capabilities.
* As of the end of December 2022
Expanding R&D and  
Production Infrastructure
ISSUES - 03
PERFORMANCE
Ratio of R&D employees
32.1% 
R&D-to-revenue ratio
18%
Annual small molecule  
production capacity 
5billion tablets 
Annual biopharmaceutical  
production capacity 
252,000L
(scheduled for 2023)
Celltrion ESG Report 2022/23
31
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Bird’s-eye view of the Celltrion Global R&D Center
Expanding R&D Infrastructure
Opening of Celltrion Global R&D Center
As a leading integrated pharmaceutical company, Celltrion is 
investing approx. 20% of its annual revenue in R&D for new 
antibody drugs and expansion of the pipeline. To strengthen fur-
ther R&D capabilities, we decided to build Celltrion Global R&D 
Center on our research institute site in Songdo International City, 
Incheon, where our headquarters is currently located. Approval 
for use of the Center was obtained in January 2023. Built on an 
area of 10,033㎡ with one basement floor and six ground floors, 
the Center can accommodate up to 2,000 researchers in the 
future.
It will facilitate efficient research across all pharmaceutical fields, 
from biopharmaceuticals to small molecules research, all in one 
location. With this, Celltrion will be able to continue research and 
development of not only biopharmaceuticals and small mole-
cules, which are Celltrion’s primary focus areas, but also ADCs, 
bispecific antibodies, platforms, and microbiomes, which are 
currently in the spotlight. Celltrion Global R&D Center, a new 
pharmaceutical R&D hub, will strengthen R&D capabilities fur-
ther and consolidate its position as a total healthcare research 
institute.
Celltrion ESG Report 2022/23
32
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Expansion of Biopharmaceutical Production Infrastructure
Celltrion has secured a total biopharmaceutical production capacity of 270,000L per year by leveraging its own domestic production 
plants and overseas CMOs. The biopharmaceutical production plant in Songdo, Incheon, was the first in Asia to obtain the US FDA’s 
cGMP certification for animal cell culture facilities. The plant can produce both drug substances and drug products. Plant 1 and Plant 2 
have a production capacity of 102,000L and 90,000L, respectively. Plant 3, with a capacity of 60,000L, will be completed in 2023 with a 
multi-variety production and supply system. Plant 3 is constructed near Plant 2 over an area of 68,900㎡ with five above-ground floors. 
It will have the latest facilities, including 8 units of 7,500L incubators, to respond more flexibly to the demand for biopharmaceutical pro-
duction. Once Plant 3 is completed, Celltrion will secure the capacity to produce a total 252,000L of biopharmaceuticals per year. We 
will continue expanding our production plants to meet the growing demand for biopharmaceuticals.
Plant 3 (scheduled)
•7,500 L × 8 units
•To be completed in 2023
Plant 2
•15,000L × 6 units
Plant 1
•12,500 L × 8 units
•1,000 L × 2 units (SUP)
CASE
Total Production 
Capacity
252,000 L
90,000 L
60,000 L
102,000 L
Celltrion ESG Report 2022/23
33
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

ENVIRON-
MENTAL
Environmental Management
35
MAKE THE PLANET GREENER
We spare no efforts in terms of investment and research to preserve the earth’s environment for future generations.

The climate crisis is a major challenge facing humankind 
and has already caused a wide range of impacts on every 
aspect of our lives.
Efforts for responsible management are required globally 
to minimize environmental impacts throughout  
a company’s business operations.
Celltrion recognizes that preserving the earth’s 
environment and complying with environmental laws 
and regulations are indispensable parts of corporate 
activities. We are exerting systematic efforts to respond 
to climate change at an enterprise level.
ENVIRONMENTAL 
MANAGEMENT
ENVIRONMENTAL - 01
Celltrion ESG Report 2022/23
35
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Environmental Safety and Health Policy
Celltrion is committed to ensure compliance with laws, regulations, and procedures related to en-
vironment, safety, and health and manage them at a level higher than legal requirements. We have 
established an Environmental Safety and Health (ESH) Policy to build trust with various stakeholders 
and ensure sustainable management by fulfilling our responsibility for environmental protection and 
conducting eco-friendly corporate activities.
Basic Principles of Environmental Management
Environmental Safety and Health Policy
risks and strive for sustainable environmental management. Going forward, Celltrion will gradually 
expand its environmental management scope to meet social demands in the area, such as ESG 
management and carbon neutrality, which have recently emerged as hot issues, by setting and 
implementing resource, environment, and energy improvement goals and tasks for all departments 
through the environmental management system certification. In addition, we will maintain the envi-
ronmental management system certification to ensure zero environmental accidents and strict com-
pliance with laws and regulations.
Since 2020, Celltrion has been operating a dedicated organization to implement an environmental 
management system (ISO 14001) and conducting risk and environmental impact assessments. We 
obtained ISO 14001 certification through an audit on the environmental management system in De-
cember 2020.
Since then, we have been conducting annual follow-up audits to assess and monitor environmental 
Environmental Management System
Environmental Management Policy
Celltrion has an enterprise-level organization dedicated to environmental management. This orga-
nization is responsible for establishing and running an environmental management system and en-
suring compliance with environmental laws and regulations. In addition, we fulfill our organizational 
roles and responsibilities for environmental management systematically by dividing tasks such as 
establishing environmental goals for each organization, evaluating them, and providing support as 
needed. The CEO reviews and approves environmental management issues, including environmen-
tal management policies and allocation of human and material resources to support the operation of 
the environmental management system. In August 2022, the ESG Committee was established un-
der the BoD to address major environmental management issues, including strategies to respond to 
climate change. Environment-related agenda items and progress in responding to climate change 
are reported to the ESG Management Council (CEO) as necessary. We are strengthening our sus-
tainable management system and capabilities, which include developing strategies and detailed 
implementation tasks for responding to climate change.
Environmental Management Organization
① Comply with domestic and international environmental laws and regulations and apply 
stringent internal management standards.
② Establish and operate an environmental management system in accordance with  
international standards.
③ Strive to improve the environment continuously.
④ Assess the potential for enhancing the efficiency of the environmental management  
system on a regular basis.
⑤ Disclose the principles and performance of environmental management practices to  
internal and external stakeholders of the company to raise their awareness.
⑥ Provide regular environmental training programs to employees and key suppliers so that 
they can understand and implement the environmental management system and try to 
minimize adverse impact on the environment.
Environmental Management Organization
CEO
Head of Unit in Charge of Environmental 
Management (Head of Administration Unit) 
Head of Division in Charge of Environmental 
Management (Head of Administration Division)
Environmental Management Leader  
(Head of Safety Management Department)
Environmental Management Leader  
(ESH Team 2 Leader)
Environment manager in each area
Water environment manager  
(Wastewater treatment/Wastewater treatment facility)
Atmospheric environment manager  
(Air pollution prevention facility)
Waste treatment manager  
(Waste treatment)
Celltrion ESG Report 2022/23
36
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Environmental Management Strategies
Eco-friendly Investment
ESH Risk Management
In response to the rapid global transition towards eco-friendly energy to mitigate climate change 
risks, Celltrion is actively making eco-friendly investments to save resources, such as initiatives to 
enhance energy efficiency and adopt new and renewable energy. The cost of eco-friendly invest-
ment is calculated considering expenses related to energy saving, response to climate change, 
outsourcing of waste and wastewater treatment, investment to improve pollutant generating/pre-
venting facilities, and various taxes and levies. The cost of energy saving and climate change miti-
gation encompass various expenses, such as replacing equipment with highly efficient alternatives, 
installing LED lighting, and purchasing carbon credits. Furthermore, investments aimed at improving 
pollutant-generating/preventing facilities involve enhancement of boilers and their operations, which 
emit air pollutants, and wastewater treatment facilities. As of 2022, Celltrion’s total eco-friendly in-
vestment is KRW 1.4 billion.
Green Management 
for Clean Future Environment
Vision
Celltrion has implemented the ESH emergency response process to identify potential emergencies 
and accidents that may have significant impact on environmental safety and health and to minimize 
damage by appropriately operating response plans in the event of an accident. The ESH emergency 
response process aims to identify types of environmental, safety, and health emergencies, develop 
action scenarios by type, conduct emergency drills, report the results, and take supplementary and 
improvement actions. We conduct drills based on various emergency scenarios at least twice a 
year. In addition, we evaluate the results of emergency drills and reflect them in planning future drills, 
and use the information for improving the emergency response process.
·	 Establish a systematic environmental management system
	 - Assess compliance with environmental laws and regulations and monitor changes on  
a regular basis
	 - Establish an annual list of environmental agencies and engage in environment-related tasks  
that require interactions with relevant environmental agencies
·	 Environmental improvement activities
	 - Establish standards for resource and energy savings to reduce unnecessary consumption,  
and implement an ongoing monitoring system 
	 - Conduct environmental impact assessments when establishing new factories or  
introducing new equipment
·	 Efforts to reduce pollutant emissions
	 - Establish self-management standards that are stricter than the permissible emission levels  
and implement continuous monitoring procedures
	 - Establish and implement annual environmental goals at both an enterprise level and  
for each department
Tasks
Goals
No environmental 
accidents
No violations of 
environmental laws 
and regulations
Reduce the intensity 
of environmental 
pollutant emissions 
ESH Emergency Response Organization
Emergency Command Center  
(Head of Production Management Unit)
Emergency Control Center  
(Head of Administration Unit)
CEO
Command Team 
(Head of Facility 
Engineering 
Department)
Guard Team 
(Security Team)
Firefighting 
Team (Facility 
Operation Team)
Control Team
(Safety 
Management 
Department)
Operation 
Action Team 
(BMS Operation 
Officer)
Contact Team 
(EHS Team)
Lifeguard 
Medical Team 
(Health Manager)
Government agencies/press offices/medical institutions/  
firefighting support team/nearby companies 
Celltrion ESG Report 2022/23
37
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Climate Change Response
Climate Change Response Strategy
Celltrion initiated proactive response to the challenges of climate change and its impact on financial 
information by joining the Task Force on Climate-related Financial Disclosures (TCFD) in January 
2023. As a member of TCFD, Celltrion takes a leading role in addressing climate change by imple-
menting systematic risk management practices in line with TCFD’s recommendations.
Governance
Celltrion’s BoD manages and oversees environmental management activities to strengthen re-
sponse to climate change and fulfill our social responsibility to protect the environment. The ESG 
Committee, under the BoD, the top decision-making body for ESG management, checks the prog-
ress and performance of the climate change agenda items. In addition, working-level departments 
are in charge of establishing and operating the environmental management system. In particular, 
in addition to establishing the ESG Committee, we identified detailed improvement tasks through 
ESG-level diagnosis. Based on these activities, we will raise employees’ awareness of the climate 
crisis and take the lead in implementing actions to respond to climate change. In the future, we plan 
to participate actively in climate change response by constantly checking and analyzing climate 
change goals and performance.
Strategy 
With the adoption of the Paris Agreement in 2015, the global community has recognized climate 
change as a critical issue. In order to respond proactively to climate change, Celltrion is also setting 
response strategies by reviewing and addressing internal and external uncertainties. We categorize 
various risks related to the environment and conduct monitoring and control activities by risk type. 
Through these activities, we will continuously manage risks related to climate change.
Risk Management
Celltrion continuously monitors international trends, such as laws and regulations related to climate 
change, to identify risks and opportunities. In addition, we identify and assess the relative impor-
tance of risks by item through a series of processes such as identifying, assessing, monitoring, and 
establishing countermeasures for climate change issues. The BoD makes a final review of financial 
and non-financial risk responses and systematically manages corporate-wide climate change risks.
GHG Reduction Targets and Indicators
Celltrion was designated as a company subject to GHG Target Management in 2012 and as a 
company subject to the allocation of emissions allowances under the Emissions Trading Scheme in 
2015. Accordingly, we have completed GHG inventories at all of our business sites and are leverag-
ing the GHG Emissions Trading Scheme guidelines for emissions reporting and certification as an in-
dicator. Each year, we get our GHG emissions (Scope 1 and 2) and energy consumption verified by 
a third party and disclose related data in our GHG verification statement. In addition, we plan to set 
reduction targets and review and manage performance continuously to respond to climate change 
risks and opportunities that may arise throughout our business activities.
Risk Type Category
Risk Factors
Opportunity Factors
Physical 
Risks
Acute
· Increased frequency and intensity of 
climatic events such as typhoons, 
floods, and wildfires.
· Strengthening climate change-related  
infrastructure across business operations
Chronic
· Long-term changes in climate 
patterns leading to increase in sea 
levels, average temperatures, etc.
· Reinforce risk response manuals in preparation  
for long-term climate changes to produce 
products and offer services smoothly
Transition 
Risks
Policies  
and Laws
· Increased price in ETS and  
stricter carbon regulations
· Tighter environmental disclosure 
standards
· Sell carbon credit surplus through reduction of 
GHG
Technology
· Shift to eco-friendly, low-carbon 
technology
· Reinforce technology investment to 
improve energy efficiency and reduce 
emissions
· Improve Celltrion’s image as an eco-friendly 
company by prioritizing eco-friendly product 
packaging and service development 
· Reduce GHG emissions and energy consumption 
by utilizing newly constructed facilities
Market
· Change in consumer behavior
· Increased uncertainty due to the 
changing market conditions
· Expanded business areas following changed 
consumer perceptions and customers’ behavioral 
patterns related to climate change
Reputation
· Growing demand for ESG information
· Change in investor and stakeholder 
preferences
· Enhance competitiveness through various ESG 
communication channels
· Develop and offer services that reflect customers’ 
preferences
Risk and Opportunity Analysis
Celltrion ESG Report 2022/23
38
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Energy Consumption Management
Celltrion continuously implements energy-saving activities by replacing old equipment, improving 
equipment operation methods, turning off every other light, and operating air conditioners in pow-
er-saving mode. In the case of Plant 2, we installed a small-capacity (2-ton) once-through boiler, which 
was planned from the design phase, in order to reduce energy consumption and reduce unnecessary 
boiler operation by controlling the number of boilers operated based on the required load. Over the 
period from 2020 to this year, we have replaced all the boilers with new ones to address aging issues. 
In addition, we have improved the operation method by adjusting the boiler air ratio and reducing the 
loss at the cooling water pump valve shaft by reflecting the results of energy diagnosis. Furthermore, 
we have been able to reduce energy consumption by turning off every other light in the machine room 
and corridors and intermittently stopping the HVAC system operation in the office space every year. In 
recognition of such energy-saving efforts, Celltrion received certification as a “Korea Energy Champi-
on” from November 28, 2017 to November 27, 2020, by the Korea Energy Agency.
Category
2020
2021
2022
LNG
357
379
415
Gasoline
2
3
3
Diesel
0
0
0
Electricity
706
736
738
Total
1,066
1,118
1,155
Sales (KRW 100 million)
18,493
18,934
22,840
Intensity of Energy Consumption (TJ/ KRW 100 million)
0.06
0.06
0.05
Energy Consumption (Unit: TJ)
GHG Emissions Management 
Since Celltrion was first designated as a company subject to GHG Target Management in 2012, 
we have established GHG inventories at all GHG emission facilities within our business sites. Since 
2015, we have been designated as a company subject to the allocation of carbon credits under the 
Emissions Trading Scheme, and have strictly complied with the allocated credits by conducting ac-
tivities to reduce GHG emissions each year and purchasing external carbon credit. To manage GHG 
emissions efficiently, we maintain a monthly GHG inventory and compare and analyze it against the 
allocated amount to establish a plan for GHG reduction and carbon credit purchase. We submit a 
third-party verified GHG emissions statement to the Ministry of Environment every March and dis-
close GHG data transparently through annual reports and environmental information. Despite our 
continued efforts to reduce GHG emissions, Celltrion has experienced a slight increase in emissions 
each year. However, our GHG emission intensity per unit of sales decreased significantly in 2022
Category
2020
2021
2022
GHG Emissions
Direct emissions (Scope 1)
18,297
19,402
21,219
Indirect emissions (Scope 2)
34,306
35,213
35,299
Total
52,602
54,615
56,518
Sales (KRW 100 million)
18,493
18,934
22,840
GHG Emission Intensity (tCO2eq/ KRW 100 million)
2.84
2.88
2.47
GHG Emissions (Unit: tCO2eq)
Response to Climate Change
Celltrion continues to implement its energy-saving activities as part of its environmental manage-
ment practices. We are reducing GHG emissions by operating the HVAC system in the power-saving 
mode, turning off lights, and utilizing new energy-efficient factory facilities. Thanks to such efforts, 
Celltrion was designated as an excellent environmental management company by City of Incheon. 
All Celltrion employees participate regularly in community councils and various networks dedicated 
to environmental management. At the ‘2022 Climate Change Response Day’ event, which was held 
in recognition of the seriousness of the climate crisis and to reduce GHG emissions, we handed out 
eco-friendly goods and explained the meaning of environmental protection to citizens who visited 
our booth in order to encourage their participation in environmental protection activities.
Climate Change Response Day
Celltrion ESG Report 2022/23
39
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Management of Water Resources 
Celltrion’s Plant 1 and Plant 2 have individual wastewater treatment facilities. Wastewater generated 
from production processes, research institutes, and utility facilities is processed through physical, 
chemical, and biological treatments before being discharged to the terminal sewage treatment facil-
ity. Until 2021, we measured the contamination level of untreated water and discharged water every 
hour using an automatic COD meter. However, starting in 2022, we have installed an automatic TOC 
meter and now monitor the levels every 30 minutes in accordance with the revised Water Environ-
ment Conservation Act. In addition, we conduct monthly water analysis in our in-house laboratory. 
Regarding specific water pollutants, we request external accredited analytical institutions to con-
duct thorough quality check on untreated water and discharged water once every six months for 
Plant 1 and once every three months for Plant 2. Celltrion operates wastewater treatment facilities at 
each of its plants in compliance with environmental laws and regulations related to the discharge of 
water pollutants, and manages wastewater at a level within 40% of the legally permissible standard 
by setting stricter internal standards than the permissible discharge standard. In addition, highly 
contaminated laboratory wastewater and wastewater generated after pipe cleaning are not treated 
at our in-house wastewater treatment facilities but by a professional treatment company.
Celltrion is reviewing various environmental improvement issues related to ESG man-
agement. As part of our efforts to reduce GHG emissions, we made sure to purchase 
eco-friendly vehicles such that they constituted more than half of the newly ordered ve-
hicles in 2022. Celltrion is considering the gradual replacement of its corporate vehicles 
with eco-friendly vehicles1). For this, we are actively participating in the government’s 
‘Targeted Purchase of Eco-friendly Vehicles’ policy to improve the environment through 
energy savings and the use of alternative energy. In addition, we have plans to install more 
EV chargers than required by the law in the underground parking lot of the new Research 
Center and to actively encourage employees to use eco-friendly vehicles by expanding 
electric vehicle charging infrastructure in the future. 
1) Electric, solar, hybrid, and fuel cell electric vehicles
* 12 out of 22 vehicles purchased in 2022 (9 hybrid vehicles and 3 electric vehicles)
** Installation of charging stations in the Research Center (6 are mandatory, 10 will be installed)
Operation of Eco-friendly Vehicles and Installation  
of EV Charging Stations 
CASE 1
Celltrion ESG Report 2022/23
40
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Management of Waste and Pollutants 
Air Pollutants Management
Since 2015, Celltrion has been gradually replacing boilers, which emit air pollutants, with low-NOx 
burner boilers that prevent the emission of air pollutants more effectively. In 2022, we completed 
replacement of all boilers with low-NOx burner boilers. We sign annual maintenance contracts with 
boiler companies and ensure the optimum efficiency in operating the boilers through regular inspec-
tions, thereby reducing unnecessary energy consumption and air pollutant emissions. We manage 
nitrogen oxides (NOx), sulfur oxides (SOx), and particulate matter (PM) through semi-annual mea-
surements conducted by an external accredited analytical agency. Celltrion, operating under a total 
emission control system, submits relevant data on air pollutant emissions (NOx) to the government 
every month and purchases additional credits from other companies, if necessary, to ensure strict 
compliance with the emission quota.
Accelerating Circular Economy
Convert to Eco-friendly Packaging Material for Resource Circulation
In 2022, Celltrion completed a multi-disciplinary review to develop packaging materials and designs 
reflecting trends in eco-friendly packaging for pharmaceuticals, and will implement related plans in 
the first half of 2023. For the nine tertiary packaging boxes used to transport medicines, we have 
identified new suppliers to change the material from conventional base paper to FSC-certified base 
paper sourced in a sustainable manner that conserves forests. We have decided to discontinue the 
use of HDPE/LDPE cushioning materials used for protecting medicines within tertiary packing box-
es. Instead, we will be adapting 100% LDPE alternatives, which is biodegradable. In addition, we 
have changed the packaging design for two medicines that used to be packaged in plastic trays to 
paper dividers; and applied packaging design that uses only paper to new projects, without using 
plastic and increasing recyclability of resources. Celltrion will stay committed to continuous research 
and development to improve the eco-friendliness of pharmaceutical packaging once we implement 
the eco-friendly packaging transition plan in 2023.
Waste Generated (Unit: ton, %)
Category
2020
2021
2022
Waste generated
General Waste
1,569
1,610
1,880
Hazardous waste 
201
213
211
Total waste generated
1,771
1,822
2,090
Processed waste
Waste recycled 1)
912
984
1,145
Incinerated (outside)
857
838
943
Landfilled (outside)
-
-
-
Others 2)
1.4
-
2.0
Total waste processed
1,771
1,822
2,090
Rate of recycling waste (%) 3)
52
54
55
1) Recycled amount (Sludge from wastewater treatment, waste activated carbon, waste oil, waste organic solvent solids)
2) Other treatment methods include the evaporative concentration of waste acid and alkali among designated wastes
3) Waste recycled / Total waste processed 
Waste Management
Celltrion manages waste by establishing a Waste Management Policy that aims to minimize the 
amount of waste generated throughout manufacturing activities, from production to disposal, and 
to recycle and reuse waste as much as possible. Waste generated across all business sites, includ-
ing production processes and offices, is classified into general, hazardous, and medical waste, and 
all employees participate in the classification of waste. The discharged waste is managed in accor-
dance with the Waste Management Act after being reclassified at the in-house waste storage based 
on the nature of the waste. Among general wastes, wastewater treatment sludge generated from 
the wastewater treatment process is being fully recycled and used as raw materials for cement man-
ufacturing since 2015. Waste oil and solid wastes that can be recycled among hazardous wastes 
are being recycled and reused from the initial discharge to the present. Medical wastes are classified 
into pathological and damaging wastes according to their nature and are stored in special contain-
ers and processed by a specialized company. With regard to the disposal of final products, the qual-
ity department directly oversees the treatment process, ensuring that they are properly incinerated.
Waste Management Policy
Celltrion ESG Report 2022/23
41
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Biodiversity
Biodiversity Policy
Celltrion has established a company-wide Biodiversity Policy to preserve the diversity of life on Earth, 
its ecosystems, and genetic diversity, and follows a Deforestation Prohibition Policy to support for-
est protection activities to combat climate change. We encourage the stakeholders we work with to 
comply with our Biodiversity Policy, minimize the environmental impact on biodiversity throughout 
our operations, and value nature and protect it for future generations. Celltrion actively complies with 
international conventions on the protection of biodiversity and land, and will continue to identify bio-
diversity risks in our operations through environmental impact assessments to ensure conservation 
and enhancement of biodiversity.
Biodiversity Policy
Deforestation Prohibition Policy
  
Activities for Biodiversity Preservation
Celltrion recognizes that many medicines we use contain ingredients derived from plants and ani-
mals. We are also aware that the preservation of biodiversity is crucial for the survival of our species.
We strive to minimize the emission of pollutants by thoroughly purifying the water used in our pro-
duction process before discharging it. In addition, to help protect local marine ecosystems, we 
sponsor non-profit organizations working on biodiversity conservation, and our employees partic-
ipate actively in volunteer activities. As the main sponsor of the ‘Blue Siren Ocean City Plogging for 
the 2030 Busan World Expo’ organized by Busan City, we promoted the importance of preserving 
marine biodiversity and participated in clean-up activities along the coastal belt and nearby city ar-
eas with more than 60 employee volunteers. 
A plogging event
Chemical Management 
Celltrion has established a Chemical Safety Management Policy to ensure compliance with do-
mestic and global laws and global standards for chemicals, protect the safety of relevant personnel 
and minimize environmental risks. We apply relevant laws and regulations such as the Chemical 
Substances Control Act, Act on the Registration and Evaluation of Chemical Substances, and the 
Dangerous Goods Management Act to the entire process of introducing, using, and disposing of 
hazardous chemicals in order to ensure the health and safety of employees and local communities.
In the case of new chemicals, we conduct a preliminary safety review through the Material Safety 
Data Sheet (MSDS) before reporting the new chemicals to the Ministry of Environment for approval. 
We continuously strive to minimize the amount of hazardous chemicals handled by recording the 
amount used and received on a real-time basis in the management ledger and monitoring the per-
formance annually. To prevent the leakage of hazardous substances, we have installed monitoring 
and control systems (leakage detectors and CCTVs) at chemical handling facilities. In addition, we 
provide safety equipment at each facility for immediate initial response. Celltrion provides training on 
the proper use of chemicals and management of safe facilities to employees and suppliers, including 
those who directly handle hazardous chemicals at manufacturing plants, as well as in-depth training 
on wearing safety equipment, using material safety data sheet, and initiating emergency responses 
to raise employees’ safety awareness and ensure safety at business sites.
Celltrion has received approval from the Ministry of Environment for its chemical accident prevention 
management plan, which is superior to similar plans adopted by peers, and will continue internal 
inspections and implementation of related tasks on a yearly basis to build a safety management sys-
tem, including special training for employees on chemicals and self-inspection.
Chemical Safety Management Policy
Celltrion ESG Report 2022/23
42
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

SOCIAL
Talent Management
Human Rights Management
Safety and Health Management
Customer Satisfaction Management
Social Contribution
44
50
55
60
64
SHARE WARM VALUE
We want to create “warm” value through generating good influence all over the world.

TALENT 
MANAGEMENT
SOCIAL - 01
As a leader in the Korean pharmaceutical industry,  
Celltrion has laid the foundations to nurture creative talents 
with the spirit of inspiring others to showcase  
their capabilities regardless of social prejudices.
We provide customized, in-depth training for each 
department and have established a management system 
where each employee can pursue growth while contributing 
to a sustainable future for the company.
We also support employees’ work-life balance by operating 
an in-house daycare center and adopting a flexible work 
system, and strive to create a healthy corporate culture by 
listening to employees’ opinions through the ‘Tongnamu 
(Communication Tree)’ communication channel, where the 
CEO replies directly.
Celltrion ESG Report 2022/23
44
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Talent Recruiting
Celltrion is creating jobs and attracting talents to develop the biosimilar business, expand pipelines, 
and reinforce competitiveness in the small molecule business. The total number of employees in-
creased from 2,111 in 2019 to 2,158 in 2020, followed by 2,207 in 2021 and 2,263 in 2022. As of 
2022, the proportion of full-time employees was 93.7%, and that of R&D staff was 32.1%, contribut-
ing to the creation of quality jobs. In the future, we plan to increase employment and pursue continu-
ous growth simultaneously, through projects such as Plant 3 and research center construction.
Talent Acquisition 
2021
2,207
2020
2,158
2022
2,263
2021
701
2020
648
2022
727
R&D staff 
2021
2,074
2020
2,041
2022
2,120
full timers 
Total number of employees (Unit: person)
2021
337
2020
261
2022
366
New recruitment
93.7%
32.1%
67.9%
Regular Employment Ratio
93.7%
Ratio of R&D Employees 
32.1%
6.3%
Celltrion ESG Report 2022/23
45
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Specialized Vocational Training
Specialized Vocational Training
Celltrion operates specialized vocational training courses to help employees enhance their job ex-
pertise. In particular, we provide advanced vocational training related to manufacturing and R&D 
that is directly or indirectly linked to the work handled by each department (R&D, Production, Qual-
ity, etc.). In 2021, we held a total of 13 specialized vocational training sessions with lecturers from 
external specialist institutes such as Thermofisher Science, a biopharmaceutical company. A total 
of 357 production and R&D employees completed specialized vocational training. Especially, we 
are expanding the base for scale-up in the latest purification technology and single-use culture pro-
cesses applied in bioprocessing. Furthermore, we are reinforcing training to expand expertise in cell 
line identification and genome analysis related to next-generation gene sequencing. As such, we are 
enhancing our understanding of future technological trends by field and reinforcing our employees’ 
expertise in the overall pharmaceutical sector: the latest trends in the development of biopharma-
ceuticals and biosimilars, industry landscape, production trends, aspects to be considered while 
applying for approval, and process development timeline. We suspended training in 2022 due to 
COVID-19, but we plan to help employees enhance their job expertise by resuming training in 2023.
E2 Basic Vocational Training
Celltrion continually monitors the rapidly-changing biopharmaceutical manufacturing technology 
and trends. As part of efforts to improve job expertise of all employees, Celltrion provides newly 
hired E2 (Manufacturing) employees with training to nurture and develop essential job competen-
cies, in areas such as manufacturing and quality management. We segmented the increasingly di-
verse expertise in the pharmaceutical industry by training items related to individual jobs depending 
on the characteristics of each department, with a focus on vocational  training by organization (e.g., 
divisions, departments), external vocational training related to biopharmaceuticals, and professional 
training at the GMP Academy. In addition, employees are required to complete assigned training 
and obtain qualifications to strengthen work expertise across the company. We manage training 
systematically by requiring employees to complete training within four years of joining the company 
and three months before the first promotion. As of the end of December 2022, 223 employees com-
pleted the E2 basic vocational training and attended a total of 14,210 hours of training to obtain the 
qualifications required for promotion.
Competency Development Program
To enhance employees’ roles, Celltrion supports them to strengthen their skills and knowledge while 
obtaining specialized technology and a broader knowledge base related to manufacturing phar-
maceutical products. In particular, we continuously provide vocational training for manufacturing 
employees to enhance their skills in the pharmaceutical manufacturing area. All of the new hires in 
the production part - 281 employees in 2019, 286 in 2020, 366 in 2021, and 96 in 2022 - complet-
ed the vocational training. In addition, we continue to identify bio-related technologies and industry 
trends and provide continuous training programs, such as training by invited instructors and online 
job training provided by outside service providers.
Nurturing Talent
Completed E2 Basic Vocational Training 
223 Employees
The E2 Basic Vocational Training hours
Total14,210
Category Production
R&D
Quality
Topic
· Culture technology related to 
peptone protein
· Cell line identification method 
using Sanger sequencing 
technology
· Analysis of animal cells and 
proteins for the production of 
biopharmaceuticals
· Purification technology to be 
applied to the next-generation 
antibody therapeutics
· NGS (Next Generation 
Sequencing)
· Situation and trends related to 
biopharmaceuticals
Celltrion ESG Report 2022/23
46
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Pursuit of Work-life Balance
Celltrion provides a variety of work types and systems to enable employees pursue work-life balance 
actively. We encourage employees to take a leave the day before or after a holiday so that they can 
take time off for several days at a stretch;  and grant special leaves to those who have completed 10, 
15, and 20 years of service. In addition, in order to help employees maximize their work efficiency 
through work-life balance, we operate various systems, including compliance with statutory working 
hours, a flexible work system, recruitment of substitutes for employees on maternity and childcare 
leave, and promote the use of leave. In particular, with the flexible working system, we allow employ-
ees to choose and use working hours and structure hours freely: selective working hours, alternative 
leave system, flexible working hours, and recognized working hours to improve their work-life bal-
ance and the efficiency of manpower utilization.
Creating a Family-friendly Working Environment
Celltrion strives to create a family-friendly working environment as we aim to remain a company 
where employees’ families are happy. We have an in-house childcare center, a childcare service, a 
maternity lounge for pregnant employees, adjustable working hours, congratulatory allowance for 
childbirth, maternity gifts, pre- and post-natal leave, childcare leave, spousal leave for childbirth, 
multiple birth leave, infertility leave, and shortened working hours. In addition, we have designated 
a pink parking zone for pregnant employees in all parking areas in Plant 1, Plant 2, and the office 
building. We provide support for children’s tuition and medical expenses to ease the burden due to 
educational and medical expenses, and encourage employees to take family care leave or leave of 
absence if they need to take care of their family, thereby promoting work-life balance of our employ-
ees.
Respect for Diversity
Celltrion has been laying the foundations to establish a culture where employees are respected. We 
strictly  prohibit discrimination based on gender, race, age, disability, religion, etc., and are creating 
a culture where people with diverse backgrounds and mindsets can reach their full potential. Every 
year, we provide mandatory training on prevention of sexual harassment, prohibition of workplace 
harassment and disability awareness for all employees, and we guarantee equal pay for equal-value 
work for all women and men, including youths and the disabled. In particular, we support women’s 
social participation and economic opportunities by assigning proper value to their labor.
Diversity in Workplace (As of the end of December 2022)
Fair Evaluation and Compensation
Celltrion operates a performance evaluation system that emphasizes collaboration between col-
leagues and departments, rather than encouraging excessive competition between individuals.
To do so, our evaluation system is comprised of three levels (special / outstanding / good) without 
any negative grade. Moreover, collaboration among colleagues and departments – as well as in-
dividual performance – is included as a crucial evaluation factor. Through our positive evaluation 
system, we select a certain percentage of employees who have shown outstanding performance in 
the current year so that evaluation may have a positive impact on corporate culture and employees’ 
morale. In order to ensure fair evaluation, we developed detailed standards and guidelines for each 
process of goal setting, mid-year review, and year-end evaluation and interview; we also distribute 
training manuals and guidebooks to enhance the employees’ self-evaluation capabilities, and con-
duct continuous HR inspection activities. We also operate a performance-based compensation 
system that links these performance evaluation results to compensation, as well as an annual salary 
system that determines the next year’s annual salary increase based on the results of the employ-
ees’ evaluation. Furthermore, we also operate a Profit Sharing (PS) system by which the company 
shares its profit with employees in order to emphasize the importance of collaboration among em-
ployees. Thus, not only individual performance but the entire company’s performance is also reflect-
ed in individual compensation.
Corporate Culture
Ratio of Female Employees
42.6%
Average Age of Employees
32.7 years old
Ratio of Remuneration of 
Women to Men
 100%
Celltrion ESG Report 2022/23
47
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Welfare Benefit System
Family
Celltrion aims to create a work environment where work-family balance can be maintained, and op-
erates an in-house daycare center for employees’ young children. We also provide financial support 
for children’s tuition fees and special education expenses for children with disabilities. In addition, we 
provide benefits such as rental of Yeongbingwan - a guest house designed to host VIPs - for family 
events, support with transportation expenses for unmarried employees to visit their home outside 
the metropolitan area (including overseas), and support for family events.
Health Management
Celltrion is committed to taking care of the health of our employees who spend most of their time at 
the company. We provide group accident insurance for our employees and operate a medical ex-
pense support system, which is not only for employees themselves, but also for their spouses and 
children. We also provide regular medical examinations to check their health status, and operate 
an in-house nurse’s office and a posture correction education program to ensure that employees 
receive the support they need to take care of their health. In addition, we operate a cafeteria with a 
dietitian-managed menu to ensure a balanced diet for our employees. Considering the 24/7 opera-
tion of the plants, we provide five meals a day to help employees maintain a healthy diet.
Convenience of Life
Celltrion operates a selective welfare system that allows employees to plan their welfare benefits 
autonomously based on their personal preferences. Celltrion provides dormitories for new hires to 
ensure a smooth onboarding experience. In addition, we operate commuter buses with a total of 
18 routes to enhance commuting convenience for employees living in the Seoul Metropolitan Area. 
Celltrion also operates an optional welfare system that allows employees to select and use the wel-
fare benefit they want in real life by giving them cash-equivalent welfare points.
Leisure Activities
Celltrion supports employees to pursue various leisure activities outside of work. We actively en-
courage employees to enjoy hobbies and socialize with each other through in-house clubs and 
support their cultural activities through in-house cultural experience classes held once a month and 
an e-library that is always open. Through partnerships with hotels and resorts, we allow our employ-
ees to use their services at a membership discount price. In addition to accommodation discounts, 
we also have established partnerships with restaurants, sports facilities, and beauty shops near the 
company, allowing employees to use such services at a discounted price.
Employee Engagement
Organizational engagement is the attitude expected of employees to accept the goals and values 
of an organization and strive for its development, acting as a source of organizational progress. We 
planned and conducted an engagement survey to assess whether we are building a highly pro-
ductive organizational culture where employees have ample opportunities to accomplish personal 
growth through their work. Following a pilot test of organizational engagement among members of 
the ESG T/F in 2022, we surveyed all our employees. The results will be used to improve organiza-
tional engagement among the employees and create a great corporate culture to work. We conduct 
the engagement survey annually to listen to employees’ opinions and improve work productivity.
Employee Engagement Survey Results
 55%
Employee Engagement Goal
 50%
Celltrion ESG Report 2022/23
48
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Operation of Labor-management Council
Celltrion has established a labor-management relationship based on trust and mutual cooperation 
and a healthy and developing corporate culture. The stable labor-management relationship and 
healthy corporate culture serve as the foundation for the company’s further growth and development 
and are the driving force for achieving high competitiveness. The operation of our internal “Employee 
Council” (Labor-management Council) serves as an opportunity for the labor and management to 
work together to improve the welfare and work environment for employees, and contributes to the 
development of the company based on employees’ grievances and free suggestions. The Employee 
Council Agreement applies to entire employees, and all employees at each business site participate 
in electing members representing the workers’ side. Currently, three labor side council members are 
active at their respective sites, and regular meetings are held with management side council mem-
bers on a quarterly basis to actively discuss issues such as improving the working environment and 
welfare benefits, enhancing productivity and work engagement, and vitalizing the organization and 
promoting communication.
Labor Management
Operation of Communication Channel Tongnamu (Communication Tree)
Celltrion recognizes that providing a pleasant office environment where employees can concen-
trate on their work is the way forward for both labor and management. Since August 2018, we have 
operated a communication channel called “Tongnamu,” where the CEO responds to employees’ 
grievances and opinions within two weeks. Through the system, we listen to employees’ grievances 
and opinions to ensure no employee is left out of the communication loop. In 2022, a total of 514 
proposals were received, including improvements to the company’s HR and welfare benefit system 
and amenities. We took improvement action on the entire items suggested. This way, the stable 
labor-management relationship has served as a positive factor in the evaluation of the company by 
external stakeholders. We will continue our efforts to maintain stable labor-management relations 
and grow further based on mutual trust.
No. of Proposals Received  
through Tongnamu
514 cases
Celltrion ESG Report 2022/23
49
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

HUMAN RIGHTS 
MANAGEMENT
SOCIAL - 02
Celltrion strives to ensure respect for the fundamental 
rights of all stakeholders, including employees,  
by proactively identifying various human rights violations 
guided by our management philosophy of prioritizing 
human rights.
To manage and prevent human rights risks, we conduct 
human rights surveys for all our employees and monitor 
potential risks.
We also take care of our employees’ mental health 
by providing education on the prevention of sexual 
harassment and workplace harassment, and by running 
our own online mental health checkup program to promote 
human rights awareness.
Celltrion ESG Report 2022/23
50
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Celltrion puts human rights first in our business philosophy and respects the human rights of all 
its stakeholders. In 2022, we established our own human rights policy to ensure that it is followed 
at all our business sites and suppliers’ facilities. Furthermore, we have established a governance 
system to support and practice the values of international human rights principles and norms, such 
as the Universal Declaration of Human Rights (UDHR), the UN Guiding Principles on Business and 
Human Rights (UNGPs), the OECD Guidelines for Multinational Enterprises, the UN Convention on 
the Rights of the Child (CRC), the Fundamental Conventions of the International Labor Organization, 
and the Corporate Human Rights Benchmark (CHRB). 
Human Rights Policy
Human Rights Policy
Human Rights Risk Management
Human Rights Management System
Celltrion practices respect for the human rights of all stakeholders as well as internal employees by 
proactively identifying and improving various human rights violations that may occur through our 
business activities. To this end, the ESG Committee under the BoD oversees ESG issues, including 
human rights, and a dedicated department promotes issues related to human rights management.
Risk Management Process for Human Rights
Celltrion established a human rights policy in 2022 and developed a human rights risk management 
system to practice human rights management. The existing management system is reviewed regu-
larly to understand social changes and respond proactively to potential risks.  In particular, Celltrion 
strives to prevent human rights violations by identifying human rights management risks that may 
arise in business activities; follows assessment and monitoring procedures for human rights risks; 
and discloses the results to communicate transparently with stakeholders. Furthermore, online and 
offline channels are operated to receive grievances anytime, anywhere. In 2022, we conducted 
a pilot test of human rights impact assessment for ESG T/F and expanded the scope to cover all 
employees to expand understanding on human rights management situations and risks across the 
business. In accordance with our human rights policy, we conduct comprehensive reviews of human 
rights issues such as forced labor, human trafficking, child labor, freedom of association, collective 
bargaining, equal pay, and discrimination. The human rights impact assessment is used to manage 
Celltrion’s human rights impact by proactively identifying and evaluating actual and potential human 
rights risks that may arise from our business activities. In addition, we diagnose mental health risks 
and provide support for psychological counseling through an online mental health screening pro-
gram. Celltrion will continue to operate and improve systems to detect and make proactive improve-
ments and thereby ensure that employees’ fundamental rights are not violated.
Establish management 
metrics and  
conduct due diligence
Identify human rights risks 
and derive improvements
Internal and external 
reporting and disclosure
Human rights training
Compliance
ESG 
Manage-
ment
Environment 
Health  
Safety
Human 
Resources 
Management
Information 
Security
…
Procurement 
Planning
ER
BoD (ESG Committee)
Top decision-making body related to  
human rights management
CEO
Decision-making/Performance review on key  
human rights management issues
Human Rights TF
Establish and operate a human rights  
management system
Publicly disclose 
the current 
status of human 
rights policy 
implementation.
Establish a human 
rights policy  
and publicly 
disclose it.
Establish  
a human rights 
risk management 
system.
Conduct human 
rights impact 
assessment and 
identify potential 
risks.
Improve and 
monitor human 
rights risks.
Celltrion ESG Report 2022/23
51
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Handling Grievances and Sexual Harassment Cases
Celltrion listens to employees’ opinions and tries to resolve grievances through online and of-
fline grievance channels such as an internal anonymous communication channel (Tongnamu), 
Labor-management Council (Employee Council), Grievance Committee, and counseling center. 
The ER Team under the Corporate Culture Department operates the grievance handling system. 
Through the representative grievance channel Tongnamu, the CEO personally replies within two 
weeks to grievances and opinions on human rights in general, from minor issues related to welfare 
benefits to complaints regarding sexual harassment, workplace harassment and HR practices, 
and opinions related to suppliers. In addition, suggestions/grievances received through the La-
bor-management Council and Grievance Committee are discussed regularly between the labor and 
management to derive improvement points. After 2020,  due to the difficulty in receiving grievances 
offline amid the COVID-19 pandemic, we are trying to receive employees’ grievances and opinions 
through various channels, including the online channel. In 2022, a total of 514 grievances were re-
ceived through the grievance handling system. In all cases, we notified the informants regarding the 
results of the actions taken. In cases that could not be solved immediately, we provided them with 
action plans and timelines within the deadline. In particular, we operate a reporting system for work-
place discrimination and harassment. In 2022, we completed taking disciplinary actions on a total of 
12 reports1) of workplace discrimination and harassment that were received through the grievance 
handling channel.
1) 5 official were reports received by the ER Team; 7 were received through Tongnamu.
Celltrion spares no effort to identify direct, indirect, or potential human rights impacts generated by 
our business activities. We survey entire employees in Korea about their human rights awareness to 
identify human rights issues that should be managed from an employee’s perspective, and imple-
ment action to improve their awareness regarding the issues identified. The human rights awareness 
survey mainly focuses on identifying issues that we have to prioritize, and it was confirmed that there 
were no serious human rights risks. We utilized an online survey that guarantees the anonymity of 
the respondents and categorized questions into 1) human rights issues and 2) risk management. 
We conducted an analysis to identify groups affected by human rights issues, including vulnerable 
groups such as children, the elderly, women, community members, sexual minority groups, religious 
minority groups, migrant workers, the poor, and the displaced/refugees. According to the survey, 
Celltrion employees, in general, are of the view that priority should be given to prohibiting discrimina-
tion, improving the work environment, human risks management systems, and managing workplace 
harassment and sexual harassment. We plan to expand the scope of human rights assessment 
to our global business sites and conduct human rights assessments every year so that we can re-
Operation of the Grievance Handling System
Human Rights Awareness Assessment
Category
Unit
Case
Cases of discrimination/harassment
No. of cases
12
Cases of disciplinary actions taken
12
Cases Related to Discriminatory Behaviors and Harassment
Key Areas of Human Rights that Should be Managed by Celltrion
Major Areas of Human Rights
Direction for Stricter Management
Prohibit discrimination
Guarantee fair performance evaluation/Compensation and 
promotion system
· Improve and strengthen assessment procedures and systems
· Listen to employees’ feedback regarding maternity protection and  
non-full-time employees
Improve  
the work environment
Manage employees’ mental health/stress 
· Reinforce employees’ mental health check-ups (Once a year)
· Continue upgrading the working environment and rest areas at the 
workplace
Human rights risk  
management system
Review the overall grievance procedure 
· Strengthen accessibility to each grievance-handling channel
· Upgrade the grievance handling procedure in terms of expertise 
Workplace harassment 
/Sexual harassment
Protect employees from unfair work instructions and  
verbal sexual harassment 
· Take vigorous improvement actions whenever issues arise 
· Stronger prevention through reinforced manager training
Celltrion ESG Report 2022/23
52
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Human Rights Training Programs
We believe that human rights awareness should be established at the enterprise level first in the pro-
cess of implementing human rights management. In order to promote the culture of mutual respect 
and understanding of diversity among employees, Celltrion introduced training programs related to the 
prevention of sexual harassment, improving the perceptions regarding the disabled, and preventing 
workplace harassment. In 2023, we will continue to develop and expand the training courses to im-
prove employees’ perceptions regarding human rights and reinforce implementation.
spond proactively to human rights risks. We will advance our management systems for each human 
rights issue identified from the human rights awareness assessment to monitor potential human 
rights issues and protect our employees’ human rights. We at Celltrion recognize that respecting 
human rights is the fundamental responsibility that a company should pursue. Celltrion will continue 
reinforcing human rights due diligence on its business sites and supply chain. We will pursue the fol-
lowing continuously to create a culture where all rights are respected without infringement. 
Furthermore, we will strengthen our efforts related to diversity, equity, and inclusion, which are close-
ly linked to human rights, and will transparently disclose related performance to stakeholders.
Category
Unit
2020
2021
2022
Training on the prevention of 
sexual harassment
Employees subject to training
Person
2,074 
2,081 
2,120 
Completion rate
%
100 
100 
100 
Training on improving perceptions 
regarding the disabled
Employees subject to training
Person
2,055 
2,088 
2,130 
Completion rate
%
100 
100 
100 
Training on preventing  
workplace harassment
Employees subject to training
Person
2,092 
2,148 
2,189 
Completion rate
%
100 
100 
100 
2021
2,088
2020
2,055
2022
2,130
Employees Who Received Training on Improving Perceptions Regarding the Disabled (Unit: person)
2021
2,148
2020
2,092
2022
2,189
Employees Who Received Training on Prohibiting Workplace Harassment (Unit: person)
2021
2,081
2020
2,074
2022
2,120
Employees Who Received Sexual Harassment Prevention Training (Unit: person)
Enhancing Human Rights Awareness
Future Plan
Phase 1 
(~2023)
· Develop and implement a human rights awareness assessment 
process
· Develop a plan to manage potential human rights issues
Phase 2 
(2024~2025)
· Conduct regular human rights impact assessment on potential 
human rights issues
· Identify human rights risks and establish improvement tasks
Phase 3
(2025~)
· Expand the scope of human rights impact assessment considering 
the scope of human rights policy application
Celltrion ESG Report 2022/23
53
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Direction of Study Ethics and Compliance
For pharmaceutical drug candidates developed at Celltrion, it is mandatory to conduct non-clinical 
animal study and clinical trials to confirm their efficacy, toxicity, and safety. Throughout this process, 
Celltrion ensures through training that its employees adhere to the ethics-related regulations re-
quired by relevant countries and rules for internal management.
Clinical Trials
Activities to Guarantee the Safety and Rights of Clinical Trial Subjects
Celltrion ensures that all clinical trials are conducted in compliance with international ethical regula-
tions, including the International Council for Harmonisation’s (ICH) Good Clinical Practice (GCP) and 
ethical regulations based on the Helsinki Declaration. Celltrion has established Standard Operating 
Procedures (SOPs) as its internal management policy to manage and oversee the implementation 
of ethical regulations in clinical trials conducted by employees as well as Contract Research Or-
ganizations (CROs). To ensure the safety of participating patients throughout all phases of clinical 
trials, Celltrion selects patients in strict compliance with the criteria for inclusion and exclusion in ac-
cordance with the pre-established clinical trial protocols; and conducts clinical trials under medical 
monitoring to manage the subject’s safety. Celltrion also manages and supervises compliance with 
the ICH-GCP and clinical trial protocols through various risk assessment and prevention measures, 
monitoring, and auditing activities to strengthen compliance with the relevant regulations and proto-
cols.
Activities for Quality Assurance of Clinical Trials
Celltrion is preparing a clinical trial management policy in line with international standards for ethical 
and scientific quality management. The policy stipulates the standards to be followed and Celltrion’s 
internal procedures that apply to them, including organizational structure, management of investi-
gational products for clinical trials, planning and management of clinical trials, data integrity, mon-
itoring, auditing, change control, reporting, training, vendor management, and risk management. 
Celltrion’s quality management system has the following procedures for clinical trials. For quality as-
surance in clinical trials, the relevant departments conduct reviews and investigations independently 
from the clinical operations department. Celltrion has established the following procedures from a 
clinical operations perspective to ensure quality management at each stage of clinical trials. 
Due to the COVID-19 pandemic, Celltrion attempted to change the process of recruiting subjects 
and operating clinical trials. In line with the rapidly changing external environment, Celltrion dis-
cussed risk mitigation plans internally and with contracted suppliers, and introduced new approach-
es such as adjusting the timepoint of supplying investigational products for clinical trials and the 
schedules for subjects of clinical trial to visit the site where the clinical trial is conducted, adjusting 
the number and frequency of monitoring/central monitoring on the clinical site and clinical trial site 
audits, and discussing in advance how to handle uncollected data considering the COVID-19 situ-
ation. With the aim of optimizing quality of the data collected during the clinical trial period, Celltrion 
operated clinical trials with the highest priority on the safety and rights of clinical trial subjects.
Overview of Clinical Trial Quality and Future Improvements
Celltrion strives continually to ensure the safety and rights of clinical trial subjects to assure the quali-
ty of clinical trials. In addition, Celltrion engages in consulting on individual cases that need to be dis-
cussed, including issues that arise during the operation of clinical trials, so that Celltrion can proceed 
with quality management procedures from an objective and independent perspective.
Animal Testing
Compliance with Quality and Ethical Standards for Non-clinical Studies
Celltrion adheres to the principles of the 3Rs (Replacement, Reduction, and Refinement) for minimiz-
ing animal use required for non-clinical research development. Through optimized study designed in 
accordance with the ICH (International Council for Harmonization) guidelines, we are able to not only 
reduce unnecessary animal sacrifice, but also clearly identify the efficacy, safety, and pharmacoki-
netic properties of drug candidates. We outsource all animal experiments for non-clinical research 
development to specialized Contract Research Organizations. All animal experiments are conduct-
ed under the review and approval of the Institutional Animal Care and Use Committee (IACUC), and 
in compliance with Standard Operating Procedures (SOPs) and Good Laboratory Practice (GLP) 
regulations.
· Evaluation of clinical trial service 
providers
· Auditing clinical trial sites
· Internal audits
· Managing noncompliance  
in clinical trials
· Providing training for Celltrion 
employees on Good Clinical Practice 
· Change controls for computerized 
systems used in clinical trials
· Review essential documents related 
to clinical trials
· Review validation plan/report and 
sample analysis plan/report for 
bioanalytical assay in clinical trials 
· Review labels of investigational 
products for clinical trials
· Training for employees in charge of clinical trials, management of non-compliance issues/investigation of fraud 
and misconduct, clinical trial preparation, management of external vendors and clinical trial sites, development/
management of clinical trial documents, management of clinical trial materials, risk-based monitoring, and 
maintenance of blinding in clinical trials
Clinical Trial/Animal Testing
Celltrion ESG Report 2022/23
54
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

SAFETY AND  
HEALTH 
MANAGEMENT
SOCIAL - 03
Celltrion has established an ESH (Environment,  
Safety and Health) Policy to ensure the safety and health of 
each employee, and applies it to all management activities.
We have obtained ISO 45001 (Safety and Health 
Management System) certification by conducting 
continuous improvement activities through internal audits 
and risk assessments.
Furthermore, we have established a systematic safety 
network by operating a dedicated organization under  
the CSO and appointing safety and health managers in 
each department.
We also conduct periodic emergency response drills 
and safety and health management for suppliers (mutual 
cooperation programs) to establish a safety culture based 
on the voluntary participation of stakeholders.
Celltrion ESG Report 2022/23
55
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

① We comply with laws and regulations at home and abroad to prevent safety accidents, 
and have established internal safety and health regulations that are stricter than the legally 
required level. Workers are required to thoroughly understand the standards prepared by 
the company, including the safety-related work manual, and perform their work according 
to set procedures.
② We have established and continually operate a safety and health management system 
according to international standards; and comply with management criteria based on the 
ILO’s Safety and Health Agreement.
③ We continue managing and improving the safety and health management system to pre-
vent occupational accidents.
④ We install and operate the Occupational Safety and Health Committee, with an equal 
number of representatives from the labor side and the management side; and conduct 
deliberation/approval of issues related to safety and health by running the committee 
once a quarter.
Environmental Safety and Health Policy
Celltrion is committed to abide by ESH laws, regulations, and procedures, managing them to stan-
dards that exceed legal requirements, and fulfill its responsibility for safety and health. In line with the 
ESH Policy, Celltrion has established measures to pursue sustainable management based on the 
trust of various stakeholders, including employees, customers, shareholders and investors, suppli-
ers, and local communities. 
Environmental Safety and Health Policy
 
Basic Principles Regarding Safety and Health Management
Safety and Health Policy
Safety and Health Management System
Safety and Health Organization
Celltrion runs a dedicated safety and health organization under the CSO. We have appointed a safe-
ty and health manager and a chemical substance manager under the supervisor of each department 
for ESH management activities.
Category
Taken by
Employees
Roles
Safety and Health 
Officer
Head of Production 
Management Unit
1 person
Oversee the safety and health management activities of 
Celltrion
Supervisor
Head of Non-office 
Workers
64 persons
Identify danger·risk factors applicable to the department 
and make improvements
Manage outsourcing activities of the department
Provide department members with safety training, etc.
Safety and Health 
Manager at each 
department
Appointed Person
114 persons
Respond to incidents
Request medication and manage first aid kits
Manage applications and distribution of safety equipment
Cooperate with other safety and health-related tasks
Chemical Substance 
Manager at each 
department
Appointed Person
36 persons
Inspect hazardous chemical handling facilities
Conduct chemical incident response drills
Organize joint inspection among chemical substance 
managers of different departments
Safety Manager
Appointed Person
3 persons
Perform the safety manager’s duties according to  
the Occupational Health and Safety Act
Health Manager 
Appointed Person
3 persons
Perform the health manager’s duties based on  
the Occupational Health and Safety Act
Fire Safety Manager
Appointed Person
3 persons
Perform the duties of the fire safety manager in accordance 
with the Fire Prevention and Safety Management Act
Hazardous Chemical 
Substance Manager
Appointed Person
2 persons
Perform the duties of the hazardous chemical substance 
manager as stipulated under the Chemical Control Act
Production Management Unit (Safety and Health Officer)
Production Development Unit
Executive Management Unit
Global Product Development Division
Research & Development Unit
Data Science Institute
Corporate Sustainability Division
CEO
Safety 
Management 
Team 
Administration Unit (CSO)
Safety Management Department
Environment 
Health Safety 
Team 1 
Environment 
Health Safety 
Team 2
Safety Manager
Supervisor
Safety and Health Manager  
at each department
Chemical Manager  
at each department
Fire Safety Manager
Health Manager
Chemical Substance 
Manager
Celltrion ESG Report 2022/23
56
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Operation of Occupational Safety and Health Committee
Celltrion runs an Occupational Safety and Health Committee comprised of an equal number of 
members representing employees and the company. Every quarter, the Occupational Safety and 
Health Committee performs deliberations and approves major matters related to safety and health 
by sharing opinions on the basic safety and health management system, safety and health manage-
ment regulations, changes in rules, inspection and improvement of the working environment, work-
ers’ medical examinations, and safety and health education. 
Safety and Health Risk Management Process
Celltrion is working to build a safe work environment by proactively identifying and improving haz-
ards and risk factors at all business sites. We have developed a six-phase corporate-wide safety 
and health risk management process to proactively prevent and manage safety and health risks for 
all employees.
Step 1
Risk assessment training
· Provide workers with training on the procedures and  
methods of assessing risks
Step 2
Process investigation
· Define all processes within a department and the sequencing of tasks by 
process
· Identify process- and task-specific characteristics
Step 3
Risk assessment
· Site due diligence by activity
· Calculate risks by hazard and risk factor
Step 4
Development of 
improvement measures
· Select hazard and risk factors with high adverse impact
· Develop measures to mitigate the selected hazard and risk factors  
(In the order of removal, engineering measures,  
administrative measures, and protective equipment)
Step 5
Implementation of 
improvement measures
· Implement the selected mitigation measures
· Validate the effectiveness of the mitigation measures
Step 6
Continuous improvement 
and management
· Share the results with relevant departments and make horizontal deployment 
· Continue to manage low-risk factors
Safety and Health Risk Management
Overview of Safety and Health Certifications Obtained
Celltrion has established and runs an ISO 45001 system (Safety and Health Management System) 
to achieve its corporate safety and health goals of preventing work-related injuries and health im-
pairments, creating a safer and healthier work environment free of risks. In accordance with the ISO 
45001 requirements, Celltrion keeps implementing improvement measures and corrective actions 
following the PDCA (Plan-Do-Check-Act) cycle by establishing company-wide safety and health 
goals; identifying risks related to internal and external issues; and conducting risk assessments, le-
gal compliance assessments, and internal audits; while taking follow-up actions for issues that arise. 
In addition, we exert efforts to manage safety and health by annually reporting on outcomes to the 
head of management. 
Safety and Health Management System
 PLAN
· Develop a health  
and safety work plan
· Secure a health  
and safety budget
· Set health and safety goals
 DO
· Identify internal and external 
risks to health and safety
· Risk assessment
· Assess compliance with health 
and safety laws and regulations
 CHECK
· Monitor health and  
safety activities
· Internal audits
· Post Audit ACT
 ACT
· Corrective action 
· Continuous 
improvement
· Executive review
Members 
20 persons in total  
(10 from the 
management side,  
10 from the labor side)
Management side
· 1 Health and Safety Officer
· 1 Safety Manager
· 1 Health Manager
· 7 other committee members 
from the management side
Labor side
· 1 labor side representative
· 9 other committee 
members from the labor 
side
Activities
A committee 
meeting is 
held once  
a quarter.
Celltrion ESG Report 2022/23
57
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Reinforcing Competency to Strengthen Safety Culture 
Regular Safety and Health Training
Celltrion conducts various safety and health training for all employees. Regular safety and health 
training programs are provided online. Celltrion offers customized safety training content depending 
on the type of work (office/non-office workers), department, and seasonal factors. In addition, we 
provide mandatory training courses such as training for new hires, training for changes in work, spe-
cial training, and vocational training. For workers subject to Process Safety Management (PSM) with 
high risk, we provide additional PSM guidelines and training, demonstration training on near miss 
cases, and training on accident cases in the same industry.
Safety and Health Training
In order to respond quickly to emergencies such as fires, Celltrion has created an emergency re-
sponse organization for each plant and provides periodic response drills. In addition, we conduct 
corporate-wide emergency evacuation drills and emergency contact network drills every half year 
to strengthen employees’ response capabilities in the event of an emergency. Further, we conduct 
periodic hands-on training on fire suppression and first aid, cardiopulmonary resuscitation, and how 
to use an automated external defibrillator.
Assessment of the Safety Culture
Celltrion conducts a quantitative assessment on the safety and health level of each department 
on a quarterly basis to strengthen the safety culture. Nine items, including education and training 
management, site management, medical examination management, document management, and 
safety accident management, are evaluated every quarter, and rewards are given to the safety and 
health manager of outstanding departments.
Spreading Safety Culture
Trainee
Q1
Office workers
927 persons
Non-office workers
1,191 persons
Total
2,118 persons
Completion rate
100%
Content
· Human characteristics 
and safety
· Job stress throughout 
the year 
· Seasonal healthcare 
(Spring)
· Management of 
the office work 
environment
· Risk assessment 
cases (Production)
· Prevention of health 
hazards caused by 
hazardous substances
· Management of 
electrical safety
Q2
Office workers
916 persons
Non-office workers
1,156 persons
Total
2,072 persons
Completion rate
100%
Content
· Importance of 
occupational health 
and safety training 
· Seasonal healthcare 
(Summer)
· Insomnia and stress 
management
· Human psychology 
and safety
· Handling dangerous 
goods, etc. 
· Preventing human 
error and unsafe 
behaviors
· Cases of accidents 
related to falling-down 
and measures for 
prevention
Q3
Office workers
919 persons
Non-office workers
1,152 persons
Total
2,071 persons
Completion rate
100%
Content
· Types of safety 
behaviors
· Safety and ergonomics 
(Office work)
· Prevention of health 
hazards in the office
· Compliance with the 
basics and principles 
is the fastest way 
to prevention of 
accidents 
· Accidents that occurred 
by collision while 
unloading from vehicles 
· Use of Material Safety 
Data Sheets (MSDS)
· Examples of falling 
accidents and 
preventative measures
Q4
Office workers
966 persons
Non-office workers
1,207 persons
Total
2,173 persons
Completion rate
100%
Content
· Combustion and 
extinguishing theory
· Firefighting planning 
and drills
· Fire and explosion 
accidents
· Seasonal healthcare 
(Autumn)
· Gas safety 
management
· Management of open 
flames
· Management of 
hazardous materials
Assessment Items
Assessment 
cycle
Every quarter
1. Education and training 
management
2. Site management
3. Medical examination 
management
4. Safety and health 
document control
5. Management of safety 
accidents
6. Management of accident 
reporting 
7. Management to prevent 
recurrence of accidents
8. Items that require 
cooperation regarding safety 
and health-related activities
9. Identification and 
improvement of risks
Celltrion ESG Report 2022/23
58
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Celltrion is working relentlessly to create a health management system that puts the health of its em-
ployees first. With various health promotion activities and management of the work system, we aim 
to build a better working environment. In particular, we support comprehensive health checkups for 
employees over 30 to enable them check for health abnormalities and take a proactive approach to 
assist those with symptoms and those whose condition needs to be observed. The in-house Health 
Management Center provides health counseling, first aid, vaccinations, and treatment to prevent 
risky diseases such as influenza and hepatitis A. In particular, the Center has a body composition 
analyzer to help employees manage their health, and has introduced massage chairs to create an 
environment where employees can take some time to rest during work. In addition to general health 
care, we provide regular job stress tests and run one-on-one psychological counseling programs 
with a professional counselor to promote employees’ health. For example, we run posture correc-
tion programs to prevent musculoskeletal diseases and smoking cessation clinics in conjunction 
with Public Health Centers, and reward employees who show outstanding results. We also support 
the development of healthy walking habits through the ‘Celltrion Healthy Walking Challenge’ event.
Fire Prevention Campaign
Celltrion conducts an annual fire prevention campaign to promote safety culture among employees.
In 2022, we provided guidance on major fire incidents in the office, as well as fire extinguishing cap-
sule stickers and fire evacuation masks, and offered instructions on how to use them. We also held 
a fire-related OX quiz and organized an event called the Hidden Hazard Hunt in the Workplace and 
rewarded outstanding employees.
Safety and Health Management for Suppliers
Celltrion runs a mutual cooperation program for safety and health with its on-site suppliers. In addi-
tion, we created a council with our suppliers, and hold monthly meetings and joint inspections every 
quarter to identify non-conformities and take corrective measures to improve the management level.
Furthermore, we conduct annual qualification evaluations for on-site suppliers and evaluations for 
outsourced suppliers before commencing work to ensure that only those who meet the evaluation 
criteria are allowed to perform the work.
Smoking Cessation Clinic
Health Management for Employees
Fire Prevention Campaign
Celltrion ESG Report 2022/23
59
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

CUSTOMER 
SATISFACTION 
MANAGEMENT
SOCIAL - 04
Celltrion spares no effort in terms of investment to secure 
safety in all processes from pharmaceutical development 
to sales, promoting the health of all customers around the 
globe as the highest priority.
We have introduced systematic quality control 
and improvement processes and vitalized various 
communication channels.
We gather the valuable opinions of our customers 
situated in various countries, which are delivered to the 
Quality Assurance Division, in order to run a strict quality 
management system.
Celltrion ESG Report 2022/23
60
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Quality Assurance Process
Biopharmaceuticals require strict and thorough quality management in all processes covering de-
velopment, production, storage, distribution, and sales. To ensure strict adherence to these require-
ments, a stringent quality management system must be established first. To provide pharmaceu-
ticals with a high level of quality, efficacy, and safety guaranteed, Celltrion has developed a quality 
management system based on global GMP and ISO standards. In addition, we apply the system 
comprehensively to the entire process from product development and production, to sales; and en-
sure the quality of pharmaceuticals by means of strict compliance with GMP standards. Celltrion’s 
quality policy objective is to achieve a level of quality assurance that exceeds global Good Manu-
facturing Practice (GMP) regulations. All Celltrion employees receive regular training on global GMP 
standards and the latest trends to enable them understand the objectives of Celltrion’s quality poli-
cies and the importance of pharmaceutical quality. This allows them to leverage their understanding 
regarding GMP-related activities. Celltrion is continuously upgrading its product quality through the 
systematic quality management and monitoring system. In the future, we will produce high-quality 
pharmaceuticals more safely based on a strict and thorough quality management system to supply 
them to patients worldwide.
Operation of the Quality System
Celltrion analyses and allocates necessary resources for pharmaceutical development, production, 
storage, distribution, and sales based on the quality policy envisioned by the CEO with the goal 
of continuous quality improvement. We have also established and operate Standard Operating 
Procedures (SOPs) for effectiveness and consistency. To ensure the quality, efficacy, and safety of 
pharmaceuticals, we implement risk management programs using Failure Mode Effect Analysis 
(FMEA) and Fault Tree Analysis (FTA), etc., to determine risk factors and implement risk mitigation 
plans, which are then applied to manufacturing processes, facilities, and systems. In addition, all 
employees who are involved in the drug manufacturing process are required to complete basic 
and advanced training related to GMP regularly. For jobs requiring specialized and sophisticated 
skills, including aseptic techniques, we provide quality training to workers through field training and 
a thorough qualification program to assess the effectiveness of the training. Critical processes that 
affect drug quality, efficacy, and safety are documented in detail and used for monitoring of the man-
ufacturing process and trend analysis. Any abnormal situations during the manufacturing process 
are investigated thoroughly to determine the root cause. We also evaluate effectiveness by running 
Corrective And Preventive Actions (CAPAs) under the quality system to prevent recurrence.
As such, Celltrion’s quality system is subject to periodic regulatory inspections and customer audits, 
internal audits, quality committees, trend analysis, and annual quality reviews to ensure the effective-
ness and systematicity of our operation methods. For items that are found to need improvements as 
a result of assessments, we revise our quality policy and standard operating procedures and reallo-
cate necessary resources. 
We also use various computer systems to ensure the effective operation of our quality system. Pol-
icy documents and standard operating procedures required for GMP operations are available to 
all workers in real-time through the Electronic Document Management System (EDMS). Celltrion 
employees acquire the knowledge required for GMP work through the Electronic Learning Manage-
ment System (ELMS), and we also run an e-learning system for effective remote training. Key quality 
systems and procedures such as deviations, change management, Corrective And Preventive 
Actions (CAPA), complaints, and supplier management are managed digitally through the Quality 
Management System to ensure effective management of quality objectives. 
Customer-Centered Quality Management System 
Celltrion ESG Report 2022/23
61
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Manufacturing Facility and Schedule Management to Ensure 
Pharmaceutical Quality
Celltrion has built its manufacturing facility in accordance with global GMP regulations to avoid 
cross-contamination between manufactured medicines. To minimize microbial contamination during 
the cell culture process, we placed each bioreactor for the cultivation process in a closed system.
The pre- and post-viral filtration for these purification processes occurs in physically separated 
areas. The filling area, where sterile products are filled, is controlled by a Restricted Access Barrier 
System (RABS) that applies strict cleanliness standards. The system was designed to minimize mi-
crobial contamination by operators. In addition, we have installed independent Heating, Ventilation 
& Air Conditioning Systems (HVAC) for each manufacturing process to prevent the possibility of 
cross-contamination between manufacturing processes. All manufacturing processes are run on a 
campaign basis, with a strict change-over program between each campaign to prevent the possibil-
ity of cross-contamination. Celltrion’s manufacturing facilities and processes are validated to ensure 
that they operate as intended and within the process range and that they can produce high-quality 
medicines consistently. Furthermore, Celltrion’s manufacturing facilities are operated with automat-
ed systems to minimize the risk of process failures due to operator error. The manufacturing data 
accumulated through this forward-looking system is used for process monitoring and trend analysis 
to ensure drug quality and evaluate the consistency of the manufacturing process. The manufactur-
ing process is optimized continuously through statistical analysis of process variables. 
Pharmaceutical Quality Management System
Celltrion thoroughly verifies the quality of its products by analyzing critical quality attributes of man-
ufactured pharmaceutical products. We have identified the quality attributes of our products based 
on more than 20 different analytical methods and clarified the complex physicochemical quality 
characteristics of biopharmaceuticals. These analytical methods are based on the International 
Conference on Harmonization (ICH) guidelines, and validated taking into account variables such as 
accuracy, precision, specificity, detection/quantitation limit, linearity, and range. Analytical methods 
that are based on the International Pharmacopoeia are subject to verification of the testing method 
to ensure reproducibility within the laboratory environment. Drug samples and analytical data are 
tracked and managed in real-time through the Laboratory Information Management System (LIMS), 
which is linked to the Enterprise Resource Planning (ERP) system to ensure that each product lot is 
controlled systematically for its disposition. We operate a pharmaceutical stability program to se-
cure evidence of changes in pharmaceutical quality over time due to environmental factors such as 
temperature, humidity, and light, and calculate appropriate storage conditions and expiry dates for 
manufactured medicines.
Quality Management Performance and Plans
From 2006 to 2022, Celltrion received more than 50 regulatory inspections in more than 20 coun-
tries, including inspections by the US FDA (US), EMA (Europe), MFDS (Korea), PMDA (Japan), and 
ANVISA (Brazil), and demonstrated and improved the effectiveness of its quality management sys-
tem. In the past four years (2019 to 2022), we received a total of 28 inspections/audits by customers 
and regulatory agencies, which were successfully completed without any significant findings. In 
particular, in May and June 2022, GMP inspections were conducted by the European EMA and the 
US FDA, which have strict GMP standards. We successfully obtained GMP certification, proving the 
efficiency of our quality management system once again. In addition to the ISO 9001 (Quality Man-
agement System) standard certification in 2020, we have obtained and maintained ISO international 
standard certifications in five areas: ISO 14001 (Environmental Management System), ISO 22301 
(Business Continuity Management System), ISO 37001 (Anti-bribery Management System), and 
ISO 45001 (Safety and Health Management System). We will continue our efforts for continuous 
quality improvement in accordance with the principles of the quality management system and strive 
to realize the value of promoting human health and welfare by providing patients with medicines that 
are guaranteed for high levels of quality, efficacy, and safety.
ISO International Standard Certification in 
5 Areas
ISO 9001
Quality Management
System
ISO 14001
Environmental 
Management System
ISO 22301
Business Continuity 
Management System
ISO 45001
Safety and Health 
Management System
ISO 37001
Anti-bribery 
Management System
Celltrion ESG Report 2022/23
62
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Classification of Customer Types
Celltrion’s customers are managed according to the characteristics of products and classification of 
the domestic and overseas markets. Regarding biopharmaceutical sales, a major revenue stream, 
Celltrion Healthcare has exclusive overseas  sales rights, while Celltrion Pharm owns domestic sales 
rights. Celltrion Healthcare’s overseas sales of biopharmaceuticals are made directly or indirectly to 
global pharmaceutical companies, including Pfizer and Teva, in more than 110 countries through 
its regional business units. Celltrion Pharm’s domestic biopharmaceuticals are sold and distributed 
through wholesale and retail companies including Geo-Young, Bulim Co., Ltd., and Namkyung Ko-
rea Co., Ltd. In addition, we are operating a CMO business and supplying drug substances  through 
a production service contract with Teva.
Vitalizing Customer Communication
Celltrion has established an ethical advertising and marketing policy to provide objective and reli-
able information on products and services, as well as conduct direct and indirect activities related 
to promotion and sales, and utilizes its owned media, such as the official website and social media 
channels, for smooth and prompt communication with customers. We share company overviews, 
the latest news, and financial information on our official website, and operate customer service com-
munication channels tailored to the needs of each stakeholder, such as investor inquiries, recruitment 
inquiries, and complaints regarding products. In addition, we communicate with customers through 
official social media channels such as corporate blogs, Instagram, Facebook, and YouTube to share 
news of our social contribution, ESG, and corporate culture activities. 
Moreover, medical practitioners recognized the excellence of our products when we disclosed the 
results of clinical trials at conferences in the US and Europe. We continue to inform shareholders and 
investors regarding new developments through press releases. Since 2010, Celltrion has participat-
ed in ‘Bio USA,’ the world’s largest business conference for the pharmaceutical industry, every year 
to communicate with customers. In 2022, we participated more in overseas exhibitions to commu-
nicate actively with global customers, engaging in partnering activities in various fields, from devel-
opment of product and formulation to raw material procurement and CMOs. Through this, we were 
able to identify global technology trends and communicate actively with existing customers and 
potential partners. Celltrion will continue to strengthen its business capabilities and focus on leading 
global pharmaceutical trends.
Ethical Advertising and Marketing Policy
Customer Inquiry Management and Responses
Process for Handling Complaints Regarding Product Quality
Celltrion runs a validated system for product quality control to manage information about product 
quality complaints in compliance with international regulations and guidelines. Country-specific 
quality complaints collected through various channels are forwarded to the Celltrion Quality Assur-
ance Division. Product quality complaints are handled in the following order: initiating an investiga-
tion into highly possible and probable causes; improvement of identified causes; and notification 
to the customer. Actions are taken for matters that require improvement to resolve them rapidly. 
Complaints regarding product quality are monitored regularly through trend analysis, and we try to 
prevent consumer complaints and the recurrence of claims preemptively. 
Creating Customer Value
2002 BIO USA
Celltrion ESG Report 2022/23
63
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

SOCIAL 
CONTRIBUTION
SOCIAL - 05
Celltrion is engaged in constant efforts to fulfill its 
responsibilities as a corporate citizen and realize the value 
of win-win cooperation.
In order to ease the difficulties faced by members of the 
local community, we carry out volunteer activities regularly 
and support food drives, donations of daily necessities, 
medical expenses support programs, and youth 
scholarship projects with the participation of employees. 
We also promote open innovation projects to identify and 
support promising start-ups to realize shared growth goals.
Celltrion ESG Report 2022/23
64
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Social Contribution Program
Finding Bio Startups
Celltrion is promoting collaboration with startups to realize the values of mutual growth and win-win 
cooperation, which are part of Vision 2030. Since 2020, we have participated in the Incheon Start-
up Park Development Project1) as a private operator to find, foster and collaborate with promising 
startups in the bio-healthcare sector. Over the two years after joining the project, we have pursued 
and reviewed more than 50 Open Innovation Projects based on our own technologies and business 
needs; and have achieved results by collaborating with startups to develop antibody-based new 
drugs and bio materials, parts, and equipment sectors.
In 2022, we selected 31 startups in the biotechnology field through the Incheon Startup Park Devel-
opment Project and pursued and reviewed a total of 14 Open Innovation Projects. Among them, we 
provided support for Pinotbio (ADC2) platform development), which was discovered and selected 
by Celltrion, to verify the efficacy of its ADC linker-payload platform technology for animals. With Pi-
notbio, we signed a technology licensing option worth up to KRW 1,776 billion related to Pinotbio’s 
ADC linker payload, in addition to an equity investment, and joint research agreement in October 
2022. A six-month demonstration test of a viral vector for cell line production was conducted jointly 
with BioDesign Lab. We provided support to Umtr in the demonstration test for a bottle-top filter 
over two years, resulting in improved technology and product quality levels. Celltrion is expanding 
its network at home and abroad to identify promising bio startups and developing its own program 
to provide customized step-by-step support for bio startups in their early phase. Efforts are being 
made to promote mutual growth and win-win cooperation by strengthening cooperation with the 
startups we are currently working with. Furthermore, we will strengthen cooperation with relevant 
organizations to further develop the bio startup ecosystem.
1) Lead: Ministry of SMEs and Startups, Organizer: Incheon Metropolitan City, Incheon Free Economic Zone Authority
2) Antibody-Drug Conjugate (ADC): a drug and a monoclonal antibody that was chemically combined using a linker. ADC binds to a specific protein 
or receptor on a particular cell, allowing the attached drug to enter the cell, killing the specific cell without harming others.
* Support local communities through the Celltrion Welfare Foundation established by Celltrion
Social Contribution Strategies
Celltrion emphasized the value of shared  growth when setting Vision 2030, and the same applies 
to our social contribution strategies. We established the Celltrion Welfare Foundation in 2006 using 
the first profits obtained from the CMO business, guided by the founder, Jungjin Seo’s philosophy of 
social contribution, which states, “As a member of society, a company must fulfill its social responsi-
bilities and grow together with society.” The Foundation has been carrying out various CSR activities 
specially in Incheon and Chungcheongbuk-do where Celltrion is located, providing direct assistance 
to families in need through pocket money support for teenagers, as well as medical expenses, food, 
daily necessities, school expenses, and seasonal sharing projects. In addition, the Foundation 
continues initiatives such as volunteer activities joined by employees and matching employees with 
scholarship students.
Social Contribution Strategies
Social Contribution Areas*
Social Contribution Activities
Community Support
· Food and daily necessity 
support for underprivileged 
classes with low-income 
· Assistance with medical expenses
· Support with living expenses 
for single person households 
and early married families 
subject to probation
· Support for welfare 
organizations that provide food 
banks, free food service, etc. 
Youth Scholarship Initiative
· “Pocket money” scholarships for 
middle and high school students
· Provide scholarships for students 
under the Guardian Program 
and Incheon National University 
students 
· Provide separate scholarships 
by matching employees with 
outstanding students from low-
income families
Employees’ Volunteer Activities 
· Seasonal sharing events
Celltrion ESG Report 2022/23
65
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Supporting the Underprivileged
Celltrion cares about the lives of the underprivileged and runs projects to provide support with their 
livelihood, medical expenses, and tuition. We deliver food (rice, instant noodles, tuna, dried sea-
weed, etc.) to low-income families, such as those subject to welfare support programs, single par-
ents, and multicultural families living in Incheon and Chungcheongbuk-do. We also provide tailored 
support for each family (essential electric appliances, formula/diapers, deposit to rent a house, etc.). 
As of 2022, we offered KRW 1 million per household for living expenses to 11 families of couples 
who got married early or were not married among families under the care of the National Probation 
Service. Through the Medical Expenses Support Program, we provided up to KRW 3 million for 
medical expenses related to tests and surgeries to underprivileged families living in Incheon and 
Chungcheongbuk-do who needed medical treatment. Furthermore, we provided pocket money 
scholarships of KRW 30,000 per month to middle school students and KRW 50,000 per month to 
middle and high school students for 12 months to children from low-income, underprivileged fami-
lies in Incheon and Chungcheongbuk-do. In 2022, the scope was expanded to provide the benefit 
to 2,195 students from 327 schools (1,559 middle school students and 636 high school students). 
Furthermore, we also provided individual scholarships by matching our employees with youths, 
such as students from low-income families who achieved excellent academic performance.
Volunteer Programs
Celltrion delivers gifts during Lunar New Year, Family Month, Chuseok (Korean Thanksgiving), and 
Christmas to selected low-income families, such as the elderly living alone, single parents, and chil-
dren from families without parents, and offers them kimchi during the kimchi-making season. During 
Chuseok (Korean Thanksgiving) in 2022, the employee volunteer program, which was suspended 
due to COVID-19, was resumed with employees participating in gift wrapping. In addition, we pro-
vide kerosene to low-income families that are having difficulty heating their homes. We will reach out 
in unison to more people from the underprivileged classes.
Supporting Welfare and Public Interest Organizations
Celltrion provides monthly food donations to social welfare institutions such as Food Bank and 
Youth Dream Market, and pays monthly food and utility bills for soup kitchens. In addition, we do-
nate portable air conditioners and child diapers to welfare facilities such as residential facilities for 
people with disabilities and nurseries, and recently expanded our support projects by donating 
portable fire extinguishers worth KRW 22 million to a fire-prone facility (A campground under the ju-
risdiction of the Incheon Environment Corporation’s Songdo office).
Donation of Portable Fire Extinguishers
Sharing Kimchi
Sharing on Chuseok (Korean Thanksgiving)
Celltrion ESG Report 2022/23
66
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

GOVER-
NANCE
Governance
Compliance and Ethical Management
Risk Management
Supply Chain Management
Information Security
68
78
82
86
91
BUILD TRUST
We want to build trust with our future stakeholders based on 
efficient organizational structure and systematic management.

GOVERNANCE
GOVERNANCE - 01
Celltrion is committed to protecting shareholders’ rights 
and establishing transparent and sound governance.
The BoD (Board of Directors) operates under the 
principles of independence, expertise, and diversity and 
has designated the Audit Committee, Compensation 
Committee, Independent Director Candidate 
Recommendation Committee, and ESG Committee to 
oversee specific matters.
In particular, the ESG Committee was established in 2022 
to meet the increasing demand for ESG information from 
key stakeholders and to ensure sustainable management, 
laying the foundations for ESG management activities in 
earnest. 
We will continue strengthening corporate value through 
the checks and cooperation between the BoD and its 
Committees.
Celltrion ESG Report 2022/23
68
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Shareholder Composition
Returning Profits to Shareholders
Type
No. of shares (common share)
Shares (%)
Preferred Stock
-
-
Common Stock - Voting Stock
137,792,707
97.86
Common Stock - Treasury Stock
3,012,503
2.14
Total
140,805,210
100.00
Types of Shares and Voting Rights (As of December 31, 2022)
Name
Relations
Number of shares
Share (%)
Celltrion Holdings
Affiliate
 28,223,603 
20.04
Celltrion Skincure
Affiliate
 2,976,330 
2.11
Hyoungki Kim
Executive member of an affiliate
 142,157 
0.10
Woosung Kee
Executive member
 129,919 
0.09
Heonyeong Yoo
Executive member of an affiliate
 64,802 
0.05
Others
 - 
566,407
0.40
Total
32,103,218
22.80
Related Party’s Shareholdings (As of December 31, 2022)
Continuous R&D investment is key to our business competitiveness. We pay a stock dividend and 
an additional cash dividend of 2-5% annually, based on a combination of free cash flow (FCF), share-
holder value enhancement, and the business environment, taking into account investments for the 
company's continued growth. We are committed to returning part of our profits to our shareholders 
through stock and cash dividends in 2021 and 2022. Dividend information is provided to sharehold-
ers on our website and through the electronic disclosure system (DART). With the aim of enhancing 
shareholder value, we made a total of three share repurchases in 2022 and two share repurchases 
in 1Q 2023. The total number of shares purchased during the period is 2,213,237, or 1.6 % of the 
total number of shares currently outstanding. We will continue our efforts to become a company that 
can grow with its shareholders and enjoys the profits generated during growth.
Shareholders
No. of shares (common share)
Shares (%)
Celltrion Holdings
 28,223,603 
20.04
Celltrion Skincure
 2,976,330 
2.11
National Pension Service
 10,706,253 
7.60
ION Investment
 6,087,954 
4.32
BlackRock
 3,506,225 
2.49
Vanguard
 3,289,287 
2.34
Treasury Stocks
 3,012,503 
2.14
Others
 83,003,055 
58.96
Total
 140,805,210 
100.00
* There are no golden shares among government holdings.
Shareholder Composition (As of December 31, 2022)
Profits Returned to Shareholders (key dividend indicators)
Division
Unit
2020
2021
2022
Stock dividends 
%/share
2
2
4
Cash dividend per share
KRW
-
750
375
Total cash dividend
KRW 100 million
-
1,025
517
Market dividend payout ratio
%
-
0.4
0.2
Cash dividend payout ratio
%
-
17.68
9.61
Cash dividend yield
%
-
0.37
0.21
Celltrion ESG Report 2022/23
69
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Strengthening Shareholder-friendly Management
Exercising Celltrion Shareholder Rights and Voting Rights
Celltrion carries out various activities to protect shareholders’ rights and interests. We aim to 
strengthen transparent governance by communicating with shareholders through various channels 
while guaranteeing shareholders’ rights following the Commercial Act in Korea. We respect the legit-
imate requests and opinions of shareholders, such as the exercise of voting rights and shareholder 
proposal rights, and have laid the foundation for sound governance through a transparent and rea-
sonable decision-making process. We also conduct regular IR activities, AGMs, corporate presen-
tations, and NDRs to strengthen communication with investors and stakeholders.
Notice of AGM
According to the Commercial Act, a company shall send the notice of a meeting two weeks before 
an AGM. Celltrion provides relevant information in compliance with the Commercial Act to ensure 
that investors have sufficient time to review the agenda. The notice of the meeting provides informa-
tion on the venue, agenda, and details of the meeting to enhance investors’ access to information, 
and the meeting is announced and notified through the company website, daily newspapers, and 
DART.
Shareholder Voting System
Celltrion ensures that shareholders can participate in decision making regarding important man-
agement matters by exercising their voting rights for the development and benefit of the company. 
One great example is the approval of the resolution for conditional delisting from the KOSDAQ 
and transfer of listing to the KOSPI in 2017, which were proposed following a request by minority 
shareholders to convene an EGM (Extraordinary shareholders’ General Meeting). The shareholder 
proposal right stipulations under the Commercial Act allow eligible shareholders to express various 
opinions to the company. Based on the Commercial Act and our Articles of Incorporation, we grant 
shareholders one voting right per each share they own, depending on the number of shares they 
hold. As of the end of December 2022, there were 140,805,210 issued shares and 3,012,503 trea-
sury shares. Therefore, the number of ordinary shares, excluding treasury shares, was 137,792,707. 
At Celltrion’s AGMs, shareholders can vote in person, by proxy, or by recommending proxies. From 
the 29th AGM in 2020, we introduced an electronic voting system to enhance shareholders’ con-
venience in exercising their voting rights. We started a system for them to participate through online 
webcasting (Video). At the 32nd AGM held in 2023, approximately 504 shareholders attended the 
meeting and 3,634 shareholders participated via webcasting.
Annual General Meeting (AGM)
AGM
Category
32nd AGM
31st AGM
30th AGM 
Peak Days
2023-03-24
2023-03-30
2023-03-31
2022-03-25
2022-03-30
2022-03-31
2021-03-26
2021-03-30
2021-03-31
Date of AGM
2023-03-28
2022-03-25
2021-03-26
Whether the meeting was held on a day  
other than peak days
⃝
×
×
Written voting
×
×
×
Electronic voting
⃝
⃝
⃝
Recommendation for proxy voting
⃝
⃝
⃝
AGM Held on Peak Days, Introduction of Written/Electronic Voting,  
Recommendation on Proxy Voting for Three Years
Celltrion ESG Report 2022/23
70
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Agenda Items
Purpose of the Meeting
Approval
Item no. 1
Approval of the 32nd Financial Statements
Approval
Item no. 2 (2-1)
Appointment of a Director (Jungjin Seo, Inside Director)
Approval
Item no. 2 (2-2)
Appointment of a Director (Woosung Kee, Inside Director)
Approval
Item no. 2 (2-3)
Appointment of a Director (Hyukjae Lee, Inside Director)
Approval
Item no. 3
Approval of Remuneration Limit for Directors
Approval
Item no. 4
Approval of Granting Stock Options
Approval
Agenda Items and Approval at the 32nd AGM
Agenda Items
Purpose of the Meeting
Approval
Item no. 1
Approval of the 31st Financial Statements
Approval
Item no. 2 (2-1)
Appointment of a Director (Keunyoung Kim, Independent Director)
Approval
Item no. 2 (2-2)
Appointment of a Director (Wonsuk Kim, Independent Director)
Approval
Item no. 2 (2-3)
Appointment of a Director (Daehyun Yoo, Independent Director)
Approval
Item no. 2 (2-4)
Appointment of a Director (Soonwoo Lee, Independent Director)
Approval
Item no. 2 (2-5)
Appointment of a Director (Younghyeh Ko, Independent Director)
Approval
Item no. 3
Appointment of Jaesik Lee (Independent Director) 
as an Audit Committee Member
Approval
Item no. 4 (4-1)
Appointment of an Audit Committee Member (Keunyoung Kim)
Approval
Item no. 4 (4-2)
Appointment of an Audit Committee Member (Wonsuk Kim)
Approval
Item no. 4 (4-3)
Appointment of an Audit Committee Member (Daehyun Yoo)
Approval
Item no. 4 (4-4)
Appointment of an Audit Committee Member (Soonwoo Lee)
Approval
Item no. 4 (4-5)
Appointment of an Audit Committee Member (Younghyeh Ko)
Approval
Item no. 5
Approval of Remuneration Limit for Directors
Approval
Item no. 6
Approval of Granting Stock Options
Approval
Agenda Items and Approval at the 31st AGM
Composition and Roles of the BoD 
Composition of the BoD 
Celltrion’s BoD consists of a minimum of three and a maximum of ten members, in accordance 
with Article 32 of the Articles of Incorporation and Article 4 of the BoD regulations. Article 383 of the 
Commercial Act stipulates that a company must have at least three directors. However, Celltrion de-
cided to have a maximum of 10, considering the size of the company and the efficiency of meeting 
operations and decision-making. At the 2022 AGM, all independent directors, including a female 
independent director, were newly appointed. At the 2023 AGM, three  inside directors were elected 
(Jungjin Seo was newly appointed, Woosung Kee and Hyukjae Lee were re-appointed). Amidst the 
recent global economic uncertainty, the BoD proposed a new candidate for the position of inside 
director, Jungjin Seo, the founder of Celltrion Group who elevated Celltrion into a global biosimilar 
company, as part of efforts to overcome the crisis and realign our strategy for the future. In addition, 
we proposed Woosung Kee, who has served as the CEO of Celltrion and has a deep understanding 
of the pharmaceutical and biotechnology industry and the ability to establish the company’s vision 
and present strategies in line with industry trends; and Hyukjae Lee, who has led the company’s 
pipeline development based on his practical experience in various fields and stable leadership. The 
BoD comprises nine members, including independent directors and inside directors. The appointed 
directors are committed to supporting the company’s continuous growth and enhancing the value 
for all stakeholders through fair and reasonable decision-making.
Category
Jungjin 
Seo
Jinseok 
Seo
Woosung 
Kee
Hyukjae 
Lee
Younghyeh 
Ko
Keunyoung 
Kim
Daehyun 
Yoo
Soonwoo 
Lee
Jaesik 
Lee
Industry
/Managementt
⃝
⃝
⃝
⃝
Accounting/Tax
⃝
Finance
⃝
Medicine
⃝
⃝
Economy/
Society
⃝
BoD Competency Evaluation
Board of Directors
Celltrion ESG Report 2022/23
71
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Category
Name
Date of 
appointment 
/expiry 
Position
Key experience
Joint 
Chairperson 
(Inside Director)
Jungjin Seo 
(Male)
2023-03-28
2025-03-28
Joint Chairperson of the BoD
Chairman of the Celltrion Group
JInseok 
Seo (Male)
2021-03-26
2024-03-26
Joint Chairperson of the BoD
Former Head of the Product Development Unit of Celltrion
Former Senior Vice President of Management of Celltrion 
Skincure
Inside Directors
Woosung 
Kee (Male)
2014-03-27
2026-03-28
CEO
CEO of Celltrion
Former Vice President of Nexol Biotech, Planning Office 
of Daewoo Motor Company
Hyukjae Lee 
(Male)
2020-03-27
2026-03-28
Head of the Executive 
Management Unit
Currently Head of the Executive Management Unit, 
Celltrion
Independent 
Directors
Younghyeh 
Ko (Female)
2022-03-25
2024-03-25
A Member of the Audit Committee
A Member of the Compensation 
Committee 
A Member of the Independent 
Director Candidate 
Recommendation Committee
A Member of the ESG Committee
Head of Department of Pathology, Jeju Halla Hospital
Visiting Professor, Department of Pathology, Korea 
National University Hospital Guro
Former Visiting Professor, Department of Pathology, the 
Korean Society of Pathologists
Former Vice President of the Korean Society of 
Pathologists
Former Associate Professor, Samsung Medical Center, 
Sungkyunkwan University
Keunyoung 
Kim (Male)
2020-03-27
2024-03-25
A Member of the Audit Committee
A Member of the Compensation 
Committee 
A Member of the Independent 
Director Candidate 
Recommendation Committee
Chairperson of the ESG 
Committee
Co-Chairperson, Incheon Citizens’ Coalition for Economic 
Justice
Former Vice President of Incheon Love Movement 
Citizens Council
Former Head of Strategic Planning Office of Songdo 
Global Complex 
Daehyun 
Yoo (Male)
2020-03-27
2024-03-25
A Member of the Audit Committee
A Member of the Compensation 
Committee
Chairperson of the Independent 
Director Candidate 
Recommendation Committee
A Member of the ESG Committee
Professor of Rheumatology, Hanyang University
Former Director of Hanyang University Rheumatology 
Hospital
Former Vice President, Asia Pacific League of 
Associations for Rheumatology
Former President of the Korean College of Rheumatology
Soonwoo 
Lee (Male)
2020-03-27
2024-03-25
A Member of Audit Committee
Chairperson of the Compensation 
Committee
A Member of the Independent 
Director Candidate 
Recommendation Committee
A Member of the ESG Committee
Distinguished Professor of Business Administration, Halla 
University
Former Chairman of the 17th Korea Federation of Savings 
Bank 
Former Advisor of Woori Card
Former Chairman of Woori Financial Group
Former President of Woori Bank
Jaesik Lee 
(Male)
2020-03-27
2024-03-25
Chairperson of Audit Committee
A Member of the Compensation 
Committee
A Member of the Independent 
Director Candidate 
Recommendation Committee
A Member of the ESG Committee
Certified Public Accountant (CPA)
Adjunct Professor of Business Administration, Hanyang 
University
Former Adjunct Professor of Business Administration, 
Daejeon University
Former Vice Chairman and Advisor, Samjong KPMG 
Former Chairman of Korea Exchange Delisting 
Substantive Examination Committee
BoD Independence/Expertise/Diversity
In order to ensure the independence of the BoD, Celltrion restricts the selection of independent 
directors from the company’s largest shareholders, who are persons with material interests in the 
company. Furthermore, in order to enhance transparency, when appointing independent directors, 
candidates are required to go through a fair recommendation process according to the Regulations 
of the Independent Director Candidate Recommendation Committee, and the appointment should 
be approved at the AGM. In the case of inside directors, candidates are recommended by the BoD. 
Directors are appointed for tenures up to three years and may be re-appointed by the AGM after 
their term expires. However, the term of independent directors cannot exceed six years. In order to 
maintain the independence of the BoD, it is stipulated that a majority of Celltrion’s BoD shall consist 
of independent directors rather than inside directors. The BoD’s chairman helps the board oversee 
corporate management more objectively, sets the atmosphere for effective discussions among di-
rectors, and sometimes acts as a mediator. In addition, independent directors exchange opinions 
freely on the overall management at each committee, including enhancing corporate value and 
building a sustainable management system. Due to the rapidly changing business environment, 
the BoD is required to make timely, strategic, and careful judgment, which necessitates high levels 
of expertise and diversity of directors. In order to maximize the growth and value of the company, 
we carefully appoint individuals who have a good understanding of the pharmaceutical industry 
and the company and also have a wide range of expertise and experience with responsibilities in 
various areas, including management, accounting, finance, medicine, economics, and society The 
Independent Director Candidate Recommendation Committee comprises experts in the pharma-
ceutical industry, finance, and accounting, and selects candidates as per strict criteria. Furthermore, 
the Committee oversees the execution of management’s duties while providing sufficient support, 
such as responding to requests for information related to decision-making to ensure efficient deci-
sion-making. Celltrion’s policy does not allow discrimination based on gender, race, nationality, eth-
nicity, or place of origin when appointing directors. Our BoD is comprised of directors with diverse 
backgrounds, experience, expertise, and capabilities. We are committed to putting diversity into 
practice. For instance, we appointed one female independent director in 2022.
Policy on the Diversity and Expertise of the BoD
Policy on the Independence of Independent Directors
Average tenure of the BoD
3.3years
Celltrion ESG Report 2022/23
72
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

BoD Activities
The BoD, Celltrion’s highest decision-making body, conducts regular and extraordinary meetings. 
Article 6 of the BoD Regulations requires regular meetings to be held once a quarter and extraor-
dinary meetings  when necessary. Other details of the BoD operations are set out in our Articles of 
Incorporation and BoD Regulations. 
In 2022, we held a total of 12 BoD meetings, with an average attendance rate of 95 % for directors at 
the meetings. The BoD performed deliberations on major management issues, including approval of 
agreements/transaction limits between affiliates, approval of the annual business plan, and acquisition 
of treasury shares. In addition to performing deliberations on agenda items, the BoD reports on im-
portant issues whenever necessary, such as the features of the industry and changes to the business 
environment, regulatory changes, and financial reporting to ensure effective business performance.
Date
Agenda Items
Attendance Rate
2022-01-10
[Item to be Approved]
· Approval of treasury share buyback
88.9%
2022-02-16
[Item to be Reported]
· Audit Report on Financial Statement and Business Report for the 31st fiscal 
period
· Report on activities of the Internal Accounting Control System for the 31st fiscal 
period
· Report on evaluation of activities conducted by the Internal Accounting Control 
System for the 31st fiscal period 
[Items to be Approved]
· Approval of Financial Statements for the 31st fiscal period
· Approval of Business Report for the 31st fiscal period
· Amendment of the Regulations of BoD
· Amendment of the Audit Committee Regulations
· Revocation of stock option grant
· Decision to convene the 31st AGM and approval of the 31st AGM agenda items
· Decision to adopt the e-voting system
88.9%
2022-02-21
[Item to be Approved]
· Approval of changes in agenda items submitted to the 31st AGM
· Revocation of stock option grant
· Approval of treasury share buyback
88.9%
2022-03-08
[Item to be Reported]
· Audit Report on Financial Statement and Business Report for the 31st fiscal period 
[Items to be Approved]
· Approval of adjustment on Financial Statements (consolidated/non-consolidated) for 
the 31st fiscal period
· Approval of adjustment on Business Report for the 31st fiscal period
· Approval of changes in agenda items submitted to the 31st AGM
88.9%
BoD’s Activities in 2022
Date
Agenda Items
Attendance Rate
2022-03-25
[Items to be Approved]
· Appointment of Compensation Committee members
· Appointment of Independent Director Candidate Recommendation Committee 
members
90.0%
2022-04-20
Items to be Approved]
· Approval of adjustment on Financial Statements (consolidated/non-consolidated) for the 
26th to 31st fiscal periods
88.9%
2022-05-12
[Items to be Reported]
· Report on 1Q22 closing accounts
[Items to be Approved]
· Approval of business plan for 2022
88.9%
2022-05-18
[Items to be Approved]
· Approval of treasury share buyback
100.0%
2022-05-30
[Items to be Approved]
· Approval of special consolation benefit payment
100.0%
2022-08-05
[Items to be Reported]
· Report on 2Q22 closing accounts
[Items to be Approved]
· Divestment of Celltrion USA, Inc.
· Revocation of stock option grant
· Approval of the trademark transfer agreement on domestic cosmetics
· Establishment of the ESG Committee and enactment of ESG Committee rules 
and regulations
· Appointment of members of the ESG Committee
100.0%
2022-11-09
[Items to be Reported]
· Report on 3Q22 closing accounts
· Report on the ESG policy establishment plan
[Items to be Approved]
· Approval of the change of 2022 limit for contracts/transactions
· Revocation of stock option grant
100.0%
2022-12-16
[Items to be Reported]
· Report on the 2022 result for inspection of the adherence to the compliance 
guidelines
[Items to be Approved]
· Decision on stock dividend for the 32nd fiscal period
· Decision on cash dividend for the 32nd fiscal period
· Approval of change in development cost claim for CT-P59 phase III clinical trials
· Approval of limit for 2023 contracts/transactions pursuant to the Korean 
Commercial Code
· Approval of limit for 2023 credit grants for related parties pursuant to the Korean 
Commercial Act
· Approval of payment of contributions to group companies for the 2022 KLPGA 
Celltrion Queens Masters tournament
· Approval of plans for 2023 Occupational Safety and Health Plan
100.0%
Celltrion ESG Report 2022/23
73
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

BoD Training and Assessment
Celltrion invites specialists and experts by area to provide training at the request of directors or when 
the company deems it necessary to ensure the smooth performance of the BoD’s duties. In addi-
tion, for the effective performance of duties, important issues such as changes in the nature of the 
industry and the company’s business environment and changes in regulations are reported when 
necessary, and materials such as management issues and agenda information are provided when 
the need arises. 
We assess the performance of registered directors, excluding independent directors, as a basis for 
compensation. For inside directors, we use quantitative assessment indicators such as sales, operat-
ing profits, and rate of achieving the production target to conduct a multifaceted assessment in terms 
of business performance, special performance, and organizational management performance. We do 
not conduct internal or external assessments for independent directors, but we are considering as-
sessments based on internal criteria such as expertise, attendance rate, and independence.
Date
Training Topic
Purpose
Method
2022-04-04
Introductory Training
Introductory training for the Audit Committee
Online
2022-08-05
Prohibition on the Use of 
Undisclosed Material Information
Training on Unfair Transactions under  
the Financial Investment Services and  
Capital Markets Act
Face-to-face
2022-10-26
Anti-bribery Management  
System (ISO37001) at a Glance
Compliance and Ethics Training
Online
2022-12-28
Internal Accounting Control  
System
Implementation of the Consolidated Internal 
Accounting Control System in 2023
Online
Training for Independent Directors in 2022
Category
Payment Criteria
Inside 
Directors
· Paid within the limit set by the AGM, based on internal standards such as criteria for  
determining executive salary and comprehensively reflecting other matters.
Independent  
Directors
· Payment level varies in consideration of integrity, fairness, expertise and the level of  
remuneration in similar industries, within the limit set by the AGM.
· There are no separate performance-based pay and stock option awards tied to business performance. 
Remuneration Criteria for Directors 
	
Operation of Board Committees
Board Committees 
Celltrion has established four Board committees: the Audit Committee, which performs the roles and 
functions related to internal control, including approval and reporting of mandatory items, as well as 
reporting of non-financial incidents; the Independent Director Candidate Recommendation Com-
mittee, which recommends candidates for the appointment of independent directors and conducts 
substantive screening of candidates in accordance with the Commercial Act and related laws; the 
Compensation Committee, which is established to ensure objectivity and transparency in determining 
the remuneration for registered directors; and the ESG Committee, which aims to realize long-term 
sustainable growth by strengthening ESG management covering the areas of environment, society, 
and governance. Each Committee has established and complies with its respective committee rules 
to ensure transparency in its operations. In addition, the ratio of appointment of independent directors 
for each Committee is specified in the relevant committee rules, and the independence of each com-
mittee is guaranteed by maintaining the ratio of independent directors above the required level.
Board Committees
Category
Composition
Purpose of Establishment, Authorities, etc.
Audit Committee
Five 
independent 
directors
· Purpose of establishment (Article 1 of the Audit Committee Regulations) 
  - Proper and effective performance of audit duties
· Authority (Article 6 of the Audit Committee Regulations)
  - Auditing the execution of directors’ duties 
  - Requesting directors, etc., to report on business and investigating  
their activities at the company and their assets, etc.
Compensation 
Committee
Five 
independent 
directors
· Purpose of establishment (Article 1 of the Compensation Committee Regulations)
  -To ensure objectivity and transparency in the process of determining directors’ 
remuneration
· Authority (Article 8 of the Compensation Committee Regulations)
  - Pre-deliberate and approve the limits of HR/remuneration to be submitted  
to the AGM for final approval
  - Review and approve the individual remuneration for directors  
(inside directors, independent directors, and other non-executive directors)
  - Review and approve the performance-based remuneration of the CEO
Independent 
Director Candidate 
Recommendation 
Committee
Five 
independent 
directors
· Purpose of establishment and authority (Article 3 of the Independent Director 
Candidate Recommendation Committee Regulations)
  - The authority to recommend independent directors to be appointed at the AGM
ESG Committee
Five 
independent 
directors
· Purpose of establishment and authority  
(Article 3 of the ESG Committee Regulations)
  - Implement strategic and systematic management of environmental, social,  
and governance issues to achieve long-term sustainable growth
  - Provide advice and review the company’s sustainability strategy and  
ESG direction
Celltrion ESG Report 2022/23
74
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Audit Committee
The Audit Committee oversees the work of the directors and reviews and performs deliberations 
on major issues so that the company can enhance corporate and shareholder value continuously 
through reasonable decision-making. The members of the Audit Committee are all independent 
directors appointed by a resolution at the AGM, and have the expertise - two of them are accounting 
and financial experts - including the chairperson of the Audit Committee. The Committee’s oper-
ations, authorities, and responsibilities are specified in the Audit Committee Regulations, and the 
committee performs its duties accordingly. Its major activities are disclosed in the annual report
Date
Agenda Items
Attendance Rate
2022-03-25
[Items to be Reported]
· Report on 2022 plans of the Internal Audit Department activities and evaluation 
of the Internal Accounting Control System
· Report on evaluations for audit activities by independent auditors in 2021
[Items to be Reported]
· Appointment of the Audit Committee Chair
100.0%
2022-04-20
[Items to be Reported]
· Report of adjustment on Financial Statements (consolidated/non-consolidated) 
for the 26th to 31st fiscal periods
· Additional report of internal audit of Financial Statements (consolidated/non-
consolidated) for the 26th to 31st fiscal periods
80.0%
2022-05-12
[Items to be Reported]
· Report on 1Q22 closing accounts
· Report on internal audit on Financial Statements for 1Q22
· Report on the 1Q22 report status of the whistleblowing program
· Report on evaluation of independence and operation of the Internal Audit 
Committee in 2021
80.0%
2022-08-05
[Items to be Reported]
· Report on the Internal Control Improvement Plan related to supervisory 
measures stipulated by the Securities and Futures Commission
· Report on 2Q22 closing accounts
· Report on internal audit of Financial Statements for 2Q22 
· Report on the status of the internal reporting system in 2Q22
100.0%
2022-11-09
[Items to be Reported]
· Report on the appointment of independent auditor
· Report on 3Q22 closing accounts
· Report on regular business audit 
· Report on internal audit of Financial Statements for 3Q22
· Report on status of 3Q22 internal reporting system
100.0%
2022-12-16
[Items to be Reported]
· Report on the evaluation of the independence and operation of the Internal 
Audit Department in 2022
· Report on the evaluation and adjustment of remuneration for the head of the 
Internal Audit Department in 2023
· Report on the independent auditor’s audit activity plan (remuneration, 
manpower, time) for 2023
100.0%
Date
Agenda Items
Attendance Rate
2022-02-16
[Items to be Reported]
· Report on activities of the Internal Accounting Control System for the 31st fiscal 
period
· Report on Financial Statements (consolidated/non-consolidated) for the 31st 
fiscal period
· Report on Business Report for the 31st fiscal period
· Report on internal audit of Financial Statements for the 31st fiscal period
· Confirmation of submission of the 31st (consolidated/non-consolidated) 
Financial Statements to the FSC and independent auditors
· Evaluation on validity of the Audit Committee Regulations
· Report on the 4Q21 report status of the whistleblowing program
[Items to be Approved]
· Submission of the evaluation report on the internal accounting control system 
for the 31st fiscal period
· Submission of the Independent Auditor’s Report for the 31st fiscal period 
(Financial Statements and Business Report)
· Amendment of the internal audit regulations
· Review of agenda items submitted to the 31st AGM
80.0%
2022-02-21
[Items to be Approved]
· Approval of changes in agenda items submitted to the 31st AGM
80.0%
2022-03-08
[Items to be Reported]
· Report on adjustment on Financial Statements (consolidated/non-consolidated) 
for the 31st fiscal period
· Report on adjustment on Business Report for the 31st fiscal period
· Additional report on the internal audit of Financial Statements for the 31st fiscal 
period
[Items to be Approved]
· Submission of Independent Auditor’s Report for the 31st fiscal period (Financial 
Statements and Business Report)
· Approval of changes in agenda items submitted to the 31st AGM
80.0%
Activities of the Audit Committee in 2022
Celltrion ESG Report 2022/23
75
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Compensation Committee
The Compensation Committee  was established to ensure objectivity and transparency in determin-
ing the remuneration for registered directors and is composed entirely of independent directors. The 
committee conducts independent reviews and approves the limits of inside directors’ remuneration 
(including salary and severance pay, fringe benefits, etc.), the individual remuneration for registered 
directors, and the performance-based payment for the CEO and inside directors, which are pre-
sented to the AGM.
Independent Director Candidate Recommendation Committee 
In accordance with applicable laws and regulations, Celltrion proposes candidates for the posi-
tion of independent directors at the AGM following recommendation by the Independent Director 
Candidate Recommendation Committee and deliberation by the BoD. To ensure independence, 
our Independent Director Candidate Recommendation Committee has been composed entirely of 
independent directors since the 2023 AGM, which is stricter than the legally required composition of 
the committee. The Independent Director Candidate Recommendation Committee is operated to 
ensure fair recommendation of candidates for the position of independent directors. The committee 
manages the process of nominating and electing candidates by reviewing their areas of expertise 
and personal capabilities in a comprehensive manner while ensuring compliance with legal require-
ments concerning the selection of independent directors. We conduct careful reviews of candi-
dates’ background to prevent the appointment of independent directors with a history of damaging 
corporate value or infringing shareholders’ rights and interests.
ESG Committee
Celltrion recognizes the importance of ESG management in light of the strengthening of ESG reg-
ulations and the increasing demand for ESG from major stakeholders such as investors, rating 
agencies, and customers. We have practiced ESG management in earnest since 2022. In August 
2022, we established the ESG Committee, comprised of all independent directors, under the BoD 
to ensure independence and transparency in ESG management. The ESG Committee reviews the 
direction of the company’s ESG strategy and plays a role in the strategic and systematic manage-
ment of the environmental, social, and governance sectors so that the company can achieve long-
term sustainable growth. It is also responsible for performing deliberations and making decisions on 
tasks, plans to be pursued, and major policies in ESG areas such as environment, safety, society, 
customer value, shareholder value, and governance. In the future, we plan to expand the BoD’s 
sustainability responsibilities and roles while continuing discussions on major ESG-related issues to 
enhance long-term corporate value.
Date 
Agenda Items
Attendance Rate
2022-01-10
· Approval of individual remuneration for registered directors
80.0%
2022-02-16
· Proposed limit (tentative) to directors’ remuneration
80.0%
2022-03-25
· Approval of the appointment of the head of the Compensation 
Committee
· Approval of individual remuneration for registered directors
100.0%
2022-04-20
· Method of determining individual remuneration for the CEO
80.0%
Activities of the Compensation Committee in 2022
Date
Agenda Items
Attendance Rate
2022-02-16
· Approval of candidates recommended for the position of independent directors
87.5%
2022-03-25
· Approval for appointment of the head of Independent Director Candidate 
Recommendation Committee
88.9%
Activities of the Independent Director Candidate Recommendation Committee in 2022
Date
Agenda Items
Attendance Rate
2022-08-05
· Approval for appointment of the chairperson of the ESG Committee
· Approval of the ESG Management Plan
100.0%
2022-11-09
· Approval for establishing ESG policies
100.0%
Activities of the ESG Committee in 2022
Celltrion ESG Report 2022/23
76
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Fair Performance Appraisal and Remuneration
The Compensation Committee determines directors’ remuneration within the limits of executives’ 
remuneration approved by the AGM. Celltrion discloses the directors’ remuneration through annu-
al reports. Inside directors’ performance is appraised in consideration of the company’s business 
performance and organizational management performance, etc.; and their annual remuneration 
amount is determined in accordance with the standards for executives’ remuneration. 
We are considering the evaluation of independent directors based on internal criteria such as exper-
tise, meeting attendance rate, and independence. We set their remuneration levels based on their 
expertise and the level of remuneration in the same industries.
In addition, we grant stock options to eligible employees after deliberations based on Article 11 of 
the Articles of Incorporation and internal regulations, and submit a proposal to the AGM to approve 
the granting of stock options but do not grant them separately to independent directors.
Category
Person
Amount Approved at the AGM 
Note
Registered directors
9
KRW 9,000 million 
Amount Approved at the AGM 
Category
Person
Total amount of 
remuneration
Average remuneration 
per person
Registered directors (Except for independent 
directors and members of the Audit Committee)
4
KRW 4,169 million 
KRW 1,042 million
Audit Committee members  
(All are independent directors as well)
5
KRW 363 million 
KRW 73 million 
* Total remuneration includes remuneration for one independent director (Won-suk Kim) who retired on April 1, 2022, and one independent director 
(Young-hyeh Ko) appointed on March 25, 2022.
Remuneration (As of December 2022)
Category
Units
2022
Total remuneration for the CEO
KRW million
1,660
Average employee remuneration
86
Median employee remuneration
74
Average (mean) pay for the CEO compared to employees’ wages
Times
19
Average (median) pay for the CEO compared to employees’ wages
22
Average Pay for the CEO Compared to Employees’ Wages
* The average employee remuneration mentioned above is the sum of the monthly average wages.
** The median employee remuneration mentioned above is the remuneration for the person in the middle of the descending order of employee 
remuneration.
*** Following the announcement of accepting the minimum wages, it was decided through the Compensation Committee that the remuneration 
for CEO Woosung Kee would be recognized as an expense only and deferred in full without even paying the minimum wages until the stock 
price reaches a certain level. Accordingly, there was no remuneration received by the CEO from April 2022 after the 31st AGM until the date of 
publishing the ESG Report.
Appraisal and Remuneration of the BoD
Celltrion ESG Report 2022/23
77
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

COMPLIANCE 
AND ETHICAL 
MANAGEMENT
GOVERNANCE - 02
As society pays closer attention to corporate ethics, 
related laws and regulations have become stricter and 
it has become more important than ever to implement 
compliance and ethical management. 
Celltrion implements compliance and ethical management 
to help employees understand the standards for correct 
value judgments in their work and daily lives and to 
establish a healthy corporate culture. 
We have also established a compliance management 
system to manage possible risks and support and 
strengthen compliance activities.
Celltrion ESG Report 2022/23
78
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Compliance Guidelines
Celltrion has established and implemented the Compliance Guidelines  through a resolution of the 
BoD to ensure compliance with laws and regulations, establish proper business ethics, and promote 
fair and transparent business activities. The Compliance Guidelines  serve as the basic regulation 
for compliance management and apply to the company’s business and its employees’ activities in 
their entirety. In 2022, we kept revising and improving related regulations to strengthen compliance 
management related to promotional and sales activities and anti-corruption. For instance, we newly 
established the Ethical Advertising and Marketing Policy and the Anti-Corruption and Anti-Bribery 
Policy after obtaining approval from the ESG Committee.
Anti-Corruption and Anti-Bribery Policy 
Code of Ethics
Celltrion has established an Ethics Charter, which serves as a standard for proper conduct and value 
judgment, and an Ethics Policy and Code of Ethical Conduct, which set specific rules and standards 
of conduct and are mandatory for all employees to follow.
Compliance and Ethical Policies
Compliance and Ethical Management System
Celltrion has formed the Compliance Team, a dedicated compliance and ethical management body, 
under the Corporate Sustainability Division directly under the CEO, and has appointed a Compli-
ance Officer who meets the legal and independence requirements after obtaining approval from 
the BoD. The Compliance Officer oversees activities of the Compliance Team and is supported by 
the Legal Department, and performs all aspects of compliance and ethical management, including 
compliance checks and reporting of results, implementation of related training, review of board 
agendas, and decision-making support. Celltrion manages compliance risks in key management ar-
eas such as anti-corruption, fair trade, intellectual property, security of personal information, human 
resources, environmental safety, and healthcare, and is strengthening its management system by 
introducing the ISO 37001 (Anti-bribery Management System). 
Compliance Risk Management 
For systematic and effective management of compliance and ethics, Celltrion has established and 
operates a compliance risk management process consisting of five steps: identification of risk, as-
sessment, mitigation planning, monitoring, and reporting. In addition, the Compliance Team focuses 
on managing key risks by running the Internal Transaction Review System, an IT system that moni-
tors internal transaction risks continually.
Risk Management Process
➊	
Identification of Risk
· Identify key trends and compliance issues
· Categorize risks and update the list of categories according to relevant 
regulations 
➋	
Risk Assessment
· Rate risks depending on impact and frequency
· Select key risks to manage
➌	
Risk Mitigation Planning
· Establish a risk mitigation plan for each relevant legal area
· Review and update the risk mitigation plan regularly
➍	
Risk Monitoring
· Check compliance status with a checklist by legal area
· Monitor the status of key risk responses and management
➎	
Risk Reporting
· Report on the status of compliance risk management on a regular basis
· Report to the BoD on the results of compliance checks conducted by 
the Compliance Officer
Spare no efforts to 
become a trusted 
company
Create value for 
customers
Maximize  
the profits for 
shareholders
Implement 
management that 
respects humans
Perform social 
responsibilities
Ethics  
Charter
Celltrion ESG Report 2022/23
79
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Celltrion runs a systematic training program categorized into basic training, advanced training, 
specialized training, and Anti-bribery Management System training, depending on the purpose and 
target, to prevent illegal and fraudulent acts at work while minimizing risks. In addition, we are intro-
ducing measures to raise employees’ compliance and ethical awareness and internalize compliance 
culture, such as collecting compliance pledges from employees every year, publishing compliance 
newsletters regularly, producing and distributing Anti-bribery PR materials, and conducting cam-
paigns.
Celltrion is striving to build an ESG management system and upgrade its compliance system to 
meet the growing demand for compliance and ethical management from stakeholders. In 2021, we 
established an Anti-bribery Management System for all of Celltrion’s domestic business sites based 
on the ISO 37001 international standard. We also obtained certification by the British Standards 
Institution (BSI), a global certification organization, in December of the same year. We manage risks 
effectively by identifying business-related stakeholder issues for all departments, identifying and as-
sessing bribery risks and establishing management measures, taking actions against major bribery 
risks, and conducting due diligence. In 2022, we conducted a post-audit to verify the effectiveness 
of our Anti-bribery Management System certification. In the future, we will continue improving our 
Anti-bribery Management System and strengthen monitoring to prepare proactively for growing 
bribery risks due to various internal and external factors.
Anti-bribery Management System
Compliance Training and Culture
Compliance Training
Anti-bribery Promotional Materials and Campaigns
Compliance Newsletters
Category
Objective
Target
Training hours/ 
Participants in 2022
Basic compliance training
Raise basic awareness  
regarding compliance and ethics
All employees
2,170 hours / 2,170 persons 
Advanced compliance 
training
Understand business-related 
regulations
Departments related 
to key risks
463 hours / 409 persons
Specialized compliance 
training
Reinforce compliance 
competency
Compliance and  
Legal Departments
122 hours / 43 persons
Anti-bribery Management 
System training
Reinforce anti-bribery 
competency
Person in charge of 
assessing bribery risks
93 hours / 62 persons
Compliance Training Hours
2,848 hours
Compliance Training Participants 
2,684 employees
Celltrion ESG Report 2022/23
80
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Reporting Compliance and Ethics Violations 
Reporting and Disciplinary Actions
Category 
2019
2020
2021
2022
Total no. of corrective actions taken 
6
27
30
15
Minor disciplinary actions
3
14
16
5
Serious disciplinary actions
3
13
14
10
Disciplinary Actions Taken (Unit: case)
Category 
2019
2020
2021
2022
Reporting (Company/Employee)
9
29
35
18
Reporting and Receipt (Unit: case)
Category
Category
2019
2020
2021
2022
Negligence
1
13
6
6
Conflicts of interest
0
0
0
0
Bribery
0
0
0
0
Embezzlement of assets
0
0
1
0
Workplace harassment/Sexual harassment 
2
6
4
5
Violation of information security
1
1
7
1
Other ethics violations
2
7
12
3
Reason for Disciplinary Actions (Unit: case)
Celltrion runs an internal reporting system to prevent illegal and fraudulent acts related to the com-
pany’s business, such as improper receipt of money and goods, unfair trade behaviors, and infringe-
ment of trade secrets, and to practice compliance and ethical management. Anyone who becomes 
aware of illegal and unfair business activities by employees or violations of the Code of Ethical Con-
duct can report anonymously to the Internal Reporting Manager. The informant’s identity and the de-
tails of the report are kept confidential to ensure that the informant does not suffer any disadvantage 
due to the report. Upon receipt of such a report, we carry out an investigation and take appropriate 
measures, including disciplinary action depending on the severity of the case, and report the details 
and the investigation results to the Audit Committee every quarter.
Reporting Compliance and Ethics Violations
What Should Be Reported
· Business-related bribery or improper solicitation
· Conflicts of interest against company interests
· Embezzlement of company funds or breach of trust 
· Use or leakage of internal information
· Unfair trade behaviors, such as preferential treatment, discrimination, or collusion against certain 
companies
· Violation of accounting laws and accounting standards
· Violation of service regulations, such as negligence
· Other illegal or unfair acts
How to report
· E-mail: InternalAudit@celltrion.com
· Post: Internal Reporting Manager, Celltrion 23, Academy-ro, Yeonsu-gu, Incheon
· Company website or internal groupware
Celltrion ESG Report 2022/23
81
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

RISK 
MANAGEMENT
GOVERNANCE - 03
With the aim of maintaining stable and sustainable 
business activities, we have established an Integrated 
Risk Management System to prevent and respond to 
various risks. 
We categorize risks into financial and non-financial 
risks (operational, strategic, legal, and external), and 
our specialized risk management department initiates 
systematic and detailed responses. 
In view of the gradually expanding scope of non-financial 
risks, we analyze and draw out potential risks in advance 
and manage them effectively to initiate preemptive 
responses.
Celltrion ESG Report 2022/23
82
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Integrated Risk Management Organization/Process
In order to maintain stable and sustainable business activities, Celltrion has established an Integrat-
ed Risk Management System with capabilities to prevent and respond to various risks. Various risks 
that may arise during business activities are classified into financial and non-financial risks for pro-
fessional management, and the departments in charge of each type perform primary risk monitoring 
and control activities. At this time, each department identifies possible issues promptly during risk 
response and shares them with the risk management department, which reports to the CEO and 
the BoD when company-wide decisions are needed to prevent or control such risks, and manages 
them separately.
On the other hand, financial risks are mainly managed through various control activities under the 
Internal Accounting Control System. Non-financial risks are managed through the ESG Committee 
according to the materiality of each issue to ensure a macro-systematic response. This reflects our 
internal decision that, as the importance of ‘social capital’ and ‘ESG management’ has increased 
in recent years, the scope of non-financial risks and the corresponding responses need to be up-
graded. We will continue improving and strengthening our Integrated Risk Management System to 
respond more actively to various risks.
Risk Management System
Internal Accounting Control System and Internal Control 
Celltrion strives not only to increase the reliability of its disclosed financial statements but also to 
prevent the occurrence of risks through compliance with laws, regulations, and policies related to 
our business activities. For this, we have implemented a high-level Internal Accounting Control Sys-
tem, and introduced measures such as the division of unit tasks, physical control, and management 
of system access rights, to establish immediate problem-solving procedures if internal control is 
insufficient to analyze the possibility of various risks and to block risks in advance. In addition, we 
subdivide internal control activities into general IT control, process control, and enterprise-wide con-
trol activities to enhance the effectiveness of risk reduction measures for each task. The department 
regularly identifies and evaluates accounting fraud risks that could lead to the provision of erroneous 
information in the financial statements, and its operational effectiveness is thoroughly verified by in-
dependent auditors every year.
ISO 22301 (Business Continuity Management System) Certification 
Celltrion has established and certified a Business Continuity Management System (BCMS) under 
the ISO 22301 international standards to ensure that we can normalize our business and produce 
medicines stably within a short period in the event of various crises such as natural disasters, fires, 
supply chain disruptions, and wars. As a result, we have identified various types of disasters as well 
as core businesses activities that require continuity, and established a Business Continuity Plan 
(BCP) to minimize the impact on us as well as our investors, customers, and suppliers. We plan to 
strengthen our inspection and surveillance system and continue monitoring internal and external 
crisis factors for stable development and production of pharmaceuticals.
Celltrion’s Integrated Risk Management Organization
BoD
CEO
Risk Management Department
ESG Committee
Audit Committee
Financial Risks
Non-financial Risks
Business Impact  
Analysis
Risk  
Assessment
Business Continuity 
Strategy
Business  
Continuity Plan
Celltrion’s BCMS Operation
Analyzed 538 critical 
activities that should 
be recovered first
Identified and 
assessed 249 risks 
that might cause 
suspension of critical 
activities
Set continuity strategies 
depending on core 
business activities/
disaster types and 
identify the resources for 
implementation
Prepare implementation 
procedures for recovery 
strategies and make  
a final confirmation of 
their effectiveness. 
BIA
RA
BCS
BCP
Financial Risk
· Capital
· Credibility
· Foreign exchange
· Liquidity
· Tax
· Interest rate
Strategic Risk
· Reputation
· Investment
· M&A
· Management
· New business
Operational Risk
· Research
· Production
· Procurement
· Supply chain
· New business
· Security
Legal Risk 
· Dispute
· Lawsuit 
· Patent
· Compliance
· Public disclosure
· Anti-corruption
External Risk
· Nation
· Policy
· Natural disaster
· Customer 
· Competitor
Celltrion ESG Report 2022/23
83
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Identification and Management of Major Risks for Celltrion
Celltrion manages financial and non-financial (operational, strategic, legal, and external) risks ac-
cording to various risk categories and types surrounding its business activities. For systematic risk 
management, departments in charge of each type of risk are designated, and the results of assess-
ment on major risk categories and response strategies are reported to the CEO, Audit Committee, 
or ESG Committee, and finally to the BoD.
Category Risk Type
Definition of Risks
Actions
Financial 
Risk
Liquidity 
Risk
Risk of inability to repay debt  
in time due to insufficient funds
· Analyze cash flow and make responses after forecasting 
short, mid and long-term balance of payments
Foreign 
Exchange 
Risk
Risk of monetary losses due to 
currency fluctuations
· Mid and long-term balance of payments planning and 
management for major foreign currencies (USD, EUR)
· Prohibit speculative foreign exchange transactions that 
are not based on real demand and potentially risky 
transactions involving derivatives
Interest 
Rate Risk
The risk of causing interest expense 
and loss of interest income due to 
changes in interest rates
· Constant monitoring of factors driving interest rates 
· Analyze fixed and variable interest rates by period and 
apply interest rates on borrowings and manage them to 
minimize net interest costs
Credit  
Risk
The risk of failure to collect on  
a receivable due to deteriorating credit 
rating or defaults of the counterparty
· Set a bad debt allowance based on each counterparty’s 
financial condition, credit rating, and past transactions.
The risk of inability to recover deposits 
due to financial institutions’ credit risk
· Manage most cash by placing it in a prime bank’s 
principal-protected product.
Non-
financial 
Risk
Operational 
Risk
The risk of worker safety and health 
being compromised by hazards in the 
workplace.
· Established an ISO 45001 system (Safety and Health 
Management System) to keep workers safe against 
occupational accidents and various dangers and reduce 
economic losses due to the accidents
· Pursue policies to promote workers’ engagement and 
support for occupational accident prevention activities
Risks of unlawful collection, use, 
disclosure, leakage, misuse,  
and distribution of personal  
information without legal grounds
· Appointed the Chief Privacy Officer (CPO); and set 
and implemented company-wide personal information 
security plans
· Destroy personally identifiable information on PCs used 
for work and in the cloud through an identification 
information cleaning system
Strategy 
Risk
The risk of failure to identify and 
sustain growth drivers in  
a rapidly changing and increasingly 
competitive global pharmaceutical 
market.
· Identify and manage mid to long-term growth drivers 
based on advice and deliberation by the Investment 
Committee consisting of experts in different areas 
(technology, legal affairs, finance) for large-scale 
facilities, product development, new business, and 
M&A investments.
Risk Management by Type
Category Risk Type
Definition of Risks
Actions
Non-
financial 
Risk
Legal Risk
Risk of financial and non-financial 
losses due to violation of various 
legal and institutional provisions such 
as enactment and amendment of 
laws, precedents, regulations, and 
contractual acts.
· Constant monitoring of domestic and foreign laws and 
regulations
· Introduced an enterprise-wide compliance system for 
regular risk checks and monitoring in seven areas
Risks that have a negative impact on 
our reputation due to corruption or 
criminal incidents or financial risks that 
cause financial losses due to legal 
violations.
· Built an Anti-Bribery Management System (ISO37001) 
to prevent and respond appropriately to bribery risks.
· Identify and assess bribery risk annually and report the 
results to the BoD.
External 
Risk
The risk of failure to meet stakeholder 
requirements related to ESG against 
the growing social interest in ESG 
management. 
· Established an ESG management governance system 
by creating a dedicated department, ESG TF, and the 
ESG Committee.
· Diagnose Celltrion’s ESG management situations 
considering global initiatives and stakeholder 
requirements and identify improvement tasks by area
Risk of foreign policy and regulatory 
changes that have a negative effect on 
the biotech industry
· Monitor policy and regulatory trends in major countries, 
such as the US and EU, related to the biotech industry
Tax Risk Management Activities
Celltrion complies with national tax laws and fulfills its tax filing and payment obligations in good 
faith, in line with its core value of “complying with principles and valuing faith and trust.” We preserve 
documentary evidence of transactions. We maintain a transparent relationship with tax authorities 
by complying with payment deadlines and submitting data promptly and transparently when re-
quested. For domestic transactions, we maintain arm’s-length transaction prices for transactions 
with third parties and related parties following relevant laws. For international transactions, we com-
ply with OECD’s guidelines for transfer pricing based on expert advice to prevent global tax risks. 
Celltrion’s dedicated tax department proactively monitors tax-related risks that may arise in business 
operations and makes decisions based on sufficient risk assessment and review following tax prin-
ciples to prevent tax transaction risks. Furthermore, tax risks are prevented by reviewing, analyzing, 
and reporting on new tax interpretation cases and revised tax laws every year.
Tax Risk Management
Celltrion ESG Report 2022/23
84
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Tax Principles
· Comply with tax laws and regulations of each country 
· Prohibit tax avoidance and exploitation of differences in tax laws between countries
· Adhere to arm’s length pricing in related party transactions 
· Manage global risk by filing BEPS reports
· Provide data transparently and promptly to tax authorities
Tax Risk Assessment
In order to ensure compliance with domestic and overseas taxation and reporting laws and regula-
tions and fulfill its social responsibilities related to taxes, Celltrion established tax policies and makes 
every effort to prevent tax risks arising from its business activities. When making important business 
decisions, such as trading goods and services, acquiring shares, conducting international transac-
tions, developing new businesses, and changing transaction structures, we review tax risks thor-
oughly in cooperation with internal organizations and external experts and reflect the results in our 
final decisions.
Tax Policy 
Major Emerging Risks
Celltrion regularly monitors major emerging risks in each area necessary for management activities, 
identifies their impact on the business, and introduces proactive activities such as establishing re-
sponse strategies and taking measures.
Management of Emerging Risks 
Major Risks
Background
Impact on Business
Strategies and Actions
Growing physical risk 
due to climate change
Keywords
· Climate change
· Rising sea levels
· Natural disasters
· Supply chain
· The headquarters is located in a 
low-lying area with a distance of 
about 600 m from the coast and an 
altitude of about -3 m from sea level.
· Major raw material and production 
equipment are sourced from 19 key 
overseas suppliers that have their 
headquarters in overseas countries. 
· Increasing natural disasters 
worldwide such as earthquakes, 
tsunami, and typhoons due to global 
warming and climate change
· Factory flooding and production 
disruption due to rise in sea 
level or tsunami
· Destruction of facilities and 
production disruption due to 
typhoons, earthquake, etc.
· Disruption of raw material 
supply and delays in production 
schedule from key suppliers 
due to natural disasters
· Established a Business 
Continuity Management System 
(ISO 22301)
· Established a company-wide 
Supply Chain Management 
System
· Drive the establishment of our 
own logistics chain
Deteriorating business 
viability due to 
excessive competition 
in the biosimilar 
sector
Keywords
· Biopharmaceuticals
· Biosimilars
· Pharmaceutical 
industry
· Marketability
· The biosimilar market share went 
down with a combined revenue 
growth of approximately 10% for 
the first movers, including Celltrion, 
compared to the annual average 
growth rate (approx. 56%) for the 
market.
· Continued growth of biosimilar 
latecomers and competing 
products, including conversion of 
major pharmaceutical companies to 
the biopharmaceutical business
· Intense price competition 
among biosimilars and 
reduction in pharmaceutical 
prices eroding profitability
· Limited patient recruitment 
due to market entrance by 
latecomers in the biosimilar 
sector; increase in costs due  
to rising R&D costs
· Reduced marketability of our 
products due to the advanced 
strategy of originators
· Product differentiation for 
improved convenience  
(e.g., Remsima SC)
· Reduce R&D costs by strategic 
planning of clinical trials and 
approval
· Platform development 
and expansion such as 
development of new medicine, 
microbiome, ADC, and 
bispecific antibodies
Increased risk of 
breach of national 
core technologies
Keywords
· Cyber terrorism
· National core 
technologies
· Protection of 
industrial technology
· Information security
· The recent escalation of the U.S.-
China technological rivalry has led to 
increased investment and activity in 
pre-empting advanced technologies 
in the short term.
· Breaches continue because it is not 
easy to prove violations of the Act 
on Prevention of Divulgence and 
Protection of Industrial Technology. 
· Growing prevalence of 
cyberterrorism following the 
increasing pace of digital 
transformation across society.
· Leakage of national core 
technologies related 
to biopharmaceutical 
manufacturing, resulting in 
significant financial losses and 
weakened competitiveness.
· Emergency suspension of 
drug production and business 
activities due to failure of  
IT systems
· Various financial and operational 
risks for the recovery
· Designated a dedicated 
information security department 
and established a dedicated 
department to protect national 
core technologies
· Strengthened the information 
leakage management system 
and established a national core 
technology protection system
· Pursuing ISO 27001 
(Information Security 
Management System)
Growing transition 
risk due to insufficient 
response to 
global eco-friendly 
regulations
Keywords
· Eco-friendliness
· Emissions Trading 
Scheme
· Carbon neutrality 
· Customers 
· Potential reduction in GHG 
emissions and increase in trading 
prices as Nationally Determined 
Contributions (NDCs) are raised and 
new roadmaps established
· EU confirms the introduction of 
the Carbon Border Adjustment 
Mechanism (CBAM)
· EU industrial sector to reach 100 % 
auctioning by 2032
· Increased production 
costs, including the cost of 
purchasing carbon credits 
due to decreased quotas and 
increased trading prices.
· Disruption of drug supply and 
sales and loss of market share 
due to non-compliance with 
global environmental rules and 
regulations such as the EU 
Supply Chain Act.
· Damage to reputation among 
investors and other customers 
due to poor ESG ratings on 
environmental factors.
· Established an Environmental 
Management System 
(ISO14001)
· Established a dedicated 
sustainability management 
department and strengthened 
climate change response
· Promoting preemptive 
responses to carbon tax 
burdens (regular monitoring of 
legislation, and investigating 
transitional measures for 
applicable product groups)
Celltrion ESG Report 2022/23
85
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

SUPPLY CHAIN 
MANAGEMENT
GOVERNANCE - 04
As supply chain risks intensify amid the global economic 
uncertainty, it has become increasingly important to 
establish a stable supply chain. 
In order to strengthen the sustainability of the supply chain, 
Celltrion is working to establish a responsible Supply Chain 
Management System and minimize risk to its partners 
through ESG-based supply chain evaluation.
In addition, we support our partners by conducting various 
win-win cooperation programs for shared growth with our 
partners.
Celltrion will maintain an organic and close relationship 
with its partners throughout the supply chain and secure 
competitive advantage through co-prosperity.
Celltrion ESG Report 2022/23
86
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Supply Chain Management System
Supplier Management System
Supplier Quality Management Process
Celltrion carries out regular quality audits at different intervals (every 1-4 years) for each of its suppli-
ers to ensure that they adhere to the current Good Manufacturing Practices (cGMPs).
* e.g. Commercial CMO: Every 1 year, Major raw/sub materials: Every 3 years, Raw materials or other services: Every 4 years
Through these regular quality audits, we share information on matters that should be improved 
or where action should be taken for each partner company’s facilities, raw material management, 
quality systems, etc., within a minimum of one month and exchange opinions on the progress of 
improvements and measures within a minimum of one month. Through this management system, 
we have been able to maintain the quality of our products and ensure that our suppliers’ products 
maintain a uniform quality level.
Take corrective actions
Close contractual relations
Action
Guidance & Monitoring
Monitoring
· Registration conditions, contractual provisions, assessment, audits
· Supplier ESG Management Policy and Purchase Rules
Policy
Awareness
Global Guidelines and Standards
Stakeholders’ Channel
Internal Risk Management Process
· RBA, EcoVadis, ILO, DJSI, CHRB, 
PSCI
· Annual review and deliberation on subcontractors/consignments/major suppliers
SCM Risk Profile
· Business review meeting 
· On/offline meeting to manage 
issues
· Weekly technical meeting 
· Monthly internal control  
(Supplier registration, management 
of procurement information 
records, etc.)
Suppliers’ Operation Status
Celltrion defines suppliers as companies involved in its biopharmaceutical and small molecule develop-
ment and production activities, and selects Tier 1 suppliers based on: 1) whether they are involved in the 
development/production of biopharmaceuticals and small molecules and 2) whether they have worked 
with Celltrion for three consecutive years. Further, 3) those who account for the top 80% in terms of the 
transaction amount are selected as key suppliers. However, in exceptional cases, a supplier may be 
selected as a key supplier regardless of the transaction amount considering the supplier’s ESG manage-
ment level and country, region, and material-specific risk through preliminary investigation.
Responsible Supply Chain Management Procedures
Category
Sub-category
2022
Suppliers
Share of procurement (%)
Tier 1 
Total suppliers
374
100
Suppliers by region
Domestic
250
15
Overseas
124
85
Key suppliers 
19
80
Key Suppliers
Procurement Management Organization
Procurement Department
* ESG Committee manages and supervises supply chain management and governance 
CMO service
Equipment and 
supplies (Including 
maintenance)
Raw/sub-materials for 
production
Shipping validation
Product  
development service
Sourcing new raw/ 
sub materials  
(Localization/dualized)
Consumables
Consumables for QC 
and QC service
Transport
Small molecule 
development and  
CRO services
Construction
Customs clearance
S/W and licenses
Procurement  
Planning Team
Manufacturing 
Procurement Team
Product Development 
Procurement Team
Integrate  
Procurement Team
Customs & Logistics 
Management Team
Supplier Management
Celltrion ESG Report 2022/23
87
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Supplier ESG Management Policy
In order to build a sustainable supply chain, Celltrion has established a Supplier ESG Management 
Policy that specifies the social responsibilities that all suppliers in business relationships must per-
form. The policy covers four areas: labor and human rights, safety and health, environment, and 
ethical management. For mutual growth with suppliers, we prevent and manage potential ESG risks 
proactively by encouraging all suppliers with whom we sign transactions to comply with this policy in 
major ESG areas.
Supplier ESG Management Policy
Supply Chain Selection and Assessment
Supplier ESG Assessment System
To build sustainable collaboration with our suppliers and strengthen their ESG competency, Celltrion 
has established a supplier ESG Assessment System and utilizes it to diagnose and improve suppli-
ers’ ESG risks. We assess suppliers’ ESG performance based on ESG assessment indicators in five 
areas: labor and human rights, safety and health, environment, ethics, and management system. 
Depending on the outcome of the evaluation, we give excellent suppliers additional points in the 
future bidding process, and if risks are found, we categorize them as low-risk/high-risk suppliers ac-
cording to the degree of risk and develop and recommend a corrective action plan.
Labor and Human Rights 
Safety & Health 
Environment 
Ethics
Management System
ESG Assessment Indicators for Suppliers
OHS management system  
and training
General
Emergency response capabilities
Reduction of pollutants
Physical labor 
Air pollutants
Occupational safety
Environment-related licenses  
and reporting
Occupational hygiene
Processed waste
Occupational accidents
Hazardous substances  
management
Maintaining the safety  
of mechanical facilities  
Water management
Food, sanitation, and housing
Energy and GHG emissions 
General
Preventing unfair trade practices 
Security of personal information 
Anti-corruption and  
conflicts of interest
Responsible sourcing of materials
Protecting intellectual property
Others  
(Minimizing animal testing, etc.)
Executives’ engagement
Supplier relationships and 
management
Performance management
Social contribution
Voluntary work
Working hours
Non-discrimination
Underage workers
Humane treatment
Wages and welfare benefits
Freedom of association
General
Celltrion ESG Report 2022/23
88
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

ESG Assessment for Suppliers
To ensure expertise, objectivity, and reliability in the ESG assessment of our suppliers, Celltrion, to-
gether with a third-party assessor, conducted a self-assessment of a total of 82 assessment items 
in the areas of labor and human rights (23), safety and health (24), environment (15), ethics (14), and 
management system (6) over a period of about two months from the second half of 2022 to the first 
half of 2023 for a total of 14 key suppliers. We conducted on-site assessment for two of them.
The ESG assessment of suppliers is conducted in the following order: self-assessment, on-site as-
sessment, and monitoring of improvement. The self-assessment analyzes answers to general and 
detailed items and supporting materials. Based on the assessment results, an on-site assessment is 
conducted for suppliers with identified ESG risks. For this assessment, we selected domestic com-
panies that can cooperate with assessment among the companies subject to the self-assessment. 
Afterward, results of the self-assessment and on-site assessment are combined to confirm the risks, 
and we request the suppliers to take active improvement measures and develop improvement plans 
regarding the identified risks. 
Implementation of ESG Assessment for Suppliers
Category
Sub-category
No. of suppliers
Note
Supplier ESG  
Assessment
Key suppliers
19
-
Self-assessment of key suppliers2)
14
74% of key suppliers
On-site assessment for key suppliers3)
2
14% of suppliers that 
conducted a self-assessment
Identify Suppliers  
with Risk1)
Suppliers with high risk
0
-
Suppliers with low risk
1
-
Results of Supplier ESG Assessment in 2022
1) Suppliers with high ESG risks: To check potential ESG risks, we used a total of 82 evaluation indicators (23 in labor rights, 15 in environment, 24 in 
safety and health, 14 in ethical management, and 6 in management system). Suppliers with serious violations are identified as high-risk suppliers. 
Suppliers that are rated below a certain level are categorized as low-risk suppliers.
2) Self-assessment: Suppliers who have completed the online ESG self-assessment
3) On-site assessment: Third-party inspections involving external experts
Results of ESG Assessment for Suppliers
According to the ESG risk assessment for suppliers, our key suppliers showed excellent ESG per-
formance overall. However, they were found to be relatively weak in reducing pollutants in the envi-
ronment category, minimizing animal testing, and developing measures in the ethics area. Based on 
the assessment results, we will develop a plan to support our suppliers in improving their ESG per-
formance and eliminating risks. To reduce pollutants, we will distribute our ESG management policy 
to our suppliers so that they can refer to it in implementing improvement measures. If necessary, we 
will assist them in improving their management capabilities by providing training on GMP, quality, 
etc., to prepare countermeasures for animal testing. 
In the future, Celltrion plans to provide training programs for suppliers to strengthen their ESG 
capabilities, and for high-risk suppliers, we plan to help them implement corrective/improvement 
measures. In addition, we will continue to provide ongoing ESG training to Celltrion’s internal pro-
curement organization and enhance our supplier assessment process to improve the overall level of 
ESG management along our supply chain.
Supplier ESG Assessment Process
Self-assessment
· Utilize online platforms
· Analyze results and identify high-risk suppliers 
* Check if suppliers obtained EcoVadis, ISO certifications, etc.
On-site Assessment
· Carry out assessment and verification on the results of self-assessment
· Identify on-site risks
· Deriving improvement tasks regarding each of the identified risks
Derivation of Results 
· Identify risks for each supplier
Development of 
Corrective Plans and 
Taking Follow-up 
Actions
· Develop corrective plans for items that need improvement
· Request suppliers to take corrective actions
· Monitor whether suppliers are implementing corrective actions
* The process is subject to change under EU Corporate Sustainability Due Diligence.
Celltrion ESG Report 2022/23
89
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Accompanied Growth and Mutual Cooperation Activities with Suppliers
Supporting the Biotech Industry Ecosystem
Celltrion is committed to fulfilling its responsibilities as the first mover in Korea’s biosimilar sector. 
Since 2020, we have been jointly operating the ‘Shinhan Square Bridge Incheon’ program with 
Shinhan Financial Group to find and foster startups in the biotech materials/parts/equipment, new 
drugs, and digital healthcare areas. We have pursued over 50 Open Innovation Projects and re-
viewed technologies through this project. Especially, in October 2022, as part of with the Incheon 
Startup Park project, we signed a joint research agreement with Pinotbio to introduce the technol-
ogy implementation option for ADC linker-payload platform, equity investment, and joint research. 
Furthermore, regarding biotech materials/parts/equipment, we provided coaching to Umtr, a mem-
brane filter development and manufacturing startup, for about two years and provided support with 
product demonstration tests using Celltrion’s development infrastructure and facilities as a test bed. 
Celltrion will continue to do its best to create momentum for the biotech industry and contribute to 
the community.
Performance of Localizing Raw/Sub Materials
As part of Vision 2030 and in preparation for disruptions in the procurement of raw materials due 
to global trends whereby countries are trying to protect their own industries amid the COVID-19 
pandemic, Celltrion, together with the Ministry of Trade, Industry and Energy and the Korea Bio, has 
been pursuing the localization of materials/parts/equipment and raw materials in the domestic bio-
tech industry. Based on the achievements made so far, we will pursue supply stability and fulfill our 
mission as the first mover in Korea’s biosimilar industry.
In August 2020, Celltrion initiated the localization 
review of several sampling bags used for test-
ing In-Process Control (IPC). Drawing, sample 
reviews and technical feedback with the involve-
ment of relevant departments (production, techni-
cal support) resulted in the production of items in 
2021 that were ready for use. In January 2022, we 
used domestic products for Celltrion’s develop-
ment project. Since there were no quality issues, 
we finally registered them in the in-house system 
and revised all quality documents in the second half of 2022. In the second half of 2023, we plan to 
introduce and use the sampling bags for commercial projects. We are currently engaged in further 
discussions on localization with several companies for the items. We will exert efforts to make sure 
that localization has a positive impact in promoting the industry’s technological competence. 
Localizing Production Process Sampling Bags
Sampling Bags
CASE 1
Celltrion reviewed the localization of consum-
ables used in single-use plants to minimize the 
risk of long lead time due to COVID-19. The 
review process began in February 2021, and we 
started using consumables used for the harvest 
phase in the culture process in June 2021. In 
addition, we localized products consumed in 
the process of removing viruses, which is one 
of the purification process steps in the same 
plant, and started using the products in January 
2022. Through this mutual  cooperation, we will 
overcome the limitations of the biotech industry, where the localization rate for equipment is rela-
tively low, and set a meaningful precedent, paving the way for becoming a biotech materials/parts/
equipment strong country.
Localization of Consumables for Single-use Plant Culture and 
Purification Processes 
Signing Ceremony for Disposable Bag Supply 
Agreement between Celltrion and ECell
CASE 2
Accompanied Growth
Celltrion ESG Report 2022/23
90
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

INFORMATION 
SECURITY
GOVERNANCE - 05
Celltrion is conducting various information security 
activities with the goal of safeguarding information assets 
based on a sophisticated and predictive security system.
To fulfill our obligation to protect national core technologies 
in the biotechnology field, we appointed a Chief Information 
Security Officer (CISO) and a Chief Privacy Officer (CPO), 
and formed a dedicated information security organization 
under the Corporate Sustainability Division supervised by 
the CEO.
In order to upgrade our information security system, we will 
acquire international standard certification (ISO 27001) to 
promote information security awareness and strengthen 
our cyber-security capabilities.
Celltrion ESG Report 2022/23
91
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Organization and System 
Information Security Organization
Celltrion has appointed executives who have relevant expertise as the Chief Information Security Of-
ficer (CISO), who oversees information security, and the Chief Privacy Officer (CPO), who oversees 
personal information security, and established a dedicated information security organization under 
the Corporate Sustainability Division directly supervised by the CEO through reorganization in April 
2022. We regularly operate the Information Security Committee, which is chaired by the CISO and 
consists of executives from each business division to share the company-wide information security 
agenda. The Information Security Committee discusses agenda items that require consultation and 
decisions on various security issues.
Objectives of Information Security
Celltrion aims to identify the information assets to be protected, diagnose potential risks to the iden-
tified information, and establish and implement appropriate security measures. Through this, we 
strive to check and protect information assets systematically. With the mission and vision of creating 
a safety net for information security based on ‘prediction-based active security,’ we pursue the  five 
core values. In addition, we are conducting various information security activities that meet the glob-
al security standards, and plan to obtain ISO 27001 certification, an international standard for infor-
mation security management systems, in 2023.
Establishment of Information Security and Privacy Policies and Guidelines
In 2019, Celltrion documented its information security policy and enacted 15 guidelines and proce-
dures, including the Information Security Management Regulation, as company regulations. All our 
information security-related regulations and procedures are revised continuously in accordance with 
compliance regulations and changes in the internal working environment and are regularly reviewed 
at least once a year. In 2021, we enacted the Personal Information Security Regulations. Similarly, 
we regularly review them at least once a year to reflect changes in relevant laws and regulations and 
disclose the findings to all employees through the internal regulations bulletin board in the group-
ware. 
Information Security Management System 
Information Security Management Organization
System Operation Control Team
Information Security Team
Information Planning Team
Head of Information Security 
Department  
CISO/CPO
Corporate Sustainability 
Division
CEO
Information Security Committee
Five Core Values
Governance
Ensure employees’ accountability for information security by 
responding proactively to changes in business and IT technologies and 
continuously optimizing our own regulations.
Responsibility  
and Trust
Based on employees’ clear understanding of their security 
responsibilities and authority, we create a sense of autonomy and trust 
through transparent disclosure and restrictions as well as sophisticated 
control of behaviors that threaten security.
Communication 
and Change 
Management
Create a mature information security culture by inducing a sense of 
responsibility and voluntarism among employees through change 
management and planning of information security to create a positive 
security mindset.
Sophisticated 
Preventive 
Security
Identify protection targets that require preventive security while 
ensuring employees’ convenience and autonomy, and utilize new 
technologies actively based on proportionality.
Digital 
Innovation
Maintain timeliness by responding proactively to security threats and 
preparing alternatives following technological changes such as DT and 
OT.
Celltrion ESG Report 2022/23
92
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Personal Information Security Activities
Celltrion complies with the standards set forth by current laws throughout the life cycle of personal 
information based on the internal management plan for personal information, and clearly notifies 
the information subject through the privacy policy posted on the website. We renew our personal 
information liability insurance annually in preparation for damages to information subjects in the 
event of personal information leakage, and take technical protection measures such as encryption 
and access control to protect personal information from cyber-attacks. In addition, we conduct reg-
ular self-diagnosis on the current status of personal information processing, develop improvement 
tasks, and establish implementation plans to improve the level of personal information security.
Information Security Disclosure
In order to fulfill its information security disclosure obligations under the revised Information Security 
Industry Promotion Act, Celltrion made its first information security disclosure in June 2022.
Celltrion has been fulfilling its disclosure obligations faithfully by submitting disclosure data, including 
information security investment status, workforce status, and information security activity details to 
the Information Security Disclosure Portal to disclose its information security status transparently.
Process for Prevention of Security Accidents and Response
Information Leakage Management System
As a company with national core technology, Celltrion is obliged to manage and control the leakage 
of core information related to its business and operates the “Information Leakage Management Sys-
tem” to prevent unauthorized leakage of crucial company information, including personal informa-
tion. Every month, we conduct self-inspections on acts that violate information security. After going 
through a justification process, we impose penalties on those violating information security rules and 
reward outstanding employees for reducing violations of information security regulations.
Cyber-Attack Simulation Training (Phishing Simulation)
To prevent security incidents caused by malicious emails, Celltrion has prepared countermeasures 
considering the possibility of being targeted by cyber-attacks. In order to prevent possible security 
incidents, we have been conducting simulations to improve employees’ ability to respond to mali-
cious emails and to allow them experience malicious email samples that are similar to the real world.
Furthermore, since 2021, we have established our own simulation system for sophisticated and 
effective training. In 2022, we doubled the frequency of simulations to enable employees experience 
and respond to more cases and thereby prevent security incidents caused by malicious emails thor-
oughly.
No special issues with what was justified
Justification process 
Step 01
Check  
for violation 
Step 02
Select who is subject 
to justification
Step 07
Case closed
Step 04
Receive the 
justification report
Step 03
Request  
justification
· Send an email to the employee 
subject to justification
① Non-cooperation, evasion, or refusal
② Repeated violations
③ Serious violations
· Once a month, led by the Information 
Security Team
Step 06
Separate actions/
Disciplinary measures
Information Security Activities
Step 05
Review the  
justification received
Celltrion ESG Report 2022/23
93
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Security Control and Monitoring
Celltrion manages its information assets safely through various pre- and post-management sys-
tems. We conduct risk analysis on services and systems subject to the information security man-
agement system, carry out constant monitoring and response to abnormal signs of information 
leakage, and establish and improve follow-up plans for discovered risks. In 2022, we implemented a 
web application firewall in preparation for cyber-attacks on our web services for external public use, 
and in 2023, we plan to establish a SIEM (Security Information and Event Management) system to 
ensure a sophisticated and immediate response to system abnormalities. We also conduct security 
reviews of our systems to meet legal requirements, and strive to create an environment where suffi-
cient security measures can be applied.
Celltrion has established procedures to strictly control permissions to access various assets and 
systems, as well as manage exceptional permissions. In accordance with the principle of granting 
the minimum permissions within the necessary scope, we grant permissions only to selected em-
ployees and record and store the history of applications for assignments, changes, and removals. 
We also conduct periodic reviews on the appropriateness of permissions and delete unnecessary 
permissions immediately. For employees with privileged access, we prevent security incidents 
caused by privileged users through mailings of security risk warnings by type.
Personal Information Security System and Compliance
Celltrion encrypts files containing personal information in accordance with the Personal Information 
Protection Act, and once a year, we conduct a full survey of unique identification information (resident 
registration numbers) stored on work PCs and file-sharing systems, destroying unnecessary data. If 
necessary, we prepare supporting rules and store encrypted information. In addition, we participate 
actively in the unique identification information survey conducted by the Personal Information Pro-
tection Commission to conduct diagnosis and make immediate improvements on necessary mat-
ters. Based on this, we have introduced a DB encryption solution to encrypt DBs containing unique 
identification information. In 2022, we have introduced a server access control solution to ensure 
personal information safety by controlling access records and access to servers. 
Information Security Training
Activities to Enhance Information Security Awareness among Employees
Celltrion conducts annual information security training for all employees to raise information security 
awareness. We provide customized security training for new employees, retirees, and those that 
handle core information when necessary. We strive to promote a corporate culture of information 
security. For employees handling personal information, we offer regular personal information secu-
rity training and recently expanded the scope of training to entire employees. In addition, we share 
security newsletters containing precautions and response guidelines for the latest security incident 
cases through the company-wide announcement channel. We also share information security pol-
icies and systems, information security practice guidelines, and the latest malicious email cases 
through the information security bulletin board. We strive to raise security awareness by sharing 
privacy policies, systems, and practices through relevant bulletin boards so that all employees can 
understand the privacy policy and safely protect personal information.
※ In 2022, 2,160 employees received information security (personal information) training, with an average of 28 new hires per month.
Information Security Campaign
Celltrion organizes an annual ‘Information Security Day’ event to help employees understand the 
importance of information security. At the event in 2022, screensavers were created and distributed 
to inform employees of information security practices. In addition, we distributed webcam covers as 
souvenirs to help them protect their personal information in real life, thereby encouraging employ-
ees’ participation and interest while spreading the information security culture. Furthermore, four 
industrial security posters were placed at each site of company to help employees recognize the 
importance of protecting industrial technology at a glance.
Establishment of Information Security Culture
Information Security Day Event
Information Security 
Training Participants
2,160 employees
Information Security Newsletter posts
Celltrion ESG Report 2022/23
94
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

As a national core technology holder in the biotechnology field (“Animal Cell Culture/Purification 
Process Technology of 10,000 Liters or More”) pursuant to Article 9 of the Act on Prevention of Di-
vulgence and Protection of Industrial Technology (hereinafter referred to as the Industrial Technology 
Protection Act), Celltrion conducts various activities to fulfill its obligation to protect national core 
technologies based on government policies and laws.
National Core Technology Protection System
Establishment of National Core Technology Protection and Management System
In order to fulfill its obligation to protect national core technologies, including export reporting, Celltri-
on established an information security organization directly under the CEO and enacted the National 
Core Technology Security Management Regulations in April 2022, including the designation of na-
tional core technologies, handling experts, physical security, system security, Deliberation Commit-
tee, and maintenance of regulations to protect national core technologies.
Protection and Management of National Core Technology
Celltrion has designated 67 employees in the Regulatory Affairs Division that handles pharmaceu-
tical Common Technical Documents (CTD) as experts in handling national core technologies, and 
conducts information security activities for those who handle national core technologies, such as 
collecting confidentiality pledges, training, and collecting confidentiality and non-competition pledg-
es when leaving the company. In addition to the CTD, a classification suitability assessment was 
conducted to select documents with high impact in the event of information leakage, in that these 
documents may cause an adverse impact on the competitiveness of national core technologies if 
taken out of the country without permission. To protect these critical technologies, we operate an 
intrusion prevention system, access control system, data leakage prevention system, and mail se-
curity system.
Reporting of Export of National Core Technology
Businesses that own national core technologies are required to safeguard the national core technol-
ogies in their possession based on government policies and laws. When businesses need to take 
the national core technology materials out of Korea, they should declare the intent and request de-
liberation to the Ministry of Trade, Industry, and Energy for exports. Celltrion made seven export dec-
larations in 2022 and delivered national core technology documents after receiving notice of report 
reception without prior leakage. For the company intending to receive the national core technology 
by transfer, we use a checklist containing 34 items to verify the company’s stability and whether it 
has an information security system to protect national core technologies. Celltrion’s Virtual Desktop 
Infrastructure (VDI) is provided to companies with inadequate security systems to protect their infor-
mation assets against information leakage.
Protecting National Core Technologies
The Outcome of National Core Technology Protection Activities and 
Direction of Improvement
In May 2022, Celltrion underwent a preliminary inspection by the National Intelligence Service in sev-
en areas related to the protection of national core technologies, including workforce management, 
security management, and management systems, and was evaluated as having a good level of pro-
tection in all areas. In 2023, we plan to introduce a document encryption system to strengthen the 
security level of materials related to national core technology. 
No. of Countries 
72
No. of Companies  
30
No. of Products 
8
40
35
30
25
20
15
10
5
0
Export Report of National Core Technology (as of 2022)
Tier 1 
Tier 2
Tier 5
Tier 3
Tier 6
Tier 4
Tier 7
● Products  ● Companies  ● Countries
Celltrion ESG Report 2022/23
95
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

ESG 
FACTBOOK
Financial Information
Non-financial Information
97
102

Financial Performance
Financial Information
Consolidated Statement of Financial Position (As of the end of December 2022; Unit: KRW million)
Category
2020
2021
2022
Assets
	 Current assets
2,516,495 
3,074,471 
2,929,792 
	 	
Cash and cash equivalents
684,294 
1,188,326 
551,187 
	 	
Short-term financial assets
14,034 
31,575 
43,277 
	 	
Trade receivables
1,252,395 
1,101,089 
1,621,890 
	 	
Other receivables
63,322 
63,294 
32,200 
	 	
Inventories
384,325 
578,057 
616,352 
	 	
Other current assets
118,125 
112,130 
64,886 
	 Non-current assets
2,503,626 
2,599,652 
2,961,860 
	 	
Long-term financial assets
31,346 
24,435 
29,274 
	 	
Long-term trade receivables
62,888 
	 	
Long-term other receivables
10,138 
12,491 
91,154 
	 	
Investments in associates
48,027 
64,841 
88,535 
	 	
Property, plant and equipment
946,280 
950,412 
1,007,038 
	 	
Intangible assets
1,404,189 
1,491,571 
1,622,326 
	 	
Other non-current assets
34,659 
27,279 
28,461 
	 	
Deferred tax assets
28,988 
28,623 
32,184 
	 Total assets
5,020,121 
5,674,123 
5,891,652 
Category
2020
2021
2022
Liabilities
	 Current liabilities
1,056,767 
1,210,480 
1,294,098 
	 	
Short-term financial liabilities
595,784 
569,598 
665,012 
	 	
Trade payables
33,963 
80,723 
50,270 
	 	
Other payables
266,224 
228,419 
320,244 
	 	
Current tax liabilities
100,356 
179,552 
88,705 
	 	
Provisions
2,617 
3,849 
1,487 
	 	
Other current liabilities
57,824 
148,338 
168,379 
	 Non-current liabilities
535,774 
413,268 
323,350 
	 	
Long-term financial liabilities
202,958 
174,757 
154,468 
	 	
Long-term other payables
15,973 
13,985 
7,576 
	 	
Other non-current liabilities
230,638 
202,950 
160,202 
	 	
Deferred tax liabilities
86,205 
21,576 
1,105 
	 Total liabilities
1,592,541 
1,623,748 
1,617,448 
Equity
	 Equity attributable to owners of the parent
3,307,677 
3,917,238 
4,139,360 
	 	
Issued capital
134,998 
137,947 
140,805 
	 	
Share premium
812,156 
840,337 
853,172 
	 	
Retained earnings
2,475,297 
3,052,474 
3,485,110 
	 	
Accumulated other comprehensive income 
6,298 
24,987 
48,746 
	 	
Other components of equity
(121,072)
(138,508)
(388,472)
	 Non-controlling interest
119,903 
133,137 
134,844 
	 Total equity
3,427,580 
4,050,375 
4,274,204 
Total liabilities and equity
5,020,121 
5,674,123 
5,891,652 
Celltrion ESG Report 2022/23
97
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Consolidated Statement of Profit or Loss (As of the end of December 2022; Unit: KRW million)
Category
2020
2021
2022
Revenue
1,849,317 
1,893,401 
2,283,967 
Cost of sales
821,452 
805,807
1,251,270
Gross profit
1,027,866 
1,087,594 
1,032,697 
Selling and administrative expenses
305,526 
343,417
385,499
Operating profit
722,340 
744,177 
647,198 
Other income
48,684 
53,500 
47,524 
Other expenses
84,478 
84,964
87,043
Finance income
9,578 
42,294 
24,945 
Finance costs
37,670 
12,798
13,507
Profit (loss) on equity method
2,590 
(3,586)
7,056 
Profit before income tax 
661,044 
738,623 
626,173 
Income tax expenses
134,474 
152,821
94,827
Continuing operations profit for the year
526,570 
585,803 
531,347 
Discontinued operation profit for the year
(868)
9,977 
11,220 
Profit for the year
525,703 
595,779 
542,566 
Attributable to:
	 Owners of the parent company
517,760 
579,465 
537,836 
	 	
Continuing operations profit
518,627 
569,488 
526,616 
	 	
Discontinued operations profit
(868)
9,977 
11,220 
	 Non-controlling interests
7,943 
16,315 
4,731 
	 	
Profits from continuing operations
7,943 
16,315 
4,731 
	 	
Profits from discontinued operations
Earnings per share:
	 Basic earnings per share (Unit: KRW)
3,855 
4,160 
3,894 
	 Diluted earnings per share (Unit: KRW)
3,834 
4,141 
3,888 
Consolidated Statement of Comprehensive Income (As of the end of December 2022; Unit: KRW million)
Category
2020
2021
2022
Profit for the year
525,703 
595,779 
542,566 
Other comprehensive income
3,241 
19,199 
23,839 
	 Other comprehensive income that may be 
reclassified as profit or loss in subsequent 
periods:
(7,038)
27,351 
22,797 
	 	
Exchange differences on translation of 
foreign operations
(7,038)
27,351 
22,797 
	 Other comprehensive income that will not 
be reclassified to profit or loss in subsequent 
periods:
10,280 
(8,152)
1,042 
	 	
Equity adjustments in equity method
138 
(270)
1,048 
	 	
Exchange differences pertaining to 
translation of foreign operations
(53)
121 
80 
	 	
Gain (loss) on valuation of financial assets 
measured at fair value through other 
comprehensive income
13,756 
(11,677)
171 
	 	
Gain on disposal of financial assets 
measured at fair value through other 
comprehensive income
396 
536 
	 	
Income tax effects relating to components of 
other comprehensive income (loss)
(3,957)
3,138 
(258)
Total comprehensive income
528,944 
614,978 
566,405 
Attributable to:
	 Owners of the parent 
521,228 
598,542 
561,594 
	 Non-controlling interests
7,717
16,436 
4,811 
Celltrion ESG Report 2022/23
98
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Consolidated Statement of Changes in Equity (As of the end of December 2022; Unit: KRW million)
Category
Issued capital
Share premium
Retained 
earnings
Accumulated other 
comprehensive income 
Other components 
of equity
Total equity attributable 
to owners of the parent
Non-controlling 
interests 
Total 
As of January 1, 2020 (Beginning Equity)
128,338 
786,358 
1,963,728 
3,000 
(121,315)
2,760,109 
112,804 
2,872,913 
	 Profit for the year
517,760 
517,760 
7,943 
525,703 
	 Gain on valuation of financial assets measured at fair value 
through other comprehensive income
10,236 
10,236 
(313)
9,924 
	 Gain on disposal of financial assets measured at fair value 
through other comprehensive income
170 
170 
139 
309 
	 Exchange differences on translation of foreign operations
(7,038)
(7,038)
(53)
(7,092)
	 Equity adjustments in equity method
100 
100 
100 
	 Stock dividends
6,360 
(6,360)
	 Cash dividends
	 Exercise and forfeit of stock warrants
300 
25,797 
(7,018)
19,079 
264 
19,343 
	 Recognition of stock warrants
21,416 
21,416 
818 
22,234 
	 Acquisition of treasury stocks
(14,762)
(14,762)
(1,104)
(15,866)
	 Other capital
	 Changes in percentage of ownership in subsidiaries, etc.
607 
607 
(607)
	 Additional acquisition of investment stocks in a subsidiary
12 
12 
As of December 31, 2020 (Ending Equity)
134,998 
812,156 
2,475,297 
6,298 
(121,072)
3,307,677 
119,903 
3,427,580 
As of January 1, 2021 (Beginning Equity)
134,998 
812,156 
2,475,297 
6,298 
(121,072)
3,307,677 
119,903 
3,427,580 
	 Profit for the year
579,465 
579,465 
16,315 
595,779 
	 Loss on valuation of financial assets measured at fair value 
through other comprehensive income
(8,466)
(8,466)
(8,466)
	 Gain on disposal of financial assets measured at fair value 
through other comprehensive income
389 
389 
389 
	 Exchange differences on translation of foreign operations
27,351 
27,351 
121 
27,472 
	 Equity adjustments in equity method
(196)
(196)
(196)
	 Stock dividends
2,676 
(2,676)
	 Cash dividends
* Continued on the next page
Celltrion ESG Report 2022/23
99
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Category
Issued capital
Share premium
Retained 
earnings
Accumulated other 
comprehensive income 
Other components 
of equity
Total equity attributable 
to owners of the parent
Non-controlling 
interests 
Total 
	 Exercise and forfeit of stock warrants
274 
28,181 
(7,914)
20,541 
925 
21,466 
	 Recognition of stock warrants
23,965 
23,965 
1,511 
25,476 
	 Acquisition of treasury stocks
(33,891)
(33,891)
(5,235)
(39,126)
	 Other capital
	 Changes in the percentage of ownership in subsidiaries, etc.
404 
404 
(404)
	 Additional acquisition of subsidiary investment shares
As of December 31, 2021 (Ending Equity)
137,947 
840,337 
3,052,474 
24,987 
(138,508)
3,917,238 
133,137 
4,050,375 
As of January 1, 2022 (Beginning Equity)
137,947 
840,337 
3,052,474 
24,987 
(138,508)
3,917,238 
133,137 
4,050,375 
	 Profit for the year
537,836 
537,836 
4,731 
542,566 
	 Gain on valuation of financial assets measured at fair value 
through other comprehensive income
191 
191 
191 
	 Gain on disposal of financial assets measured at fair value  
through other comprehensive income
	 Exchange differences on translation of foreign operations
22,797 
22,797 
80 
22,878 
	 Equity adjustments in equity method
770 
770 
770 
	 Stock dividends
2,732 
(2,732)
	 Cash dividends
(102,468)
(102,468)
(102,468)
	 Exercise and forfeit of stock warrants
126 
12,835 
(3,971)
8,989 
854 
9,843 
	 Recognition of stock warrants
28,017 
28,017 
1,736 
29,754 
	 Acquisition of treasury stocks
(275,973)
(275,973)
(4,577)
(280,549)
	 Other capital
844 
844 
	 Changes in percentage of ownership in subsidiaries, etc.
1,962 
1,962 
(1,962)
	 Additional acquisition of subsidiary investment shares
As of December 31, 2022 (Ending Equity)
140,805 
853,172 
3,485,110 
48,746 
(388,472)
4,139,360 
134,844 
4,274,204 
Celltrion ESG Report 2022/23
100
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Consolidated Statement of Cash Flows (As of the end of  December 2022; Unit: KRW million) 
Category
2020
2021
2022
Net cash flows provided by operating activities
350,747 
911,159 
864 
	 Cash generated from operations
415,187 
1,047,103 
217,904 
	 Income tax paid
(64,440)
(135,943)
(217,041)
Net cash flows used in investing activities
(471,983)
(355,825)
(297,051)
	 Cash inflows from investing activities
112,963 
97,726 
110,315 
	 	
Interest received
5,897 
4,310 
12,632 
	 	
Dividend received
243 
2,239 
233 
	 	
Decrease in short-term financial assets
87,584
17,034 
35,283 
	 	
Decrease in long-term financial assets
1,527 
1,638 
546 
	 	
Decrease in other receivables
27,518 
	 	
Decrease in long-term other receivables
3,990 
604 
8,019 
	 	
Decrease in investments in associates
8,793 
11,863 
8,551 
	 	
Receipt of other grants
271 
73 
	 	
Proceeds from the disposal of property, plant and 
equipment
958 
13 
3 
	 	
Proceeds from disposal of intangible assets
1,500 
27,823 
10 
	 	
Disposal of investment property
2,200 
	 	
Receipt of government grants
32,129 
31 
	 	
Changes in consolidation scope
17,488 
Cash outflows from investing activities
(584,946)
(453,551)
(407,367)
	 	
Increase in short-term financial assets
(32,582)
(49,951)
(44,575)
	 	
Increase in other receivables
(41,014)
(676)
	 	
Increase in long-term financial assets
(940)
(4,834)
(6,295)
	 	
Increase in long-term other receivables
(3,143)
(2,858)
(7,468)
	 	
Acquisition of investments in associates
(6,250)
(32,782)
(32,880)
	 	
Acquisition of property, plant and equipment
(87,008)
(63,379)
(111,169)
	 	
Acquisition of intangible assets
(454,384)
(258,186)
(200,817)
	 	
Acquisition of other assets
(639)
(548)
	 	
Changes in consolidation scope
(3,487)
Net cash flows used in financing activities
265,988 
(69,278)
(350,219)
	 Cash inflows from financing activities:
458,519 
228,911 
190,652 
	 	
Increase in short-term financial liabilities
246,713 
182,431 
118,163 
	 	
Increase in long-term financial liabilities
192,411 
24,994 
62,626 
	 	
Issuance of ordinary shares
19,395 
21,486 
9,862 
Category
2020
2021
2022
	 Cash outflows from financing activities
(192,531)
(298,188)
(540,871)
	 	
Interest paid
(14,869)
(16,022)
(22,667)
	 	
Dividend paid
(4)
(102,451)
	 	
Decrease in short-term financial liabilities
(107,107)
(108,023)
(77,524)
	 	
Decrease in current portion of long-term borrowings
(52,043)
(132,043)
(54,481)
	 	
Decrease in lease liabilities
(2,633)
(2,951)
(3,163)
	 	
Decrease in guarantee deposits
(17)
	 	
Stock issuance costs
(13)
(19)
(19)
	 	
Acquisition of treasury stocks
(15,866)
(39,126)
(280,549)
Net increase (decrease) in cash and cash equivalents
144,752 
486,056 
(646,407)
Net foreign exchange difference
(6,595)
17,976 
9,268 
Cash and cash equivalents at the beginning of the year
546,138 
684,294 
1,188,326 
Cash and cash equivalents at the end of the year
684,294 
1,188,326 
551,187 
Corporate Tax Payments by Business (As of the end of December 2022, Unit: KRW million)
Tax juris-
dictions
Legal entities 
Business activities
Number of 
employees
Revenue
Profit 
(loss) 
before 
tax
Income tax 
payable 
(current 
year)
Income 
tax paid
Korea
Celltrion, Inc.
Sales and manufacturing 
of pharmaceuticals
2,263 1,937,469 606,390 
83,068 230,625
Korea
Celltrion Pharm, 
Inc.
Sales and manufacturing 
of pharmaceuticals
841
386,040 
30,469 
5,636 
4,204
Philippines Celltrion Global 
Safety Data Center
Global drug safety data 
management
178
3,877 
314 
Hong 
Kong
Celltrion Group 
Hong Kong 
Biopharmaceuticals 
business in China
5
(2,507)
China
Shanghai  
Vcell Biotech
Biopharmaceuticals R&D 
(Including clinical trials)
89 
Singapore
Celltrion Asia 
Pacific PTE
Sales and R&D of small 
molecule drugs
13
136,046
1,207
United 
Kingdom
Celltrion  
Europe
Conducting clinical trials 
of biosimilars in EU 
Ireland
Celltrion  
Biopharma
Clinical trials for 
biopharmaceuticals
* The data presented is based on Celltrion's Tax Reconciliation Statement for 2022, and income taxes paid represent the cash payments made in 2022.
Celltrion ESG Report 2022/23
101
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Environmental Performance
Non-financial Information
Reduction of Energy Consumption
Category
Unit
2019
2020
2021
2022
Energy savings through control of lighting 
systems in mechanical rooms and corridors1)
Plant 1
MJ
 1,536 
 1,536 
 1,536 
 1,536 
Plant 2
 1,824 
 1,824 
 1,824 
 1,824 
Energy saving effect through control of lighting 
systems in mechanical rooms and corridors
Plant 1
KRW 
Million
 18 
 18 
 18 
 18 
Plant 2
 22 
 22 
 22 
 22 
Energy savings through operating HVAC on 
energy saving mode2)
Plant 1
MJ
 1,920 
 1,920 
 1,920 
 1,920 
Plant 2
 5,088 
 5,088 
 5,088 
 5,088 
Energy saving effect through operating HVAC 
on energy saving mode
Plant 1
KRW 
Million
 23 
 23 
 23 
 23 
Plant 2
 60 
 60 
 60 
 60 
Energy savings through upgrading  
the cooling water pump3)
Plant 1
MJ
-
 768 
-
-
Plant 2
-
-
-
-
Energy saving effect through upgrading  
the cooling water pump
Plant 1
KRW 
Million
-
 9 
-
-
Plant 2
-
-
-
-
1) Save energy through control of lighting systems in mechanical rooms and corridors 
- Method used for calculation of energy savings: Rated capacity of light (kW) × Quantity of lighting turned off (EA) × Hours of lighting turned off  
  a year (hr.) × 9.6GJ/MWh × 10-3    
- Method used for calculation of energy saving effect: Electricity saved (kWh) x Electricity rate (KRW 114 /kWh)
2) Reducing energy consumption by intermittent stopping of the air conditioner in the office spaces 
- Method used for calculation of energy saving: Electricity consumption per HVAC (kW) × Annual HVAC shutdown time (hr.) × 9.6 GJ/MWh × 10-3 
- Method used for calculation of energy saving effect: Electricity saved (kWh) x Electricity rate (114 KRW/kWh)
3) Reducing energy used for cooling water pumps by installing additional flow control valves in the cooling water line and adjusting them to the rated 
flow rate of equipment that use cooling water 
- Method used for calculation of energy saving: (Operating power (kWh) before improvement - Operating power (kWh) after improvement) x Annual 
  operating hours (8,760 h/year) x Utilization rate (70%) 
- Method used for calculation of energy saving effect: Electricity saved (kWh) x Electricity rate (KRW 114/kWh)
Energy Consumption
Category
Unit
2019
2020
2021
2022
Plant 1
Fuel
TJ
121 
152 
152 
167 
	 - LNG
1)
118 
150 
150 
164 
	 - Gasoline
2)
3 
2 
3 
3 
	 - Diesel
3)
0 
0 
0 
0 
Electricity
4)
246 
275 
278 
282 
Total energy consumption
367 
427 
430 
449 
Plant 2
Fuel
TJ
211 
207 
229 
251 
	 - LNG
1)
210 
207 
229 
251 
	 - Gasoline
2)
- 
- 
- 
- 
	 - Diesel
3)
0 
0 
0 
0 
Electricity
4)
406 
431 
458 
456 
Total energy consumption
617 
639 
688 
707 
Total energy consumption
TJ
983 
1,066 
1,118 
1,155 
Revenue (Consolidated)
KRW 100 
million
11,285 
18,493 
18,934 
22,840 
Intensity of energy consumption  
(Based on revenue)
TJ/KRW 
100 million
0.09 
0.06 
0.06 
0.05 
*	Energy consumption by source
	 1) LNG: Plant 1 (Boiler, emergency generator, cafeteria), Plant 2 (Boiler, cafeteria)  
	 2) Gasoline: Executive vehicles
	 3) Diesel: Executive vehicles, forklifts, trucks, emergency generators at Plant 2
	 4) Electricity: Plant 1 and 2
Celltrion ESG Report 2022/23
102
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Water
1) Consumption
Category
Business site
Unit
2019
2020
2021
2022
Water intake
Plant 1
Ton
165,600
210,904
222,606
 222,051 
Plant 2
283,846
273,921
288,562
 304,532 
Total water intake
449,446
484,825
511,168
 526,583 
Water withdrawals (Usage)
Plant 1
165,600
210,904
222,606
 222,051 
Plant 2
283,846
273,921
288,562
 304,532 
Total water withdrawals (Usage)
449,446
484,825
511,168
 526,583 
Water discharged
Plant 1
94,605
136,454
147,208
 147,078 
Plant 2
185,263
174,663
173,718
188,486
Total water discharged2)
279,868
311,117
320,926
 335,564 
Recycled and reused water
Plant 1
-
-
-
-
Plant 2
-
-
-
-
Total recycled and reused water
-
-
-
-
1) All water used at business sites is municipal water. 
2) Total water discharged corresponds to the amount of wastewater discharged at a wastewater treatment facility. Domestic wastewater (from toilet, 
restaurants, etc.), treated at a sewage treatment facility is not included in the total water discharged.
Management of Water Pollutants
Category
Business site
Unit
2019
2020
1)
2021
2022
2)
BOD
Plant 1
Ton
0.18
0.12
0.49
2.22
Plant 2
1.18
0.37
0.63
1.09
Total BOD
1.36
0.49
1.12
3.32
COD
Plant 1
1.03
6.03
2.99
5.01
Plant 2
3.10
3.25
1.61
1.44
Total COD
4.13
9.28
4.60
6.45
SS
Plant 1
1.22
1.73
0.29
0.64
Plant 2
3.11
3.66
0.54
0.78
Total SS
4.34
5.39
0.83
1.42
T-N
Plant 1
1.23
2.65
3.77
2.85
Plant 2
1.58
1.42
1.20
1.33
Total T-N
2.81
4.06
4.97
4.18
T-P
Plant 1
0.21
0.25
0.01
0.04
Plant 2
0.06
0.27
0.10
0.10
Total T-P
0.26
0.53
0.11
0.13
1) We maintain the discharge of water pollutants within the permissible level by using a COD meter, water analysis at our own lab (SS, T-N, T-PP), 
and analysis by an authorized third-party analysis institute (for all items). However, it was found that, when highly concentrated wastewater is 
generated, the concentration of pollutants goes up, resulting in high emissions (2020).
2) According to the revision of the Water Environment Preservation Act, COD was excluded from the list of water pollutants, and TOC was included. 
Accordingly, COD analysis was not conducted in 2022, and the discharged amount was calculated based on the analysis of TOC.
Category
Business site
Unit
2019
2020
2021
2022
Scope 1 : Direct emissions
Plant 1
tCO₂eq
 6,179 
 7,779 
 7,769 
 8,490 
Plant 2
 10,685 
 10,517 
 11,634 
 12,728 
Total scope 1: Direct emissions
 16,864 
 18,297 
 19,402 
 21,219 
Scope 2: Indirect emissions
Plant 1
 11,944 
 13,353 
 13,287 
 13,495 
Plant 2
 19,723 
 20,953 
 21,926 
 21,804 
Total scope 2: Indirect emissions
 31,667 
 34,306 
 35,213 
 35,299 
Total GHG emissions
 48,531 
 52,602 
 54,615 
 56,518 
Revenue
KRW 100 million
 11,285 
 18,493 
 18,934 
 22,840 
GHG emission intensity
tCO₂eq/ 
KRW 100 million
 4.30 
 2.84 
 2.88 
 2.47 
* Emissions were calculated in accordance with the Guidelines on Emission Reporting and certification of emissions based on the Greenhouse Gas 
Emissions Trading system
Environmental Goal and Performance (In intensity) in 2022
Category
Unit
Goal
1)
Performance
Goal/ 
Performance
GHG emissions 
tCO₂eq/KRW 100 million
2.86
2.47
115%
Energy consumption 
TJ/KRW 100 million
0.06
0.05
116%
Waste generated
Ton/KRW 100 million
0.10
0.09
104%
Water consumption
26.73
23.06
116%
1) Environmental goal: Reduce the intensity of environmental pollutant emissions and energy consumption by 1% from the previous year. 
GHG Emissions
Celltrion ESG Report 2022/23
103
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Waste Management
Category
Unit
2019
2020
2021
2022
Waste generated
Plant 1
Ton
	 General waste
 581 
 821 
 835 
 1,052 
	 Hazardous waste
 51 
 41 
 42 
 47 
	 Total waste generated
 631 
 862 
 878 
 1,099 
Plant 2
	 General waste
 812 
 748 
 774 
 828 
	 Hazardous waste
 155 
 160 
 170 
 164 
	 Total waste generated
 966 
 909 
 944 
 992 
	 	 Total general waste
Ton
 1,393 
 1,569 
 1,610 
 1,880 
	 	 Total hazardous waste
 205 
 201 
 213 
 211 
	 	 Total waste generated
 1,598 
 1,771 
 1,822 
 2,090 
Management of Air Pollutants
1)
Category
Business site
Unit
2019
2020
2021
2022
Dust
Plant 1
Ton
 0.08 
 0.10 
 0.10 
 0.11 
Plant 2
 0.14 
 0.14 
 0.16 
 0.17 
Total dust
 0.23 
 0.24 
 0.26 
 0.29 
Sulfur oxides (SOx)
Plant 1
 0.03 
 0.03 
 0.03 
 0.04 
Plant 2
 0.05 
 0.05 
 0.05 
 0.06 
Total volume of sulfur oxides (SOx)
 0.08 
 0.08 
 0.09 
 0.10 
Nitrogen oxides (NOx)
Plant 1
 9.95 
 12.35 
 12.75 
 13.99 
Plant 2
 17.78 
 17.49 
 19.60 
 21.46 
Total volume of nitrogen oxides (NOx) 
 27.72 
 29.84 
 32.35 
 35.45 
1) Air pollutant emissions were calculated using the emission coefficient in Annex 10 of the Enforcement Rules of the Air Environment Preservation Act.
Category
Unit
2019
2020
2021
2022
Waste processed
Plant 1
Ton
	 Waste recycled 
1)
 305 
 476 
 492 
 664 
	 Incinerated (outside)
 319 
 385 
 385 
 433 
	 Landfilled (outside)
-
-
-
-
	 Others 
2)
 7.5 
 0.6 
-
 1.7 
	 Total waste processed
 631 
 862 
 878 
 1,099 
Plant 2
	 Waste recycled 1)
 563 
 436 
 492 
 481 
	 Incinerated (outside)
 403 
 472 
 453 
 510 
	 Landfilled (outside)
-
-
-
-
	 Others 2)
 0.4 
 0.8 
-
 0.3 
	 Total waste processed
 966 
 909 
 944 
 992 
	 	 Total waste recycled 1)
Ton
 868 
 912 
 984 
 1,145 
	 	 Total incinerated 
(outside)
 722 
 857 
 838 
 943 
	 	 Total landfilled (outside)
-
-
-
-
	 	 Others 2)
 7.9 
 1.4 
-
 2.0 
	 	 Total waste processed
 1,598 
 1,771 
 1,822 
 2,090 
Waste recycled
Plant 1
%
48
55
56
60
Plant 2
58
48
52
49
Total waste recycled 3)
54
52
54
55
1) Recyclable items (Sludge from waste treatment, waste activated carbon, waste oil, waste organic solvent solids)
2) Other treatment methods are evaporative concentration treatment of waste acid and waste alkali among the designated wastes.
3) Waste recycled/total waste processed
Celltrion ESG Report 2022/23
104
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Environmental Compliance
Category
Business site
Unit
2019
2020
2021
2022
Financial penalties
Plant 1
KRW 
million
-
1.6
-
-
Plant 2
-
-
-
-
Total financial penalties
-
1.6
1)
-
-
Prosecutions
Plant 1
Case
-
-
-
-
Plant 2
-
-
-
-
Total prosecutions
-
-
-
-
Non-financial sanctions
Plant 1
-
-
-
-
Plant 2
-
-
-
-
Total non-financial sanctions
-
-
-
-
1) Paid a fine of KRW 1.6 million on account of failure to self-measure air pollutants pursuant to Paragraph 1, Article 39 of the Air Environment 
Protection Act, which was identified during an instruction/inspection by the Metropolitan Air Quality Management Agency on November 11, 2020..
Environmental Investment Plan
Item
Busines site
Unit
2019
2020
2021
2022
Installation of air pollution prevention facilities  
(low-NOx burners)
Plant 1
KRW million
-
-
-
-
Plant 2
-
100
1)
-
935
2)
Total
-
 100 
-
 935 
Air pollutant generating facilities  
that were improved (Boilers)
Plant 1
 19 
 12 
 33 
 38 
Plant 2
 67 
 30 
 44 
 111 
Total
 86 
 42 
 77 
 149 
Water pollutant prevention facilities that were 
improved (Wastewater treatment facilities)
Plant 1
 38 
 33 
 51 
 119 
Plant 2
 4 
 4 
 44 
 67 
Total 
 42 
 36 
 95 
 187 
Costs of outsourcing wastewater and  
waste treatment 
Plant 1
 208 
 223 
 277 
 246 
Plant 2
 318 
 377 
 365 
 360 
Total
 527 
 600 
 642 
 606 
1) Replaced two boilers with low-NOx burner boilers at Plant 2 in 2020 (The existing boilers were not low-NOx burner type)
2) Replaced eight boilers with low-NOx burner boilers at Plant 2 in 2020 (The existing boilers were not low-Nox burner type)
Amount of Raw/Sub Materials Used
Category
Unit
2019
2020
2021
2022
Amount of raw/sub materials usage
kg
 430,147 
 615,547 
 577,413 
 519,273 
Training on 
hazardous 
chemical 
substances 
Training
Total training hours
Hour
 32 
 608 
 608 
 496 
Participants
Person
 2 
 38 
 38 
 31 
Training hours per person
Hour
 16 
 16 
 16 
 16 
Training
Total training hours
Hour
 4,080 
 6,176 
 3,808 
 5,488 
Participants
Person
 255 
 386 
 238 
 343 
Training hours per person
Hour
 16 
 16 
 16 
 16 
ESH Training
Category
Unit
2019
2020
2021
2022
ESH 
training
(Common 
training)
Total training hours
Hour
 38,436 
37,428
38,484
 40,560 
Participants
Office workers
Person
 867 
 873 
 957 
 966 
Non-office workers
 1,168 
 1,123 
 1,125 
 1,207 
Training hours per 
person
Office workers
Hour
 12 
 12 
 12 
 12 
Non-office workers
 24 
 24 
 24 
 24 
Category
Unit
2019
2020
2021
2022
Training on 
hazardous 
chemical 
substances 
Training
Total training hours
Hour
 2,864 
 1,970 
 2,126 
 1,958 
Participants (Total)
Person
 1,432 
 985 
 1,063 
 979 
Participants (Employees)
Person
 1,214 
 860 
 918 
 843 
Participants (Suppliers)
Person
 218 
 125 
 145 
 136 
Training hours per person
Hour
 2 
 2 
 2 
 2 
* Annual no. of participants is obtained by multiplying the average no. of participants per quarter by four
Celltrion ESG Report 2022/23
105
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Employee Profile
Category
Unit
2019
2020
2021
2022
Total number of 
employees
Total number of employees
Person
2,111
2,158
2,207
2,263
Male
1,250
1,267
1,286
1,299
Female
861
891
921
964
By employment 
type: Regular & 
Fixed-term
Total number of employees
2,019
2,041
2,074
2,120
Male
1,205
1,231
1,230
1,241
Female
814
810
844
879
By employment 
type: Contract
Total number of employees
92
117
133
143
Male
45
36
56
58
Female
47
81
77
85
New hires
Total number of employees
593
261
337
366
Male
335
125
152
150
Female
258
136
185
216
Under 30
Male
 571 
 561 
 500 
 414 
Female
493
 484 
 440 
 397 
30 to 50
Male
660
 690 
 772 
 863 
Female
362
 396 
 468 
 554 
Above 50
Male
 19 
 16 
 14 
 22 
Female
 6 
 11 
 13 
 13 
By 
gender
Male
Number of employees
1,250
 1,267 
 1,286 
 1,299 
Permanent employees 1)
1,221
 1,235 
 1,257 
 1,275 
Temporary employees 2)
 29 
 32 
 29 
 24 
Daily workers 3)
0
0
0
0
Full-time employees 4)
1,250
 1,267 
 1,286 
 1,299 
Part-time employees 5)
0
0
0
0
Female
Number of employees
861
 891 
 921 
 964 
Permanent employees
822
 852 
 887 
 912 
Temporary employees
 39 
 39 
 34 
 52 
Daily workers
0
0
0
0
Full-time employees 
861
 881 
 911 
 957 
Part-time employees 
0
 10 
 10 
 7 
Category
Unit
2019
2020
2021
2022
By 
nation-
ality 6)
Korea
Number of employees
Person
 2,074 
 2,127 
 2,177 
 2,239 
Permanent employees
 2,006 
 2,056 
 2,114 
 2,163 
Temporary employees
 68 
 71 
 63 
 76 
Daily workers
 0 
 0 
 0 
 0 
Full-time employees 
 2,074 
 2,117 
 2,167 
 2,232 
Part-time employees 
 0 
 10 
 10 
 7 
USA
Number of employees
 15 
 13 
 14 
 12 
Permanent employees
 15 
 13 
 14 
 12 
Temporary employees
 0 
 0 
 0 
 0 
Daily workers
 0 
 0 
 0 
 0 
Full-time employees 
 15 
 13 
 14 
 12 
Part-time employees 
 0 
 0 
 0 
 0 
India
Number of employees
 6 
 5 
 5 
 3 
Permanent employees
 6 
 5 
 5 
 3 
Temporary employees
 0 
 0 
 0 
 0 
Daily workers
 0 
 0 
 0 
 0 
Full-time employees 
 6 
 5 
 5 
3
Part-time employees 
 0 
 0 
 0 
 0 
Others
Number of employees
 16 
 13 
 11 
 9 
Permanent employees
 16 
 13 
 11 
 9 
Temporary employees
 0 
 0 
 0 
 0 
Daily workers
 0 
 0 
 0 
 0 
Full-time employees 
 16 
 13 
 11 
 9 
Part-time employees 
 0 
 0 
 0 
 0 
By management 
position
Employees in manager positions
 219 
 230 
 249 
 268 
Employees in mid-level manager positions
 160 
 170 
 179 
 192 
Executives
 35 
 39 
 33 
 42 
Ratio of female employees  
in manager positions
%
28
27
33
32
Ratio of female employees  
in mid-level manager positions
34
30
34
33
Ratio of female executives
9
5
21
17
Social Performance
Celltrion ESG Report 2022/23
106
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Category
Unit
2019
2020
2021
2022
Professional/
Special/General 
contract workers
Total number of employees
Person
92
117
133
143
Male
45
36
56
58
Female
47
81
77
85
Female
employees
Total number of female employees
Person
861
891
921
964
Female employees in manager positions
61
62
81
87
Female employees in mid-level manager 
positions
54
51
60
64
Female executives
3
6
7
7
Female employees in revenue-generating 
positions 7)
0
0
0
0
Female employees in STEM positions
769
786
796
815
Average length  
of service
Male
Year
4.2
5.0
5.5
6.2
Female
4.0
4.6
5.1
5.4
Workers who 
were not hired 
directly by  
the company 8)
Dispatched workers
Person
 1 
 0 
 0 
0
Apprentices
 0 
 0 
 0 
0
Contractors
 0 
 0 
 0 
0
Remote workers
 0 
 0 
 0 
0
Interns
 0 
 0 
 0 
0
Self-employed
 0 
 0 
 0 
0
Subcontractors
 251 
 271 
 281 
298
Volunteers
 0 
 0 
 0 
0
Minority
Employees with disabilities
Person
2
2
2
2
By position
Director and above (Male)
Person
 61 
 67 
 66 
75
Director and above (Female)
 12 
 19 
25
30
Manager - Senior Manager (Male)
 255 
320
371
398
Manager - Senior Manager (Female)
142
 180 
 228 
257
Assistant Manager and below (Male)
934
880
849
826
Assistant Manager and below (Female)
 707 
692
 668 
677
1) Employees with more than 1 year contract or employees hired through the formal recruitment process, who are subject to employment regulations 
(Except for part-time workers) 
2) Contract period is 1 month to less than 1 year
3) Contract period is less than 1 month 
4) Working more than 40 hours a week
5) Working less than 40 hours a week (Those working at the daycare center) 
6) Data on the number of workers by nationality is based on the nationality of Celltrion employees, not on the basis of overseas workplaces. 
7) There is no sales department; hence, the no. of employees within the revenue-generating department is zero
8) Limited to workers representing the in-house sub-contractors 
Employee Profile
Employee Turnover Rate
Category
Unit
2019
2020
2021
2022
Turnover (Retirement) 
rate
Total turnover rate
%
12
10
13
14
Voluntary turnover rate
6
5
8
9
By gender
Male
Person
114
94
133
140
Female
142
118
155
177
By age
Under 30
189
116
225
194
30 to 50
66
93
60
111
Above 50
1
3
3
12
Internal hire rate 1)
%
55
70
89
61
1) Internal department transfer/ Internal department transfer + Experienced hires
Equal Pay (Pay for female employees compared with male employees) 
1)
Category
Unit
2020
2021
2022
Executives
Base salary
%
85
116
92
Base salary + other cash incentives
147
217
100
Managers
Base salary
%
102
117
100
Base salary + other cash incentives
89
95
98
Non-managers
Base salary + other cash incentives
%
92
85
88
1) Salaries depend on the years of service and performance appraisals with no influence based on gender, position, or business site.
* Based on business sites in Korea
Celltrion ESG Report 2022/23
107
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Employees Using Parental Leave and Employees Returning from Parental Leave
Category
Unit
2019
2020
2021
2022
Employees who used childbirth leave
Total (Female)
Person
28
27
30
34
Employees  
who availed childcare leave
Total
40
35
33
57
Male
7
7
5
8
Female
33
28
28
49
Employees who returned to work  
after childcare leave
Total
40
35
33
54
Male
7
7
5
8
Female
33
28
28
46
Employees who served for  
12 months or more after returning  
from childcare leave
Total
33
40
34
31
Male
1
7
7
5
Female
32
33
27
26
Employees who served for  
less than 12 months after returning  
from childcare leave 1)
Total
0
0
1
2
Male
0
0
0
0
Female
0
0
1
2
1) Employees who served for less than 12 months after returning from childcare leave: No. of employees who returned to work last year – No. of 
employees who served for more than 12 months after returning from childcare leave in this year
Performance Appraisal
Category
Unit
2019
2020
2021
2022
Performance appraisal rate 1)
%
80
80
80
80
Male
80
80
80
80
Female
80
80
80
80
Management by objectives (MBO)
 2),  
systematic use of measurable targets agreed  
in consultation with the line superior
50
50
50
50
Formal comparative ranking of employees  
within the same employee category 3)
100
100
100
100
Multi-source performance appraisal 4)
0
0
0
0
1) Rate of performance appraisal: Rate of performance appraisal among the appraisal items
2) MBO: Although objectives are established at the beginning of the year, reviewing one’s performance in line with the set goals is not mandatory
3) Formal comparative ranking of employees within the same employee category: This relative review process involves dividing employees into 
managers or higher levels and assistant managers or lower levels
4) Multi-source performance appraisal: This method is not applicable to general employees. Leadership diagnosis is conducted for high-ranking 
officials, and the result is used for organizational management evaluation.
Development of Employees by Education/Training
Category
Unit
2019
2020
2021
2022
Participants
Total
Person
 175 
 153 
 156 
352
Male
 83 
 82 
 92 
174
Female
 92 
 71 
 64 
178
Training hours
Total
Hour
 3,066 
 2,779 
2,669 
9,580
Male
 1,586 
 1,910 
 1,728 
4,667
Female
 1,480 
 869 
 941 
4,913
Training 
expenditures
Total
KRW 100 
million
 1.2 
0.9
 1.0 
3.0
Training hours  
per person
Male
Hour/person
 19 
 23 
 19 
27
Female
 16 
 12 
 15 
28
Korean
 18 
 19 
 17 
27
Others
 8 
 8 
 8 
12
Executives 
 18 
 0 
 0 
23
Mid-level managers
 0 
 0 
 0 
10
Non-managers
 18 
 19 
 17 
29
Training 
expenditures  
per person
Male
KRW 
10,000/
person
 69 
 79 
 76 
129
Female
 73 
 37 
 50 
44
Korean
 72 
 59 
 66 
85
Others
 7 
 113 
 34 
115
Executives 
 423 
 0 
 0 
377
Mid-level managers
 0 
 0 
 0 
27
Non-managers
 65 
 59 
 65 
90
Ratio of investment in education
%
0.0122
0.0053
0.0062
0.0156
* Based on the number of employees who applied for external education (external seminars, academic conferences, programs, etc.)   
in 2019, 2020, 2021, and 2022.
** This section does not include basic mandatory training provided to all employees (sexual harassment prevention training provided  
at KRW 2,500/person for 1 hour and disability awareness training provided at KRW 2,500/person for 1 hour)
*** Ratio of investment in education= Training expenditures/Revenue
Celltrion ESG Report 2022/23
108
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Training Programs
Category
Unit
2019
2020
2021
2022
General training  
(Job skills, leadership, etc.)
Training hours
Hour
5,856
0 
2,652
0 
Participants
Person
366 
0 
156 
0 
Sexual harassment  
prevention training
Training hours
Hour
1,953 
2,074 
2,081 
2,120 
Participants
Person
1,953 
2,074 
2,081 
2,120 
Other internal training 1)  
(Disability awareness training)
Training hours
Hour
1,947
2,055 
2,088 
2,130 
Participants
Person
1,947 
2,055 
2,088 
2,130 
Other internal training 2) (Workplace 
harassment prevention training)
Training hours
Hour
1,967 
2,092 
2,148 
2,189 
Participants
Person
1,967 
2,092 
2,148 
2,189 
Other internal training 3) (Basic job 
training for E2 employees)
Training hours
Hour
4,708 
4,025 
4,587 
3,472 
Participants
Person
281 
286 
366 
96 
Other internal training 4)
(Training for new employees)
Training hours
Hour
14,801 
5,535 
6,314 
7,708 
Participants
Person
361 
135 
154 
188 
Basic compliance training 
(Compliance and ethics)
Training hours
Hour
1,982 
2,103 
2,136 
2,170
Participants
Person
1,982 
2,103 
2,136 
2,170
Advanced compliance training
Training hours
Hour
0 
0 
1,775 
463 
Participants
Person
0 
0 
1,775 
409
Specialized compliance training
Training hours
Hour
0 
0 
136 
122 
Participants
Person
0 
0 
56 
43
Anti-corruption management 
system training
Training hours
Hour
0 
0 
84 
93 
Participants
Person
0 
0 
56 
62 
1) Disability awareness training (Online training in 2019-2021, 1 hour/person)
2) Workplace harassment prevention training (Online training in 2019, paper-based training in 2020 and 2021, 1 hour/person)
3) Other internal training: basic job training for E2 employees (Average training hours per person each year)
4) Other internal training: Training for new employees (Training hours for subjects each year)
*  With the launch of the dedicated compliance department in 2021 and the establishment of a company-wide compliance system and anti-
corruption management system (ISO 37001), compliance training and training on the anti-corruption management system are being provided 
based on a systematic training plan since 2021. In addition to the basic compliance and ethics training for employees in 2019 and 2020, 
conducted by the existing Internal Audit Team (the Compliance Team took over the training in 2021), there was no separate training regarding the 
compliance/anti-corruption management system. 
Occupational Safety and Health
Category
unit
2019
2020
2021
2022
Lost Time Injury 
Frequency Rate (LTIFR)
Domestic employees
Case / 1 million 
working hours
0.21
0.00
0.00
0.57
Suppliers
0.00
1.49
0.00
1.44
Rate of industrial 
accidents
Domestic employees
%
0.05
0.00
0.00
0.14
Suppliers
0.00
0.36
0.00
0.34
Industrial  
accidents
Domestic
Case 
 1 
 1 
 0 
 4 
Overseas
 0 
 0 
 0 
 0 
Employees
 1 
 0 
 0 
 3 
Suppliers
 0 
 1 
 0 
 1 
Fatalities
Domestic
Person
 0 
 0 
 0 
 0 
Overseas
 0 
 0 
 0 
 0 
Employees
 0 
 0 
 0 
 0 
Suppliers
 0 
 0 
 0 
 0 
* Scope of reporting by suppliers: Based on the industrial accident questionnaire
** Industrial accidents: Any work-related fatality, injury, or illness
*** For in-house suppliers 
Celltrion ESG Report 2022/23
109
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Labor-Management Council
Category
Unit
2019
2020
2021
2022
Ratio of employees that are part of  
the Labor-Management Council
%
100
100
100
100
Labor-Management Council meetings 
regarding organizational changes such as 
restructuring and outsourcing
Case
4
4
4
4
Members
Person
1,982
2,074
2,081
2,120
Membership rate
%
100
100
100
100
* No labor union in operation
Employee Engagement
Category
Unit
2022
Target employees for surveys
Person
2,263
Participants in surveys
619
Rate of participation in surveys
%
27
Rate of highly engaged employees
55
Compliance Reports and Action  
Category
Unit
2019
2020
2021
2022
Reports submitted
9
29
35
18
Corrective 
actions taken 
for each 
category
Neglect of duty
Case
1
13
6
6
Conflict of interest
0
0
0
0
Bribery
0
0
0
0
Misappropriation of assets
0
0
1
0
Workplace harassment/Sexual 
harassment
2
6
4
5
Violations of information security
1
1
7
1
Other ethics violations
2
7
12
3
Corrective 
actions taken
Total
6
27
30
15
Minor disciplinary actions
3
14
16
5
Serious disciplinary actions
3
13
14
10
* For reported cases involving baseless claims or minor offenses, a simple warning was issued without any further punishment.
Empowerment of R&D Capability 
1)
Category
Unit
2019
2020
2021
2022
R&D  
manpower status
PhD degree
Person
55
52
54
55
Master’s degree
293
302
322
345
Others
295
294
325
327
Total
643
648
701
727
R&D investments
R&D expenditure 
KRW million
303,177
384,774
397,967
412,283
R&D intensity
%
27
21
21
18
1) R&D investments against revenues in the consolidated financial statements
Quality Inspection
Category
Unit
2019
2020
2021
2022
Customers 1)
Quality inspections
Case
3
2
6
5
Health authorities 2)
Due diligence
4
2
1
3
FDA
Due diligence
1
0
0
1
Total
8
4
7
9
1) Customers: Distributors, Qualified Certifiers (BSI - ISO 9001 )
2) Health authorities: Korea, Russia, Türkiye, and Europe (FDA not included)
Celltrion ESG Report 2022/23
110
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Recall
Category
Unit
2019
2020
2021
2022
Recalled products 1)
Product
0
0
0
1
1) Celltrion USA recalled the DiaTrust COVID-19 Ag Rapid Test kits 
* Celltrion Healthcare, an affiliate of Celltrion, acquired Celltrion USA in August 2022.
Information Security Violations
Category
Unit
2019
2020
2021
2022
Complaints 
where violation 
of information 
security was 
proven  
Complaints raised from outside and  
proven internally
Case
0
0
0
0
Complaints raised by the regulatory authorities
0
0
0
0
No. of cases regarding customer data leakage, 
theft, and loss that are proven
0
0
0
0
Occurrence 
of regulation 
violations and 
major penalties
Volume of major penalties related to the violation 
of information security rules and regulations
KRW 
million
0
0
0
0
If there are no precedent cases,  
briefly mention the facts
0
0
0
0
Information Security Investment and Training
Category
Unit
2019
2020
2021
2022
Investment in information security
KRW million
2,033
1,032
1,071
1,466
Information security training 1)
Training hours
Hour
1
1
1
1
Participants
Person
1,987
2,094
2,106
2,160
1) Information security training is divided into information security training for all employees (once a year), information security training for new 
hires (once a month), and training for employees handling personal information (once a year). The above figures represent the no. of hours and 
employees pertaining to information security training conducted once a year for all employees.
Social Contribution Activities
Category
Unit
2019
2020
1)
2021
2)
2022
Employees
volunteering
Volunteer hours per person
Hour/person
5
0
2
1
Total volunteer hours
Hour
2,388
0
4
74
Volunteers
Person
500
0
2
74
1) Employee volunteering activities were not conducted due to COVID-19
2) Only a minimum number of individuals participated to maintain the Volunteer Management System(VMS) certification
Contribution by Type
Category
2022
Amount (KRW million)
Ratio (%)
Charitable donations 1)
420
19
Community investments 2)
1,816
81
Commercial initiatives 3)
0
0
Total
2,236
100
1) Charitable donations: One-time or short-term contributions
2) Community investments: Long-term engagement and investment in communities 
3) Commercial initiatives: Contributions and volunteering related to business activities
Celltrion ESG Report 2022/23
111
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Political Contributions and Association Dues 
1)
Category
Unit
2019
2020
2021
2022
Association 
dues
Total
KRW 
million
59
59
59
74
Korea Biomedicine Industry Association
36
36
36
36
Korea BIO
18
18
18
33
Korea AEO Association
5
5
5
5
1) Celltrion, Inc. complies with the Political Funds Act (Corporations or organizations shall be prohibited from contributing political funds) and does 
not provide any lobbying and political funds.
ESG Training for Suppliers
Category
Unit
2022
Ethical management training of suppliers
Suppliers to be trained
No. of 
suppliers
19
Suppliers who completed training
19
Category
Sub-category
No. of suppliers Notes
Supplier  
ESG assessment
Key suppliers
19
-
Self-assessment of key suppliers 2)
14
74% of key suppliers
On-site assessment for key suppliers 3)
2
14% of suppliers that
conducted a self-
assessment
Identify suppliers with risk 1)
Suppliers with high risk
0
-
Suppliers with low risk
1
-
1) Suppliers with high ESG risks: To check potential ESG risks, we used a total of 82 evaluation ind icators (23 in labor rights, 15 in environment, 
24 in safety and health, 14 in ethical management, and 6 in management system). Suppliers with serious violations are identified as high-risk 
suppliers. Suppliers that are rated below a certain level are categorized as low-risk suppliers.
2) Self-assessment: Suppliers who have completed the online ESG self-assessment
3) On-site assessment: Third-party inspections involving external experts
Results of Supplier ESG Assessment in 2022
Key Suppliers
Category
Sub-category
2022
Suppliers
Share of 
procurement(%)
Tier 1
Total suppliers
374
100
Suppliers by region
Domestic
250
15
Overseas
124
85
Key suppliers
19
80
Celltrion ESG Report 2022/23
112
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

APPENDIX
GRI Standards Index
TCFD
SASB
UN SDGs
Independent Assurance Statement
GHG Verification Report 
Awards and Association Memberships
ESG Guidelines
114
116
117
118
119
121
122
123

GRI Standards Index
Topic
Index Contents 
Reference 
page number
Additional 
information
General Disclosures
The
Organization
and its
Reporting
Practices
2-1
Organizational details
13-15 
2-2
Entities included in the organization’s  
sustainability reporting
2
2-3
Reporting period, frequency and contact point
2
2-4
Restatements of information
No amendments/ 
changes to the previous 
report (initial report) 2021 
Corporate governance 
report  
2-5
External assurance
2
2-6
Activities, value chains, and other business relationships
15
2-7
Employees
106 
2-8
Workers who are not employees
107 
2-9
Governance structure/composition
71-72 
2-10
Nomination and selection  
of the highest governance body
71-74, 76 
2021 Corporate 
governance report  
36-38p
2-11
Chair of the highest governance body
72 
2-12
Role of the highest governance body in overseeing the 
management of impacts
18-19, 71-76 
2-13
Delegation of responsibility for managing impacts
18-19, 71-76 
2-14
Role of the highest governance body in  
sustainability reporting
18-19
2-15
Conflicts of interest 
69 
2021 Corporate 
governance report  
28, 59p
2-16
Communication of critical concerns
71-76 
2-17
Collective knowledge of the highest governance body 
74
2-18
Evaluation of the performance of  
the highest governance body
74, 76-77
2-19
Remuneration policies
76-77
2021 Corporate 
governance report 75p
2-20
Process to determine remuneration
76-77
2021 Corporate 
governance report 75p
2-21
Annual total compensation ratio 
77
2-22
Statement on sustainable development strategy 
8
Topic
Index Contents 
Reference 
page number
Additional 
information
The
Organization
and its
Reporting
Practices
2-23
Policy commitments 
123-132
2-24
Embedding policy commitments 
51-53 
2-25
Processes to remediate negative impacts
52-53 
2-26
Mechanisms for seeking advice and raising concerns
52
2-27
Compliance with laws and regulations
79-81, 105, 
110, 111
2-28
Membership associations
120 
2-29
Approach to stakeholder engagement
22 
2-30
Collective bargaining agreements 
49, 110 
Material Topics
Disclosure 
of Material 
Topics
3-1
Process to determine material topics 
23 
3-2
List of material topics 
24
3-3
Management of material topics 
25-33 
      Material topic 1. 
25-27 
      Material topic 2. 
28-30 
      Material topic 3. 
31-33 
Topic Standards
Economic 
Performance
201-1 Direct economic value generated and distributed
17, 97 
201-2 Financial implications and other risks and opportunities 
due to climate change
38, 85, 116
201-4 Financial assistance received from government
29, 101 
Market 
Position
202-1 Ratios of standard entry level wage by gender 
compared to local minimum wage
107 
202-2 Proportion of senior management hired from the local 
community
106-107 
Indirect 
Economic 
Impacts
203-1 Infrastructure investments and services supported
65-66 
203-2 Significant indirect economic impacts
25-27 
Procurement 
Practices
204-1 Proportion of spending on local suppliers
87
Celltrion ESG Report 2022/23
114
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Topic
Index Contents 
Reference 
page number
Additional 
information
Anti-
corruption
205-1 Operations assessed for risks related to corruption
80, 83-85 
205-2 Communication and training about anti-corruption 
policies and procedures
80, 129
205-3 Confirmed incidents of corruption and actions taken
81 
Taxation
207-1 Approach to tax
84-85, 131 
207-2 Tax governance, controls, and risk management 
84-85, 131 
207-4 Country-by-country reporting
101
Energy
302-1 Energy consumption within the organization
39, 102 
302-3 Energy intensity
39, 102 
302-4 Reduction of energy consumption
39, 102
Water
303-2 Management of water discharge-related impacts
40, 103
303-3 Water withdrawal
103 
303-4 Water discharge 
103 
303-5 Water consumption
103 
Biodiversity
304-2 Significant impacts of activities, products and  
services on biodiversity
42, 124 
Emissions
305-1 Direct (Scope 1) GHG emissions
39, 103 
305-2 Energy indirect (Scope 2) GHG emissions
39, 103 
305-4 GHG emissions intensity 
39, 103 
305-5 Reduction of GHG emissions
38-40 
305-7 Nitrogen oxides (NOx), sulfur oxides
(SOx), and other significant air emissions
41, 104 
Wastewater 
and Waste
306-3 Waste generated
41, 104 
306-4 Waste diverted from disposal
41, 104 
306-5 Waste directed to disposal
41, 104 
Supplier 
Environmental 
Assessment
308-1 New suppliers that were screened using  
environmental criteria
89 
308-2 Negative environmental impacts  
in the supply chain and actions taken
89  
Topic
Index Contents 
Reference 
page number
Additional 
information
Employment
401-1 New employee hires and employee turnover
45, 107 
401-2 Benefits provided to full-time employees that are not 
provided to temporary or part-time employees
48 
401-3 Parental leave 
47, 108
Occupational 
Safety and 
Health
403-1 Occupational safety and health Management Systems
57 
403-2 Hazard identification, risk assessment, and incident 
investigation
57 
403-3 Occupational safety and health services
59 
403-4 Worker participation, consultation, and  
communication on occupational safety and health
56 
403-5 Worker training on occupational safety and health
58-59 
403-6 Promotion of worker health
59 
403-7 Prevention and mitigation of occupational safety and 
health impacts directly linked by business relationships 59 
403-8 Workers covered by an occupational safety and health 
management system
59 
403-9 Work-related injuries
109
Training and 
Education
404-1 Average hours of training per year per employee
108 
404-2 Programs for upgrading employee skills and transition 
assistance programs
109 
Diversity 
and Equal 
Opportunity
405-1 Diversity of governance bodies and employees
72, 106-107 
405-2 Ratio of basic salary and remuneration of women to men 107 
Non-
Discrimination 406-1 Incidents of discrimination and corrective actions taken 52
Communities 413-1 Operations with local community engagement,  
impact assessments, and development programs
65-66 
Marketing & 
Labeling
417-1 Requirements for product and service information  
and labeling
54 
Celltrion ESG Report 2022/23
115
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Celltrion is monitoring the impact of climate change on its business continuously in order to respond to the climate crisis, a global issue. The ESG Committee of the Board of Directors reviews climate 
change-related risks and opportunities and discloses related potential risks based on recommendations of the TCFD.
TCFD (Task Force on Climate-related Financial Disclosures)
TCFD Requirements
Reference Page Number
1. Governance
Disclose the organization’s governance around climate-related risks  
and opportunities
A. Describe the board’s oversight of climate-related risks and opportunities
38 
B. Describe management’s role in assessing and managing climate-related risks and opportunities.
38 
2. Strategy
Disclose the actual and potential impacts of climate-related risks  
and opportunities on the organization’s businesses, strategy,  
and financial planning where such information is material.
A. Describe the climate-related risks and opportunities the organization has identified over the short, medium,  
and long term.
38 
B. Describe the impact of climate-related risks and opportunities on the organization’s businesses, strategy,  
and financial planning.
38 
C. Describe the resilience of the organization’s strategy, taking into consideration different climate-related scenarios, 
including a 2°C or lower scenario.
-
3. Risk Management
Disclose how the organization identifies, assesses,  
and manages climate-related risks.
A. Describe the organization’s processes for identifying and assessing climate-related risks.
38 
B. Describe the organization’s processes for managing climate-related risks.
38 
C. Describe how processes for identifying, assessing, and managing climate-related risks are integrated  
into the organization’s overall risk management.
38 
4. Metrics and Targets
Disclose the metrics and targets used to assess and manage relevant 
climate-related risks and opportunities where such information is 
material.
A. Disclose the metrics used by the organization to assess climate-related risks and  
opportunities in line with its strategy and risk management process.
38 
B. Disclose Scope 1, Scope 2, and, if appropriate, Scope 3 greenhouse gas (GHG) emissions, and the related risks.
38, 103 
C. Describe the targets used by the organization to manage climate-related risks and opportunities and  
performance against targets.
38 
Celltrion ESG Report 2022/23
116
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Celltrion discloses qualitative and quantitative data for each of the topics applicable to the Biotechnology & Pharmaceuticals industry in accordance with the US SASB recommendations, and manages our 
internal data in compliance with recognized international standards.
SASB (Sustainability Accounting Standards Board)
Topic
Measurement Indicator
Category
Unit
Code
Reference  
Page Number Note
Safety of Clinical 
Trial Participants
Discussion, by world region, of the management process for ensuring quality and patient safety during clinical trials
Qualitative
N/A
HC-BP-210a.1.
54 
Number of FDA Sponsor Inspections related to the management of clinical trials and pharmacovigilance that resulted in:  
(1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)
Quantitative
Number
HC-BP-210a.2.
-
Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries
Quantitative 
Reporting currency
HC-BP-210a.3.
-
Access to 
medicines
Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries  
as defined by the Access to Medicine Index
Qualitative 
N/A
HC-BP-240a.1
26 
List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)
Qualitative 
N/A
HC-BP-240a.2
14, 29 
Affordability  
and pricing
Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions  
to delay bringing an authorized generic product to market for a defined time period
Quantitative 
Number
HC-BP-240b.1
-
Percentage change in: (1) average list price and (2) average net price across the U.S. product portfolio compared to the previous year
Quantitative 
Percentage (%)
HC-BP-240b.2
-
Percentage change in: (1) list price and (2) net price of the product with the largest increase compared to previous year
Quantitative 
Percentage (%)
HC-BP-240b.3
-
List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database
Qualitative 
N/A
HC-BP-250a.1
-
Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System
Quantitative 
Number
HC-BP-250a.2
-
Number of recalls issued, total units recalled
Quantitative 
Number
HC-BP-250a.3
111 
Total amount of product accepted for take-back, reuse, or disposal
Quantitative 
Metric tons (t)
HC-BP-250a.4
-
Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type
Quantitative 
Number
HC-BP-250a.5
-
Counterfeit 
Drugs
Description of methods and technologies used to maintain traceability of products throughout the supply chain and  
prevent counterfeiting
Qualitative 
N/A
HC-BP-260a.1
-
Discussion of the process for alerting customers and business partners of potential or known risks associated with counterfeit products
Qualitative 
N/A
HC-BP-260a.2
-
Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products.
Quantitative 
Number
HC-BP-260a.3
-
Ethical Marketing
Total amount of monetary losses as a result of legal proceedings associated with false marketing claims
Quantitative 
Reporting currency
HC-BP-270a.1
-
Description of the code of ethics governing promotion of off-label use of products
Qualitative 
N/A
HC-BP-270a.2
131 
Employee 
Recruitment, 
Development 
and Retention
Discussion of talent recruitment and retention efforts for scientists and research and development personnel
Qualitative 
N/A
HC-BP-330a.1
45-46, 110 
(1)Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals,  
and (d) all others
Quantitative 
Rate
HC-BP-330a.2
107 
Supply Chain 
Management
Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in the Rx-360 International Pharmaceutical Supply Chain 
Consortium audit program or equivalent third-party audit programs for ensuring the integrity of supply chain and ingredients
Quantitative 
Percentage (%)
HC-BP-430a.1
-
Business Ethics
Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery
Quantitative 
Reporting currency
HC-BP-510a.1
-
Description of the code of ethics governing interactions with health care professionals
Qualitative 
N/A
HC-BP-510a.2
-
Celltrion ESG Report 2022/23
117
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Celltrion actively supports the United Nations Sustainable Development Goals (SDGs) to address the economic, environmental and social challenges facing humanity.
Celltrion is committed to conducting our business activities in line with the goal of promoting human health and well-being and the UN SDGs to exercise good influence and contribute to achieving shared 
global objectives.
UN SDGs (UN Sustainable Development Goals)
SDGs
Description
Reference  
Page Number
No Poverty
End poverty in all its forms, everywhere.
65-66 
Good Health and 
Wellbeing
Ensure healthy lives and promote well-being for all,  
at all ages.
36-37, 47-48,  
56-59, 61-62,  
65-66  
Quality Education
Ensure inclusive and equitable quality education and 
promote lifelong learning opportunities for all.
45-46 
Gender Equality
Achieve gender equality and empower all women  
and girls.
47-48, 51-53 
Clean Water and 
Sanitation
Ensure availability and sustainable management of  
water and sanitation for all.
36-42 
Affordable and 
Clean Energy
Ensure access to affordable, reliable, sustainable,  
and modern energy for all.
36-42 
Decent Work and 
Economic Growth
Promote sustained, inclusive, and sustainable  
economic growth, full and productive employment,  
and decent work for all.
11-12, 45-48,  
56-59, 71-77,  
87-90 
SDGs
Description
Reference  
Page Number
Industry, Innovation  
and Infrastructure
Build resilient infrastructure, promote inclusive and 
sustainable industrialization, and foster innovation.
11-12, 15,  
29-30, 32-33
Responsible 
Consumption and 
Production
Ensure sustainable consumption and  
production patterns
61-63 
Climate Action
Take urgent action to combat climate change and its 
impacts
36-42 
Life Below Water
Conserve and sustainably use the oceans, seas,  
and marine resources for sustainable development
36-42 
Life on Land
Protect, restore, and promote sustainable use of terrestrial 
ecosystems, manage forests, combat desertification and 
biodiversity loss, and halt and reverse land degradation.
36-42 
Peace, Justice and 
Strong Institutions
Promote peaceful and inclusive societies for sustainable 
development, provide access to justice for all, and build 
effective, accountable, and inclusive institutions.
47-48, 79-81
Partnerships for the 
Goals 
Strengthen the means of implementation and revitalize 
the Global Partnership for Sustainable Development 
116 
Celltrion ESG Report 2022/23
118
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Independent Assurance Statement
Introduction and Objectives of Work
BSI Group Korea (hereinafter “the Assurer”) was requested to verify Celltrion 2022/2023 ESG Report (herein-
after “the Report”). This assurance statement applies only to the relevant information included in the scope of 
the assurance. Celltrion is solely responsible for all information and assertion contained in the Report. The re-
sponsibility of the Assurer is to provide Celltrion Management with independent assurance statement based 
on its expert opinions by applying the verification methodology for the specified assurance scope. It is also to 
provide the information to all stakeholders of Celltrion. 
Standards and Levels
This assurance was based on the AA1000AS (Assurance Standard) v3 (2020) Assurance Standard and 
confirmed that the Report was prepared in accordance with the GRI Standards, the international standards 
guidelines of sustainability reports. In accordance with the AA1000 AS, the assurance level was Moderate 
Level, and conducted against Type 1 to confirm compliance with the four principles of the AA1000 AP (Ac-
countAbility Principles) 2018.
Scope 
The scope of assurance applied to the Report is as follows; 
- Report contents during the period from January 1st to December 31st 2022 included in the report, some 
data included 2023.
- Major assertion included in the Report, such as sustainability management policies and strategies, goals, 
projects, and performance, and the Report contents related to material issues determined as a result of ma-
teriality assessment.
- Appropriateness and consistency of processes and systems for data collection, analysis and review
The following contents were not included in the scope of assurance. 
- Financial information in Appendix
- Index items related to other international standards and initiatives other than the GRI
- Other related additional information such as the website, business annual report.
To: The Stakeholders of Celltrion Co., Ltd. 
Methodology 
As a part of its independent assurance, the Assurer has used the methodology developed for relevant evi-
dence collection in order to comply with the verification criteria and to reduce errors in reporting. The Assurer 
has performed the following activities; 
- Review of the system for sustainability management strategy process and implementation
- Review of materiality issue analysis process and prioritization by reviewing materiality issue analysis process 
and verifying the results
- Review of the supporting evidence related to the material issues through interviews with senior managers in 
the responsible department
- Verification of data generation, collection and reporting for each performance index
Limitation 
The Assurer performed limited verification for a limited period based on the data provided by the reporting 
organization. It implies that no significant errors were found during the verification process, and that there are 
limitations related to the inevitable risks that may exist. The Assurer does not provide assurance for possible 
future impacts that cannot be predicted or verified during the verification process and any additional aspects 
related thereto. 
Results of Assurance
According to our assurance review, nothing has come to our attention that causes us to believe that the in-
formation and data presented in Celltrion’s report are misstated in any material respect. We believe that the 
report is in accordance with the GRI Standards, and our assurance opinion on the four principles set out in 
the AA1000 AP (2018) is as below.
Assurance Opinion   
On the basis of our methodology and the activities described above, it is our opinion that 
- The information and data included in the Report are accurate and reliable and the Assurer cannot point out 
any substantial aspects of material with mistake or misstatement.
- The Report is prepared in accordance with the GRI Standards. (Reporting in accordance with the GRI stan-
dards)
- The assurance opinions on the four principles presented in the AA1000 AP (2018) are as follows.
Celltrion ESG Report 2022/23
119
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

AA1000 AP (2018)
	 Inclusivity: Stakeholder Engagement and Opinion
	 Celltrion defined customers, employees, shareholders/investors, central and local governments, suppliers 
and local Communities as key stakeholder groups, and operated communication channels for each stake-
holder group for engagement. Celltrion reflected key issues derived from stakeholder channels to sustain-
ability management decisions and disclosed the process in the Report. 
	 Materiality: Identification and reporting of material sustainability topics 
	 Celltrion established the strategy related to sustainability management and established the process to de-
rive reporting issues. Celltrion identified financial and social/environmental impacts and derived 10 material 
topics based on the analysis of media research, benchmarking global advanced companies in its field, and 
analysis of major global initiatives related to sustainability. 
	 Responsiveness: Responding to material sustainability topics and related impacts 
	 Celltrion established the management process for material topics determined by the materiality assess-
ment, and implemented a response plan for each topic to appropriately respond to the derived material 
topics that reflects the expectations of stakeholders. Celltrion disclosed the relevant process including es-
tablishing policy and indicators, activity and response performance on key reporting issues in the Report. 
	 Impact: Impact of an organization’s activities and material sustainability topics on the organiza-
tion and stakeholders 
	 Celltrion established the process to identify and evaluate the impact on organizations and stakeholders 
related to material topics. Celltrion used impacts, risk and opportunity factor analysis results for material 
topics to make decisions to develop response strategies for each issue, and disclosed the process in the 
Report. 
Key areas for ongoing development 
- It may be helpful to further clarify sustainability-related mid- to long-term goals and strategies to internalize 
ESG management, and to disclose monitoring indicators under the ESG roadmap.
- It may be helpful to establish roles and responsibilities associated with ESG’s board of directors.
Statement of independence and competence
The Assurer is an independent professional institution that specializes in quality, health, safety, social and 
environmental management with almost 120 years history in providing independent assurance services. No 
member of the assurance team has a business relationship with Celltrion. The Assurer has conducted this 
verification independently, and there has been no conflict of interest. All assurers who participated in the as-
surance have qualifications as an AA1000AS assurer, have a lot of assurance experience, and have in-depth 
understanding of the BSI Group’s assurance standard methodology. 
	 Evaluation against GRI ‘In Accordance’ Criteria
	 [Universal Standards] 
	 2-1 to 2-5 (The organization and its reporting practices), 2-6 to 2-8 (Activities and workers), 2-9 to 2-21 
(Governance), 2-22 to 2-28 (Strategy, policies and practices), 2-29 to 2-30 (Stakeholder engagement), 3-1 
to 3-3 (Material Topics Disclosures)
	 [Topic Standards] 
	 201-1~2, 201-4, 202-1~2, 203-1~2, 204-1, 205-1~3, 207-1~2, 207-4, 302-1, 302-3~4, 303-2~5, 304-
2, 305-1~2, 305-4~5, 305-7, 306-3~5, 308-1~2, 401-1~3, 403-1~9, 404-1~2, 405-1~2, 406-1, 413-1, 
417-1 
25 Apr 2023 
S. H. Lim
BSI Group Korea, Managing Director 
Celltrion ESG Report 2022/23
120
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

GHG Verification Report
Scope of Assurance
Assured all business sites and emission facilities under the operational control of Celltrion, Inc.
Assurance Standard
· ISO 14064-1:2006, ISO 14064-3:2006 
· WRI/WBCSD GHG Protocol
· IPCC Guidelines for National Greenhouse Gas Inventories (2006)
· Operational guidelines for emissions reporting and certification in greenhouse gas emissions trading programs
Assurance Limitations
The assurance has inherent limitations that may arise from the application of criteria and methods.
Celltrion, Inc.
Korea Management Registrar has assured the GHG emissions (Scope 1 and 2) of Celltrion for the year 2022.
Assurance Opinion
· The Assurance Engagement was conducted to arrive at a reasonable level of assurance based on the Assurance Standards.
· We indicate that no material errors in the calculation of the emissions were found during the assurance engagement and that 
the relevant activity data and evidence were managed and calculated properly. We issue a final opinion that the result is “appro-
priate.”
· Materiality: The threshold of less than 5% met
April 18, 2023
(Unit: tCO2-eq/yr.)
GHG emissions 
Direct emissions (Scope 1) 
Indirect emissions (Scope 2) 
Total (tCO2-eq)
2022
21,219
35,299
56,517
Energy usage 
Fuel 
Electricity 
Steam 
Total (TJ)
2022
418
738
0
1,155
* Scope 1 and Scope 2 emissions are from statements submitted to the Ministry of Environment.
Celltrion ESG Report 2022/23
121
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Awards
Association Memberships and Sponsorship (As of 2022)
Awards and Association Memberships
Name of Award
Year
Details
Awarding Body
5th Korea KOSDAQ Award
2011
Won the Grand Prize (Minister of 
Knowledge Economy Award)
KOSDQA Listed Companies 
Association
3rd Asia Women Index Award
2018
Won the Grand Prize (Minister of 
Gender Equality and Family Award) Asia Business Daily
iR52 Jang Young-Shil Award
2019
Won iR52 Jang Young-Shil Award 
for two consecutive years  
(2018-2019)
Korea Industrial Technology 
Association
28th Dasan Management Award
2019
Won the Entrepreneur 
 of the Year Award
Korea Economic Daily
2020 Korea Trade Research 
Association’s Grand Trader Award
2020
Won the Grand Prize
Korea Trade Research 
Association
25th National Academy of 
Engineering of Korea Award
2021
Won the Grand Prize
National Academy of 
Engineering of Korea
EY World Entrepreneur  
Of The Year™
2021
Won the Best Entrepreneur Award, 
a first among Koreans
EY
The 5th Tax Payment Award
2022
Won the Grand Prize in the 
pharmaceutical and bio sector 
more than three times
Joseilbo
Organization
Amount (KRW million)
Incheon Chamber of Commerce & Industry
80
Korea Biomedicine Industry Association
36
Korea Biotechnology Industry Organization
33
Korea Exchange
30
Korea Listed Companies Association
14
Korea Pharmaceutical and Bio-Pharma Manufacturers Association
9
KSH (Korean Society of Hypertension) 
6
ICDM (International Congress of Diabetes & Metabolism) 
6
ESH (European Society of Hypertension) 
6
ESC (European Society of Cardiology) 
6
Others (Korea Chemicals Management Association, etc.)
40
Total Expenditures
266
Celltrion ESG Report 2022/23
122
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Article (Objective)
Celltrion established the Environmental Safety Health Policy to pursue sustainable management based on 
the trust of various stakeholders, such as employees, customers, shareholders and investors, suppliers, and 
local communities, by ensuring compliance with laws, regulations, and procedures related to environment, 
safety, and health (ESH), managing emissions and hazardous substances at a standard stricter than the 
legal requirements, and conducting eco-friendly business activities to fulfill our responsibility to protect the 
environment.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles of Environmental Management)
①	 We comply with domestic and international environmental laws and regulations and apply strict internal 
management standards.
②	 We establish and operate an environmental management system in line with international standards.
③	 We strive continuously to protect the environment and minimize environmental impacts, including 
greenhouse gas emissions, in all business activities, including the production and distribution processes, 
management of business sites, and performance of services.
④	 We take all measures to enhance resource efficiency and reduce resource use, and thoroughly manage 
waste.
⑤	 We check the development potential of the environmental management system and improve its efficiency.
⑥	 We comprehensively consider ESG performance, including environmental management, when evaluating 
suppliers (supply, contract, and service), and communicate this policy to key business partners to promotes 
a corporate culture that cares for the environment.
⑦	 We identify the environmental impacts of a company’s business activities during due diligence and mergers 
and acquisitions, and reflect them in major decisions.
⑧	 We disclose environmental management policies and performance to internal and external stakeholders to 
raise awareness.
⑨	 We provide regular environmental education for all employees and major suppliers to help them understand 
and practice the environmental management system, and spare no efforts to minimize environmental 
impact.
ESG Guidelines
Environmental Safety and Health Policy
Article 4 (Goals of Environmental Management)
Celltrion establishes the following objectives for environmental management and discloses the implementation 
progress on the official website and ESG.
	
1.	We monitor the progress in achieving emission targets on a regular basis and upgrade our environmental 
management system to respond to climate change proactively.
	
2.	We strive to internalize an eco-friendly corporate culture by introducing environmental management KPIs, 
strengthening environmental education for employees, and disclosing environment-related information 
transparently to create an eco-friendly corporate culture.
Article 5 (Basic Principles of Safety and Health Management)
①	 We comply with relevant domestic and international laws and regulations to prevent safety accidents/
disasters, and establish internal safety and health regulations that are stricter than legal requirements. 
Workers are provided training related to the standards established by the company, including the safety-
related work manual, and perform their work according to the established procedures. 
②	 We establish and operate a safety and health management system in accordance with international 
standards, and comply with management standards under the International Labor Organization (ILO) Safety 
and Health Convention. 
③	 We strive to prevent industrial accidents by continuously managing and improving the safety and health 
management system. 
④	 We create and run an Occupational Safety and Health Committee consisting of an equal number of 
workers and management representatives. We conduct safety and health-related deliberations and 
approvals by holding committee meetings once a quarter.
Article 6 (Goals of Safety and Health Management)
Celltrion establishes the following objectives for implementing safety and health management, and discloses 
related progress through its website and ESG Report.
	
1.	Zero major accidents / major industrial accidents at all worksites
	
2.	Minimize the occurrence of work-related injuries and diseases among employees
Article 7 (Organization)
For responsible ESH management, the ESG Committee, a committee under the BoD, serves as the top 
decision-making body. Major issues of ESH management are reported to the CEO, who makes decisions 
on major issues to be resolved and reports the outcome to the ESG Committee. Dedicated working-level 
organizations that implement ESH management are the ESG Management Team, which is in charge of 
planning policies; the Environment Health Safety 2 Team, which is in charge of implementing environment-
related policies (including Biodiversity Policy and Deforestation Prohibition Policy); and the Safety Management 
Team, which is in charge of implementing safety and health-related policies.
Celltrion ESG Report 2022/23
123
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Article (Objective)
Celltrion supports the protection of biodiversity around the globe, including communities, and has established 
the Biodiversity Policy to minimize the environmental impact of its business operations on biodiversity.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	 We conduct an environmental impact assessment before starting a business site in a new region to 
minimize the impact of the business on local life.
②	 If we operate the business in and near areas that are important from a biodiversity perspective and cause 
negative environmental impacts, we take all measures to restore these areas immediately to minimize 
damage.
③	 All business sites subject to international agreements related to the protection of biodiversity and land (World 
Heritage Areas, IUCN Category I-IV Protected Areas) shall comply with the relevant country’s and region’s 
legal requirements.
④	 This policy applies to all business sites, and we make efforts to apply it to our key supply chains.
⑤	 We work with civil and environmental organizations in the vicinity of our business sites to implement this 
policy and communicate with various stakeholders to enhance biodiversity.
⑥	 We have developed a system to check risks that threaten biodiversity when expanding business sites and 
operating new business sites; and established a monitoring system to check for the occurrence of negative 
environmental impacts.
⑦	 We establish biodiversity goals for prioritized areas to achieve No Net Loss (NNL).
Article 4 (Goals)
Celltrion has established the following objectives to implement this policy and will disclose the implementation 
progress on its website and in the ESG Report.
- Achieve Net Positive Impact (NPI) 1) and No Net Loss (NNL) 2) by 2050 at business sites with critical habitats.
1) Net Positive Impact (NPI): Activities that have a positive impact on ecological diversity, such as conservation, restoration,  
and enhancement of biodiversity.
2) No Net Loss (NNL): Business operations without degradation or loss of biodiversity.
Article 1 (Objective)
Celltrion recognizes that the best nature-friendly solution to the climate crisis is the protection of forests, 
supports activities to stop deforestation and protect forests around the world, and establishes this policy to 
minimize the impact of its business operations on forests.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	We do not cause destruction of forests through forest clearance. 
②	We restore green areas, including forests, when we withdraw from existing business sites. 
③	This policy applies to all business sites, and we make efforts to apply it to our major supply chains. 
④	We work with civic and environmental groups near our business sites to implement this policy. 
⑤	We establish a system to check risks that threaten the protection of forests when expanding the existing 
business sites and operating new business sites, and establish a monitoring system to check for the 
occurrence of negative environmental impacts.
Article 4 (Goals)
Celltrion has established the following objectives to fulfill this policy and will disclose the implementation 
progress on its website and in the ESG Report.
- Achieve Zero Net Deforestation by 2050
Article 5 (Operating System)
①	Deforestation Risk Management System: 
	
Celltrion practices forest protection in accordance with this policy and has established the necessary 
deforestation risk management system. Accordingly, we evaluate and monitor deforestation risks regularly, 
disclose the results, and communicate with stakeholders.
② Scheme for Communication with Stakeholders
	
Celltrion’s forest protection goals and performance are disclosed on its website and in ESG Report, and any 
interested party may report any violations of this policy via email (ESG@celltrion.com).
Biodiversity Policy
Deforestation Prohibition Policy
Establish and publicly 
disclose a Deforestation 
Prohibition Policy
Develop  
a deforestation risk 
management system
Conduct deforestation 
monitoring activities
Measure the effective-
ness of forest  
protection activities and 
check implementation 
performance
Publicly disclose  
the implementation 
progress of the 
Deforestation Prohibition 
Policy
Celltrion ESG Report 2022/23
124
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Article 1 (Objective)
Celltrion has established this policy to prevent environmental accidents and create a pleasant environment by 
complying with domestic and foreign laws and regulations related to waste; establishing and operating its own 
waste management system; collecting, storing, transporting, and treating waste properly; and minimizing the 
generation of waste.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	 Celltrion and its business sites shall discharge wastes in accordance with local waste management laws. 
They shall dispose of industrial wastes themselves or outsource them for disposal in accordance with the 
Waste Management Act.
②	 Designated wastes shall be discharged in accordance with local waste management laws. Furthermore, 
Celltrion shall dispose of designated wastes generated at the business sites themselves or outsource them 
to be disposed of in accordance with the Waste Management Act.
③	 When storing and transporting the waste, we shall comply with our waste management and treatment 
guidelines, be careful and always check not to cause environmental pollution. 
④	 We shall submit appropriate documents in accordance with local waste management laws when reporting 
waste discharge.
⑤	 Waste managers must complete related training.
Article 1 (Objective)
Celltrion has established this policy to comply with domestic and international laws and regulations and 
global standards related to chemicals; protect the safety of all persons involved in handling chemicals; and 
minimize environmental risks by procuring, storing, transporting, using, and disposing of chemicals safely and 
systematically.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	 All employees, as well as employees of all suppliers working at our business sites, receive training related 
to hazardous chemicals and emergency response training to remain prepared for any chemical accidents.
②	 Facilities that handle hazardous chemicals are subject to regular inspections, safety diagnosis, frequent 
inspections, and external impact assessments (when changes to chemical facilities or substances are 
planned), and we make immediate improvements if found necessary as a result of inspections.
③	 Inspectors and those in charge shall regularly and internally inspect facilities handling hazardous chemicals.
④	 Chemical managers of relevant departments shall conduct regular joint inspections.
⑤	 The system manages performance related to hazardous chemicals, and the person in charge manages the 
history.
⑥	 We check whether emissions are subject to investigation, and if so, we prepare the investigation results.
⑦	 When importing chemicals, check the review request.
⑧	 We prepare and manage the site layout map of hazardous chemical facilities.
⑨	 We handle hazardous chemicals in accordance with MSDS standards and display MSDS on site.
⑩	 We notify workers that the storage area for specially managed substances is where specially controlled 
substances are handled, and post a warning sign instructing them to wear appropriate protective gear. 
We keep a log when work involves the handling of specially controlled substances, which the chemical 
manager and the person in charge of relevant departments should manage.
⑪	 We conduct periodic measurements of the work environment regarding chemicals handled in the 
workplace and share the results with the department that uses the chemicals.
Waste Management Policy
Chemical Safety Management Policy
Celltrion ESG Report 2022/23
125
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Article 1 (Objective)
Celltrion puts human rights first in its business philosophy and respects the human rights of all stakeholders. 
We have established this policy to practice human rights management by supporting human rights principles 
proposed by the Universal Declaration of Human Rights (UDHR), the UN Guiding Principles on Business and 
Human Rights (UNGPs), the OECD Guidelines for Multinational Enterprises, the UN Convention on the Rights 
of the Child (CRC), the Fundamental Conventions of International Labor Organization (ILO), and the Corporate 
Human Rights Benchmark (CHRB). 
Article 2 (Scope of Application)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	 No Discrimination 
	
We prohibit all discriminatory behavior based on an individual’s sex, race, religion, nationality, ethnicity, 
gender identity, social status, or political opinion without a reasonable cause. Discriminatory behaviors 
include any unfair behaviors in hiring, promotion, evaluation and compensation, retirement and termination, 
and educational opportunities.
②	 Increase Diversity and Inclusion
	
We respect the diverse perspectives of our employees based on the principles of non-discrimination and 
strive to build an inclusive corporate culture. We also make efforts to increase organizational diversity and 
help employees reach their potential.
③	 No Workplace Harassment
	
We prohibit all physical and mental bullying that takes advantage of one’s position and relationships in 
the workplace. Bullying includes intimidation, ostracism, and sexual harassment/sexual violence in the 
workplace, and immediate actions shall be taken to protect the victim in the event of damage. When 
verifying the facts, the cases will be strictly handled in accordance with the principle of zero tolerance, 
including appropriate disciplinary measures.
④	 Preventing Human Trafficking and Modern Slavery
	
We prohibit acts of intimidation, confinement, and assault for work and allow zero tolerance to infringement 
upon human rights, such as human trafficking and modern slavery.
⑤	 No Forced Labor
	
We do not force individuals to work against their free will, nor store the original copy of workers’ personal 
documents such as identification cards, passports, or work permits issued by the government as a 
condition for employment.
⑥	 Prohibition of Child Labor
	
We do not employ children, and prevent risks in the recruitment process by checking the age of new hires. 
If child labor is found, we check the child’s condition immediately and take measures to protect the child’s 
human rights according to due procedure.
⑦	 Freedom of Association and Collective Bargaining
	
We respect the labor relations laws of each country or region and provide sufficient communication 
opportunities for all employees.
⑧	 Equal Pay Guaranteed
	
We guarantee equal opportunities and treatment for men and women in evaluation to determine 
employment, wages, etc.
Article 4 (Operating System)
①	 Human Rights Risk Management System
	
Celltrion shall practice human rights management in accordance with this policy and has established the 
necessary human rights risk management system. Accordingly, we assess and monitor human rights risks 
regularly and disclose the results to communicate with stakeholders. In addition, we review the human 
rights risk management system regularly to respond to social changes and potential risks proactively.
② Grievance Handling Process
	
1. Celltrion operates the following channels to receive cases of human rights violations. 
	
	
A. We receive opinions through relevant managers. 
	
	
B. We operate an anonymous communication channel (Tongnamu).
	
	
C. We receive cases online (Tong@celltrion.com).
	
	
D. We operate the Organizational Culture Office Grievance Consultation Channel (ER Team).
	
	
E. We operate the Grievance Handling Committee Member System
	
2. Upon receiving a report of human rights violations, the contents shall be verified and investigated, and 
appropriate actions will be taken. If a case of damage is confirmed, it will be reported to a committee 
or management meeting involving top decision-makers, etc., and measures will be taken to prevent 
further damage. All reports and the informant’s identity are treated anonymously and anonymity is 
thoroughly guaranteed, and any kind of disadvantage or retaliation due to reporting is prohibited. If gross 
misconduct or unfair behavior is identified in a report, it shall be handled in accordance with internal 
regulations.
Human Rights Policy
Develop and disclose 
Human Rights Policy
Establish  
a human rights risk 
management system.
Conduct human rights 
impact assessments and 
identify potential risks.
Improve and monitor 
human rights risks.
Publicly disclose 
Human Rights Policy 
implementation progress.
Celltrion ESG Report 2022/23
126
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Article 1 (Objective)
Celltrion has established this policy to improve human health and welfare through the development of next-
generation medicines, improve the health of patients in the underprivileged class who have difficulty accessing 
medicines, and provide them with high-quality medicines.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	We try to develop innovative products that facilitate access to medicines. Innovative product development 
includes research and development of medicines for neglected diseases.
②	We recognize the need to improve access to medicines for the underprivileged classes who lack medical 
services, including patients in the Least Developed Countries (LDCs), and participate in initiatives that make 
joint efforts to strengthen local healthcare capacity and establish pricing policies in LDCs. 
③	We support improving local capacity to monitor the post-marketing effectiveness and side effects of 
pharmaceutical products.
④	We support local manufacturers to meet international GMP standards.
⑤	We provide support to local healthcare practitioners to improve their ability to administer medicines and 
manage patients properly.
⑥	We work with local regulatory authorities of different regions to ensure widespread drug registration so that 
patients in as many countries as possible have access to the proper treatment.
⑦	We strive to increase access to medicines by providing free medicines to vulnerable classes and improve 
the effectiveness of free medicines by managing eligible patients.
⑧	We recognize that not exercising patent rights on intellectual property for products related to diseases 
within the scope of the Access to Medicine Index in least-developed and Low-Income Countries (LICs) can 
help increase access to medicines for vulnerable classes. Accordingly, we consider access to medicines in 
least-developed and Low-Income Countries (LICs) when filing patent applications in those countries.
Article 1 (Objective)
Celltrion has established this policy based on international norms and standards, laws and regulations, and the 
Responsible Business Alliance’s Code of Conduct in order to build a sustainable supply chain by specifying the 
global social responsibilities that all suppliers with whom we do business must fulfill, and by defining compliance 
in the areas of labor and human rights, safety and health, environment, and ethical management.
Article 2 (Scope)
This policy applies to all suppliers Celltrion has entered into a business agreement with. All suppliers shall try to 
comply with this policy and encourage their workers and vendors (subcontractors) to comply with it.
Article 3 (Basic Principles)
①	 Labor and Human Rights
	
1.	Voluntary Labor
	
	
A. Suppliers shall not allow any form of forced labor and shall prohibit work that is not guaranteed to be 
voluntary.
	
	
B. Labor contracts must specify working conditions, such as wages and working hours, and shall be 
written in a language that workers can understand, and be provided in writing.
	
	
C. Suppliers shall not demand or store original copies of workers’ personal documents such as 
identification cards or passports. 
	
	
D. Suppliers shall not unreasonably restrict workers’ access to and movement within workplace facilities, 
including cafeterias, restrooms, and dormitories. 
	
	
E. Money and valuables shall not be requested in exchange for employment, and if a worker is found to 
have provided money, it must be repaid immediately.
	
2. Prohibition of Child Labor and Protection of Child Workers
	
	
A. Suppliers shall prohibit all forms of child labor. A child is defined as a person below 15 or the age subject 
to mandatory education in accordance with the ILO Core Conventions. If the age criteria set by local 
laws and regulations is different, the lower age shall apply. 
	
	
B. Suppliers shall verify the age of applicants using official documents, such as IDs and birth certificates, to 
prevent child labor when hiring workers. 
	
	
C. If a child worker is found in the workplace, appropriate measures shall be taken, such as checking the 
child’s health condition regularly and supporting mandatory education according to the child’s wishes. 
	
	
D. Workers below 18 are prohibited from harmful or dangerous work, including night work, and are 
required to observe working hours as set by international standards and local laws and regulations.
	
3. Working Hours
	
	
A. Suppliers shall comply with the working hours defined by the local laws and regulations of the area 
where the business site is located and the core conventions of the International Labor Organization, and 
if the standards are different, the stricter one shall apply. 
	
	
B. Suppliers shall respect workers’ voluntary willingness to work overtime and pay overtime wages in 
accordance with local laws and regulations. 
	
	
C. At least one paid holiday per week on average shall be guaranteed for workers.
Access to Medicines Policy
Supplier ESG Management Policy
Celltrion ESG Report 2022/23
127
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

4. Wages and Benefits 
	
	
A. Suppliers shall pay wages to workers on a predetermined date in accordance with local laws and 
regulations. 
	
	
B. Suppliers shall disclose the details of wage payments through pay stubs written in a language that the 
workers can understand.
	
5. Humane Treatment
	
	
A. Suppliers shall prohibit bullying, including sexual harassment or sexual violence, mental or physical 
coercion, verbal abuse, punishment, and unreasonable restrictions in the workplace against workers, 
and shall take all measures to prevent sexual harassment and bullying in the workplace.
	
	
B. Partners shall guarantee that anyone can report acts specified in Paragraph 1 by creating a channel for 
reporting cases of damage, and the reporting channel shall ensure the anonymity of the informant and 
also make sure that the informant does not suffer any disadvantage for reporting.
	
	
C. Suppliers shall develop procedures for dealing with damage cases and take appropriate measures that 
respect the affected worker.
	
6. Prohibition of Discrimination and Harassment
	
	
A. Suppliers shall specify that they apply the principle of zero tolerance for any discriminatory behavior.
	
	
B. Suppliers shall prohibit bullying or discrimination in hiring, performance appraisal, compensation, 
promotion, wages, and benefits, and provision of education and training opportunities based on gender, 
age, race and ethnicity, color, gender orientation and identity, disability, religion, political affiliation, labor 
union membership, nationality, or marital and pregnancy status, etc. 
	
7. Freedom of Association
	
	
A. Suppliers shall guarantee workers’ freedom of association and collective bargaining. Workers may 
establish legitimate bargaining organizations and join and leave labor unions freely.
	
	
B. Workers shall be able to communicate with the management about working conditions without fear of 
retaliation, intimidation, penalization, or discrimination.
②	 Safety and Health
	
1. OHS Management System and Training
	
	
A. Suppliers shall comply with local safety and health laws and regulations and obtain and renew safety 
and health-related licenses necessary for business operations.
	
	
B. Suppliers shall establish a safety and health-related organization, develop management plans and 
procedures, and check and improve risk factors regularly to prevent safety accidents during business 
operations.
	
2.	Industrial Safety
	
	
A. Suppliers shall check and evaluate the safety of production facilities and processes regularly.
	
	
B. Suppliers shall provide workers with personal safety gear, which shall be replaced and maintained 
periodically.
	
3.	Preparation for Emergency 
	
	
A. Suppliers shall minimize damage by identifying risks and developing emergency response procedures to 
prevent emergency situations. They shall create response scenarios by situation and prepare a manual 
for response measures. Based on this, suppliers shall conduct regular evacuation drills to enable 
workers respond effectively to emergency situations.
	
	
B. Firefighting facilities such as fire detectors and alarms shall be installed in appropriate locations and shall 
be checked for operation on a regular basis.
	
	
C. Evacuation lighting shall be installed along emergency evacuation routes to enable rapid evacuation in 
the event of an emergency, and an evacuation map shall be displayed to guide workers to evacuation 
routes at all times. Firefighting facilities and emergency evacuation routes shall be kept free of loads to 
enable quick response to emergencies. 
	
4.	Industrial Accidents
	
	
A. Suppliers shall establish procedures to prevent, track, manage, and report industrial accidents and 
occupational diseases.
	
	
B. In the event of an industrial accident or occupational disease, the scope of the damage caused by the 
accident or disease shall be investigated, and its cause shall be analyzed, and efforts shall be made to 
mitigate the risk by establishing appropriate improvement measures.
	
	
C. In accordance with local laws and regulations, regular medical examinations shall be conducted for 
workers, and improvement measures shall be established and implemented if occupational diseases 
are identified through medical examinations.
	
5.	Industrial Hygiene 
	
	
Suppliers shall conduct regular risk assessments to identify chemical, biological, and physical hazards at 
the workplace. They shall also check the hazards in the workplace, including measuring the hazardous 
environmental factors in the workplace. Suppliers shall disclose identified hazards and harmful elements to 
workers and devise measures to mitigate the risks.
	
6.	Physical Labor
	
	
Suppliers shall regularly check whether physically demanding work is causing musculoskeletal disorders to 
workers. If the possibility of musculoskeletal disorders or diseases is identified, efforts should be made to 
change the workplace or improve processes.
	
7.	Maintaining the Safety of Machinery and Equipment
	
	
A. Suppliers shall conduct regular safety inspections to control and eliminate risks of machinery and 
equipment, and manage machinery and facilities through appropriate maintenance activities. 
	
	
B. Suppliers shall provide workers with clear and complete instructions on how to use machines and 
equipment and operate them safely, and shall provide emergency stop buttons to prevent safety 
accidents.
	
8.	Sanitation, Food, and Housing
	
	
A. In the case of operating a cafeteria, necessary licenses shall be obtained and managed. Regular 
cleaning and inspections shall be carried out for the sanitization of cooking facilities.
	
	
B. In the case of operating a dormitory, emergency escape facilities, and firefighting facilities shall be 
inspected regularly, and the dormitory shall be kept clean and safe through regular cleaning and pest 
control activities.
Celltrion ESG Report 2022/23
128
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

③ Environment
	
1.	Environmental License and Reporting
	
	
A. Suppliers shall obtain and renew the necessary environmental licenses needed in the course of business 
operations.
	
	
B. Suppliers shall comply with the requirements stipulated by local environmental laws and regulations in 
the course of business operations.
	
2.	Hazardous Substances
	
	
A. Suppliers shall establish and manage procedures for handling, transporting, storing, using, recycling, 
and disposing of hazardous chemicals to prevent the leakage of hazardous substances to the outside.
	
	
B. Suppliers shall check whether the raw materials, parts, products, etc., they handle are harmful to the 
human body or the environment.
	
	
C. In locations and on containers where hazardous chemicals are used and stored, signs shall be posted 
to inform workers of the hazards of the chemicals.
	
3.	Waste
	
	
A. Suppliers shall discharge waste in accordance with the legal disposal methods specified in local laws 
and regulations.
	
	
B. Suppliers shall introduce measures to reduce waste emissions by measuring and managing waste 
emissions.
	
4.	Air Pollutants
	
	
A. Suppliers shall discharge air pollutants in accordance with the legitimate treatment methods specified in 
local laws and regulations.
	
	
B. Suppliers shall measure and manage the emission of air pollutants and strive to reduce air pollutant 
emissions.
	
5.	Water Management
	
	
A. Suppliers shall use water and discharge wastewater in a lawful manner as specified by local laws and 
regulations.
	
	
B. Suppliers shall measure and manage the status of water use, including the volumes of water 
consumption and wastewater discharge, and strive to reduce water consumption and increase 
recycling.
	
6.	Energy Use and Greenhouse Gas Emissions
	
	
Suppliers shall measure and manage energy consumption and greenhouse gas emissions and establish a 
plan to reduce them.
	
7.	Biodiversity
	
	
Suppliers shall introduce measures to protect biodiversity and shall manage negative impacts on the 
ecosystem.
④	 Ethical Management
	
1.	Anti-corruption and Adherence to Management by Principles
	
	
A. Suppliers shall prohibit, as a matter of policy, any acts of corruption such as bribery, embezzlement, 
brokering, and solicitation; any act of promising, offering, granting, providing, or accepting other forms 
of compensation to obtain improper benefits; and any act of demanding unfair compensation by taking 
advantage of weaknesses. All transactions shall be conducted in a transparent manner and recorded 
and managed accurately.
	
	
B. Suppliers shall operate channels for reporting unethical behavior of workers. The reporting channel shall 
ensure the informant’s anonymity and also ensure that the informant does not suffer any disadvantage 
for reporting.
	
2.	Fair Trade
	
	
Suppliers must comply with the fair trade regulations set forth by local laws and regulations and prohibit 
all unfair transaction practices. Acts that interfere with fair competition, including collusion, and acts that 
unfairly restrict the conditions of competition with other businesses are prohibited.
	
3.	Protecting Intellectual Property Rights
	
	
Suppliers must respect all intellectual property rights. Information of customers and business partners must 
be managed safely, and suppliers are prohibited from storing, using or leaking such information without 
prior authorization.
	
4.	Protection of Personal Information
	
	
Suppliers shall protect the personal information of all information subjects, such as workers and 
consumers. The information subject’s consent must be obtained in all processes such as collection, use, 
provision, and outsourcing of personal information, and personal information-related laws and regulations 
shall be complied with.
	
5.	Responsible Sourcing of Raw Materials
	
	
A. Suppliers shall establish policies related to the responsible procurement of raw materials and establish a 
process to ensure that serious human rights violations and environmental damage have not occurred in 
the production and distribution of raw materials, parts, products, etc., handled by them.
	
	
B. Suppliers shall confirm through regular due diligence that the raw materials, parts, products, etc. they 
handle are not related to social and environmental issues.
Article 4 (Supplier Risk Assessment and On-site Due Diligence)
Celltrion strives to improve the level of sustainable supply chain management and shares this policy with its 
suppliers when entering into business agreements. Celltrion may conduct risk assessments or on-site due 
diligence for any supplier to check compliance with this policy. The purpose of risk assessments and due 
diligence is to identify potential risks associated with suppliers. The risk assessments and due diligence will be 
conducted by Celltrion or a third-party organization at Celltrion’s request, to the extent permitted by law. 
Celltrion may share the assessment results and due diligence with the suppliers and recommend the mitigation 
of any risks identified by due diligence. Suppliers shall take steps to develop and implement a risk mitigation 
plan.
Celltrion ESG Report 2022/23
129
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Article 1 (Objective)
Celltrion established this policy to guarantee the independence of independent directors in compliance 
with laws and regulations related to the appointment of independent directors, including the Commercial 
Act. Based on this policy and the relevant laws and regulations, the independence of independent director 
candidates is verified in accordance with strict procedures in establishing requirements for the appointment of 
independent directors.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	 Celltrion shall define the following requirements for the selection of an independent director with guaranteed 
independence.
	
1. The independent director candidate has not been hired as an employee of the Company within one year
	
2. The independent director candidate has not been employed as an executive of an affiliated company 
within the last three years (including the independent director candidate and his/her family members)
	
3. The independent director candidate has not received compensation of KRW 80 million (equivalent to 
USD 60,000) or more in 12 months from the Company/parent company/subsidiary within the last three 
years (including the independent director candidate him/herself and his/her family members). 
	
4. The independent director candidate, his/her spouse and immediate dependents, or non-dependent 
relatives are not the largest shareholder.
	
5. If the largest shareholder is a corporation, the independent director candidate is not a director, auditor, 
executive officer, or other employee of such a corporation.
	
6. The independent director candidate is not an advisor or consultant to the Company.
	
7. The independent director candidate does not have a material interest in any of the Company’s significant  
customers1) or suppliers 2)
	
8. The independent director candidate is not an employee of a corporation with which the Company has 
an advisory contract, such as the Company’s main legal/management advisory contract.
	
9. The independent director candidate does not have a material interest in a non-profit organization, etc., 
that receives significant donations from the Company.
	
10. The independent director candidate does not have any other conflicts of interest with the Company.
	
11. The independent director candidate is not serving as a director, executive officer, or auditor of two or 
more companies other than the Company.
②	 In addition to the above requirements, Celltrion considers the domestic and international trend and the 
company’s internal circumstances in ensuring independence and comprehensively considers whether the 
independent director candidate has any significant relationship with the Company.
1) Significant customers: Corporations that account for 10% or more of the Company’s revenue or operating income.
2) Significant suppliers: Corporations that account for 10% or more of the Company’s expenses.
Article 1 (Objective)
Celltrion has established this policy to enhance the diversity and expertise of its Board of Directors. The goal is 
to enable the BoD to consider the perspectives of several stakeholders and make important decisions for the 
Company based on a broad perspective.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	 Celltrion considers the following requirements to ensure the diversity and expertise of the Board of 
Directors.
	
1. Gender diversity: There shall be no discrimination based on gender in the selecting members of the 
Board of Directors, and equal opportunities shall be given to both genders. 
	
2. Age diversity: The Board of Directors shall be of a wide age range to ensure harmony between 
experience and fresh perspectives, and enable flexible responses to internal and external business 
environments.
	
3. Diversity in nationality: To enhance our global competitiveness and respond flexibly to the external trend, 
we appoint directors without discrimination based on nationality.
	
4. Diversity of professional experience: We strive to find candidates with rich experience and expertise in 
various fields.
	
5. Diversity in terms of race/religion/ethnicity: We do not discriminate based on race/religion/ethnicity and 
appoint directors based on comprehensive consideration of diversity.
②	 Celltrion verifies that the above requirements are fully considered in selecting members of the Board of 
Directors, and tries to ensure that diverse perspectives are reflected and reviewed in major decisions. In 
addition, we set a minimum attendance requirement of 50% at BoD meetings consisting of members with 
diverse backgrounds and expertise. If a member fails to meet the minimum attendance requirement without 
a justifiable reason, it will be reflected in his/her evaluation.
Policy on the Independence of Independent Directors
Policy on the Diversity and Expertise of the BoD
Celltrion ESG Report 2022/23
130
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Article 1 (Objective)
Celltrion recognizes that the rightful payment of taxes in accordance with tax laws is an important obligation to 
contribute to national finances and social development, and established this policy to ensure compliance with 
domestic and international laws and regulations, such as the rightful payment and reporting obligations, and to 
fulfill its social responsibilities related to taxes.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries.
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①  We understand the purpose of the tax laws and related regulations of each country where we operate 
our business, and pledge to comply with the principles in good faith. For this, we abide by the tax laws of 
the countries where we operate our business and fulfill our obligations to pay taxes and file tax returns. In 
addition, we provide relevant facts and evidence transparently when investigated by tax authorities, submit 
data, and communicate transparently to the outside.
②  We do not transfer income to low-tax countries to take advantage of differences in tax laws between 
countries or exploit loopholes in the international tax system for tax evasion. In addition, we comply with 
the arm’s length principle for international transactions with overseas corporations and establish and 
implement a reasonable transfer pricing policy with external experts in line with domestic tax laws and the 
OECD’s transfer pricing guidelines.
③  We do not transfer income to overseas subsidiaries in secret jurisdictions or tax havens for tax avoidance 
purposes. We faithfully fulfill our tax obligations in international transactions through normal tax structures. 
We do not use tax structures that lack commercial substance for tax avoidance.
④  When making important decisions such as winning new businesses, strengthening business 
competitiveness, and expanding investment, we prioritize tax legitimacy and actively utilize the guidance 
of external experts. In addition, we obtain approval from the BoD for important matters related to taxation, 
including the approval of tax policies.
Article 1 (Objective)
Celltrion established this policy to eradicate corrupt behaviors such as bribery and illegal solicitation that 
impede employees’ fair performance of duties, and to raise Celltrion’s level of ethical management by 
expressing a strong anti-corruption commitment to internal and external stakeholders.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries.
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	 We strictly prohibit all forms of corrupt behavior, including bribery, illegal solicitation, illegal kickbacks, 
express fee, and gifts and entertainment that exceed the socially acceptable levels, and express our firm 
anti-corruption commitment internally and externally.
②	 We comply with domestic and international laws and regulations related to anti-corruption, such as the 
Criminal Act, the Act on Aggravated Punishment of Specific Crimes, the Act on Combating Bribery of 
Foreign Public Officials in International Business Transactions, the Improper Solicitation and Graft Act, the 
Pharmaceutical Affairs Act, the Fair Competition Code on Pharmaceutical Trade of the Republic of Korea 
and the Foreign Corrupt Practice Act of the United States, and the Bribery Act of the United Kingdom.
③	 We conduct charitable donations and sponsorships fairly in accordance with internal standards and 
procedures and prohibit donations and sponsorships for political purposes.
④	 We have established and operate an effective anti-corruption management system to prevent and minimize 
corruption risks and monitor and continuously improve its performance.
⑤	 To prevent corruption, we periodically identify and evaluate corruption risks, take prompt actions when 
we recognize the possibility of corruption or corruption occurring, and make active efforts to prevent a 
recurrence.
⑥	 We grant and guarantee independent authority for anti-corruption management to the anti-corruption 
compliance officer, who shall manage and supervise all requirements and procedures for the Anti-
corruption Management System.
⑦	 We operate a reporting system so anyone can quickly and easily report corruption. We keep the informant’s 
identity strictly confidential and protect them from any disadvantage caused by the report.
⑧	 If an employee commits a corrupt act, such as violating this policy or anti-corruption-related laws and 
regulations, appropriate measures, such as disciplinary action, shall be taken in accordance with relevant 
regulations.
⑨	 All employees are required to declare that they will comply with this policy and practice it continuously to 
realize corporate values and settle a fair and transparent organizational culture.
Tax Policy
Anti-Corruption and Anti-Bribery Policy
Celltrion ESG Report 2022/23
131
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Article 1 (Objective)
Celltrion established this policy to ensure compliance with relevant laws and regulations as well as company 
regulations in conducting direct and indirect activities related to promotion and sales; to make sure that 
such activities lead to respect for and further development of value for customers and society and to provide 
customers with objective and reliable information about products and services.
Article 2 (Scope)
This policy applies to Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries. 
Compliance with this policy is also encouraged for all stakeholders with whom Celltrion has business 
relationships, including suppliers.
Article 3 (Basic Principles)
①	 As a specialized pharmaceutical company, we comply strictly with domestic and foreign laws and 
regulations, including the Pharmaceutical Affairs Act, regarding advertising and marketing, and do our best 
by way of responsible marketing activities. In addition, we have established a control department within the 
company to monitor marketing and advertising activities fairly per this policy.
②	 In order to maintain dignity and fairness in advertising and marketing, we do not engage in marketing and 
advertising activities using expressions that belittle human dignity and life; encourage violence, crime, or 
antisocial behavior; or create excessive fear or disgust; or other expressions that cause discomfort or 
disgust and go against viewers’ sense of ethics or sentiments.
③	 In advertising and marketing, we do not compare or intentionally demean competing companies or 
products and services with false and objectively unfounded content. Nor do we exaggerate or understate 
the environmental benefits of purchasing and using products and services.
④	 Employees of Celltrion’s headquarters, domestic and foreign corporations, and subsidiaries shall perform 
their duties in accordance with this policy, and the Company shall provide training to help them understand 
and comply with this policy. In addition, companies that have business relationships with Celltrion, such as 
suppliers, contractors, joint ventures, and outsourcing partners, are also encouraged to comply with this 
policy, and policy education materials are distributed to spread awareness.
Ethical Advertising and Marketing Policy
Celltrion ESG Report 2022/23
132
BUSINESS STORY     ·     OVERVIEW     ·     MATERIAL ISSUES     ·     ENVIRONMENTAL     ·     SOCIAL     ·     GOVERNANCE     ·     ESG FACTBOOK     ·     APPENDIX

Bongkwan Koo
Yeongae Kwon
Kitae Kim
Daeyoung Kim
Daehwan Kim
Bongjung Kim
Yeonju Kim
Yubeom Kim
Jongjin Kim
Taeheon Kim
Jiwon Park
Heejin Park
Wonjae Bae
Hyunkyoung Byun
Haksub Shin
Sunghoon Yoo
Sul Lee
Yoonju Lee
Eunkyoung Lee
Jaeyoung Lee
Jieun Lee
Changkeun Lee
Minseok Chang
Myungho Jung
Seyoung Jeong
Jongwon Jung
Hongjae Jung
Jinhwan Cho
Muryong Choi
Yeseul Choi
Yongchul Choi
Eunsun Ha
Heeseok Han
Moonhee Heo
Acknowledgments
We would like to thank the following individuals for their contribution to this report.
CELLTRION ESG REPORT 2022/23
Published in	
June 2023
Published by	
Celltrion (www.celltrion.com)
Address		
23 Academy-ro, Yeonsu-gu, Incheon
For Inquiries	
Celltrion ESG Management Team (ESG@celltrion.com)
This report is printed with soybean oil ink.
The FSC® (Forest Stewardship Council®) label can only be applied to 
products that are produced using trees grown in forests that are managed 
sustainably from the social, economic, and environmental perspectives.
Design  The Moments